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Summary of Thesis
In the United Kingdom, colorectal cancer creates a significant health burden, with 
over 34 000 new cases diagnosed each year and over 16 000 deaths per year. Almost 50% 
of patients with colorectal cancer will develop liver métastasés: up to 25% will have liver 
métastasés at time of initial presentation with the remaining 25% developing liver 
métastasés during the course of their disease. Death from hepatic métastasés accounts for a 
large percentage of colorectal cancer mortalities and if left untreated the prognosis is poor, 
with median survival from 5 to 21 months with almost none alive at 5 years.
Surgical resection offers the only potential curative treatment for colorectal liver 
métastasés with the five year survival rate varying in the literature from 25% to 51%. 
Hepatic surgery was associated with high morbidity and mortality and it is only since the 
1990s that an evidence base has been published showing improved long term outcomes. 
Radiological imaging plays an essential role in the detection and characterisation of 
colorectal liver métastasés. Accurate staging of the disease allows patient selection for 
hepatic surgery. Despite recent and significant technological advances in radiological 
imaging, up to 50% of patients that have undergone curative partial hepatectomy will 
develop hepatic recurrence in the first two years after surgery. Evidence from growth rate 
studies has shown that colorectal liver métastasés are slow growing and that these 
recurrences were present at the time of initial staging. Therefore, the problem of occult 
liver métastasés remains.
This thesis has assessed the potential clinical role of a new imaging modality in the 
detection of colorectal liver métastasés: contrast enhanced ultrasound (CE-US). Initially a 
prospective trial using percutaneous CE-US with intravenous administration of an 
ultrasound contrast agent that has been used primarily in cardiac imaging was performed.
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The results of this study found that CE-US enhanced late phase vascular imaging. This is 
an important finding as the persistence of a hypoechoic liver lesion in to the late phase of 
CE-US imaging is typical of a colorectal liver metastasis and an agent that optimises the 
late phase would allow improved characterisation of colorectal liver métastasés. As a 
result, CE-US was then compared to percutaneous unenhanced ultrasound and found to 
have improved sensitivity and accuracy in the detection of colorectal liver métastasés 
(sensitivity 100%, accuracy 90.8% versus 64.4% and 64.4% respectively). Furthermore, 
the optimal late phase imaging was achieved by the lowest dose of agent (0.4mL) that 
would allow repeated injections if incorporated into routine clinical practice. These 
findings support the growing evidence base for percutaneous CE-US and it is likely that 
CE-US will replace unenhanced ultrasound in routine clinical practice.
With promising results in the percutaneous detection of colorectal liver métastasés, 
it was a logical step to perform CE-US intraoperatively. Unenhanced intraoperative 
ultrasound (lOUS) is widely regarded as the superior imaging modality for colorectal liver 
métastasés and this thesis has documented the first prospective trial using CE-IOUS. CE- 
lOUS detected significantly more lesions than lOUS and preoperative CT/MRJ as well as 
detecting smaller liver métastasés than the other imaging modalities (mean lesion size 
1.71cm versus 2.73cm for combined CT/MRI/IOUS). With smaller lesions being detected 
(the smallest was 0.4cm), alterations in staging and surgical management would be 
expected and this occurred in 35.1% and 29.8% of patients respectively. This prospective 
study contained 60 patients and inclusion of more patients with long term follow up will 
confirm if CE-IOUS is the superior imaging modality.
Previous researchers have developed techniques to detect the altered hepatic blood 
supply that occurs in the presence of colorectal liver métastasés. This thesis developed a
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novel and reproducible technique to measure hepatic perfusion using CE-US that found 
differences in perfusion between healthy controls and patients with overt colorectal liver 
métastasés. To assess the ability of this novel technique to differentiate accurately between 
healthy controls and patients with colorectal liver métastasés, ROC curves were drawn and 
the highest sensitivity and specificity achieved was only 85% and 58%, limiting the 
technique’s clinical applicability as a screening tool for occult colorectal liver métastasés.
Hepatic perfusion using CE-US was then used to assess changes in perfusion in 
patients undergoing curative partial hepatectomy with perioperative fluctuations occurring 
that were potentially reflecting the SIRS after surgical trauma. Perioperative perfusion 
changes were analysed for any relationship to hepatic recurrence with one parameter 
significantly higher in the recurrence group 3 months after the operation (peak intensity).
These two trials have shown that the measurement of hepatic perfusion in colorectal 
liver métastasés can be reliably performed by percutaneous contrast enhanced ultrasound. 
However, this measurement of preoperative or postoperative hepatic perfusion does not 
accurately predict the likelihood of hepatic recurrence. Further work analysing the 
individual contributions of the hepatic blood supply to both healthy and diseased liver, 
alongside improved understanding of the physics of the microbubbles in the hepatic 
circulation may develop a clinically applicable technique for the detection of occult 
colorectal liver métastasés.
With no widely accepted approach to performing partial hepatectomy this thesis 
analysed one small volume centre’s novel approach to performing partial hepatectomy for 
colorectal liver métastasés. The triphasic approach consists of: preoperative dehydration 
(using bowel preparation with no supplementary fluids); intraoperative fluid restriction (to 
allow CVP <5cmH20) and continuous selective vascular occlusion (Half-Pringle).
29
Preoperative dehydration was shown to be well tolerated by patients as well as allowing 
straightforward maintenance of a low intraoperative CVP, with no intravenous 
nitroglycerins administered. The Half-Pringle renders the hemi liver under resection 
ischaemic whilst protecting the liver remnant and has been confirmed by Doppler studies. 
All three components minimised blood loss with a median intraoperative loss of 400mL 
(range 50-3000mL). As a result, postoperative morbidity and mortality were low with 
disease-free survival and long-term survival comparing favourably to the published 
literature from larger volume centres.
Particular attention was paid to the perioperative changes in renal and hepatic 
function with the triphasic approach since dysfunction in these organs is likely after 
undergoing partial hepatectomy. Using specific markers for renal fiinction, in addition to 
routine biochemical blood markers, it was found that perioperative dehydration did not 
compromise renal function with no documented incidence of renal failure. No hepatic 
failure was documented and hepatic function blood tests displayed a distinct pattern which 
can be used as a guide to liver function postoperatively.
Colorectal cancer with hepatic métastasés presents a unique opportunity to deal 
with the primary and secondary disease at the same laparotomy. It has been the choice of 
this surgical department to perform combined primary and secondary resections, with RF 
ablation as appropriate. A case matched study was performed that found no 
differences in blood loss, number of recurrences, disease free survival and overall survival 
between staged and synchronous procedures. There was increased morbidity and longer 
stay in hospital in the synchronous group, but these results are likely to be limitations of the 
study design rather than actual differences. Overall, the combination of major colonic
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resections with synchronous bowel and /or RF ablation appears to be safe and does not 
compromise long term patient outcomes.
As a result of improved long term outcomes after hepatic resection for colorectal 
liver métastasés, interest has increased in the development of prognostic scores to optimise 
patient treatment. This thesis assessed the potential clinical application of preoperative C- 
reactive protein as a predictor of outcome after partial hepatectomy. Although a significant 
predictor in other malignancies, C-reactive protein was not found to be an influence in this 
cohort. For comparison the clinical risk score (CRS) that was developed by one of the 
largest volume centres for hepatic resections in the world was applied in this study’s 
cohort. The CRS was found to be predictive of poor outcome, thus validating it in another 
population and supporting its use in routine clinical practice.
This thesis has investigated the potential clinical role of contrast enhanced 
ultrasound in the detection of colorectal liver métastasés. Improved percutaneous and 
intraoperative detection of métastasés has led to optimised disease staging with significant 
alterations in surgical management. Partial hepatectomy using the triphasic approach has 
resulted in excellent short- and long-term patient outcomes and, with the inclusion of 
synchronous colonic and hepatic procedures, could extend the number of patients 
considered for surgical resection.
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Section 1: Introduction.
The background of colorectal cancer and liver métastasés
1.1 Natural history of colorectal cancer
1.1.1 Incidenee of colorectal cancer
Incidence o f colorectal cancer worldwide
Cancer of the colon and rectum is the fourth commonest cancer worldwide 
accounting for 9.7% of all new cancer cases. With an incidence of 500 000 new cases in 
1975, 783 000 in 1990 and approximately 1 000 000 in the year 2000, colorectal cancer is a 
major cause of morbidity and mortality that continues to affect millions of the world’s 
population. It is estimated that colorectal cancer results in 437 000 deaths each year (8.4% 
of all cancer deaths)
Colorectal cancer affects men and women in almost equal proportion accounting for 
9.4% of all cancer incidence in men (third most common malignancy in man) and 10.1% in 
women (second most common malignancy in women).
Colorectal cancer is not distributed evenly throughout the world. Indeed, it is more 
common in westernised countries (North America; Northern, Southern and Western 
Europe; Australasia and New Zealand) with an overall incidence in these countries of 
12.6% and 14.1% in men and women respectively, which is significantly greater than 7.7% 
and 7.9% of all incident cases in men and women in the remaining areas of world. Of these 
Westernised countries, the United States has the highest incidence with 53.1 cases per 100
ooo\
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Incidence o f colorectal cancer in the United Kingdom
Colorectal cancer causes a significant health burden in the United Kingdom with 
over 34 000 new cases diagnosed each year: approximately 18 700 in men and 16 800 in 
women. In both sexes, it accounts for over 16 000 deaths a year in the United Kingdom" .^
In Scotland in 2000, colorectal cancer was the third commonest cancer in both 
sexes with over 3000 new cases diagnosed and 95% occurring in people over the age of 50. 
In 2002, 842 men and 713 women died from this disease^. The majority of colorectal 
cancers occur in the colon with incidence increasing with increasing age. Typically, the 
peak incidence of colorectal cancer occurs in the seventh decade, with over 80% of 
diagnosed patients being over the age of sixty. In comparison, less than 1% of cases are 
younger than 40 years at presentation'*.
1.1.2 Aetiology of colorectal cancer
Colorectal cancers can be classified as: hereditary (isolated gene); familial 
(tendency within family, but unknown gene); colitic (arising from inflammatory bowel 
disease) and sporadic (no family history). It is widely accepted that the majority of 
colorectal cancers arise from pre-malignant adenomatous polyps, the so-called adenoma- 
carcinoma sequence^'^. This multi-step process starts with normal colonic mucosa, but 
from the accumulation of several mutations, ends with malignant adenocarcinoma [Figure 
1]. Colorectal cancer is clonal in origin, but becomes heterogenous by the time patients 
become symptomatic. This process of clonal evolution driven by mutation has been 
confirmed by molecular studies identifying specific gene mutations: p53 and adenomatous 
polyposis coli (AFC). p53 is a DNA binding protein transcriptional activator and can arrest 
the cell cycle in response to DNA damage and is termed the guardian of the genome. AFC
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is a tumour suppressor gene and is called the gatekeeper as it prevents the build up of 
molecules associated with cancer, such as catenins, which if left to accumulate, result in 
oncogene transcription.
Steps can be influenced by genetic mutations, environmental factors or a 
combination of both. With the majority of colorectal cancer cases being sporadic, 
environmental factors are thought to play a large role. However, it has been estimated that 
up to 30% of cases have a genetic component, a number that is likely to change as genetic 
research advances Currently, true hereditary cancer (families with strong histories and 
tumours developing at less than 50 years of age) accounts for less than 5% of colorectal 
cancer cases.
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Figure 1: Proposed adenoma to carcinoma sequence in colorectal cancer.
Adenomatous polyposis coli (AFC) gene mutations and hypermethylation occur early, 
followed by k ras mutations. Deleted in colon cancer (DCC) and p53 gene mutations occur 
later in the sequence, although the exaet order may vary. Environmental influences affect 
normal epithelium and/or hyperproliferative epithelium^®.
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Hereditary Colorectal Cancer
Most hereditary cancers can be attributed to two syndromes: Hereditary Non 
Polyposis Colon Cancer (HNPCC) or Familial Adenomatous Polyposis (FAP). The 
remaining causes are rarer: Peutz-Jeghers Syndrome; Juvenile polyposis; Turcot Syndrome 
and Cowden Disease.
HNPCC or Lynch Syndrome is the commoner of the two syndromes and manifests 
as multiple adenomatous polyps. Patients are diagnosed on average at 45 years with 
tumours being classically right sided and potentially synchronous or metachronous. The 
lifetime risk of developing malignant disease is high at 80% and tumours can change 
rapidly from benign to malignant. HNPCC results from germline mutations in DNA 
mismatch repair genes which normally remove misincorporated single or multiple 
nucleotide bases as a result of random errors during recombination or replications. There 
are several documented mismatch genes involved (MHS2, MLHl, PMSl and PMS2) and 
mutations are particularly demonstrable in DNA with multiple micro satellites 
(microsatellite instability). As only 50% of patients will have mismatch gene mutation on 
genetic testing, diagnosis is made using the Amsterdam Criteria^ ^  or Bethesda Guidelines'^. 
Patients will then undergo routine colonoscopy every 1-2 years alongside investigations to 
exclude other associated malignancies (ovarian, uterine, gastric, small bowel and renal).
FAP is also an autosomal dominant condition and is characterised by multiple 
(hundreds to thousands) adenomatous polyps in the large bowel with extra-colonic 
manifestations (congenital hypertrophy of retinal pigment epithelium, sebaceous cysts, 
desmoid tumours or osteomas). The majority of tumours are left sided and there is an 
associated risk for gastric and duodenal polyps, which have a high chance of becoming 
malignant. FAP also has associations with other malignant diseases: hepatoblastoma;
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medulloblastoma; adrenal; pancreatic; biliary and thyroid. Polyps can appear as early as 
puberty to the second or third decades of life with approximately 100% being malignant by 
the age of 40. FAP has a clearer genotype than HNPCC with 90% of cases resulting from 
mutations of gene for adenomatous polyposis coli (APC) on chromosome 5. These patients 
will undergo yearly colonoscopy with upper gastrointestinal endoscopy every 3 years.
Familial colorectal cancer
In addition to these well recognized syndromes, clusters of colorectal cancer occur 
in families more often than could be explained by chance with immediate family members 
having an increased risk of developing the disease. Postulated reasons for this familial 
group include mild APC and mismatch repair gene mutations, as well as polymorphisms of 
genes involved in nutrient or carcinogen metabolism.
Colitic colorectal cancer -  ulcerative colitis
Compared with the normal population, several studies have shown that patients 
with ulcerative colitis have a 2-8.2 relative risk of colorectal cancer, accounting for 2% of 
all colorectal cancers. One major factor influencing an individual's risk is duration of 
colitis: at 15 years disease duration the risk of malignancy is 5%, which increases to 
between 8 and 13% after 25 years of disease. The extent of disease is also important with 
the presence of pancolitis more likely to develop colorectal cancer. In addition, coexisting 
primary sclerosing cholangitis independently increases the relative risk of ulcerative colitis 
associated neoplasia by 3-15%. Finally, colorectal cancer resulting from ulcerative colitis 
may evolve fi*om microscopic dysplasia with or without a mass lesion rather than from 
adenomas.
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Colitic colorectal cancer — Crohn’s disease
Crohn’s disease was previously thought to carry a smaller risk of cancer 
development than ulcerative colitis. However, it is now thought that the risk is 
approximately the same as the risk for an equivalent extent and duration of ulcerative 
c o l i t i s ^ A  large study from Sweden found a relative risk of colorectal cancer for all 
patients with Crohn’s disease of 2.5 (95% Cl: 1.3 -  4.3)^ "^ . However, the relative risk 
potentially varies with the distribution of disease: ileal disease had no increased risk; 
ileocolonic disease had a relative risk of 3.2 (95% Cl: 0.7 -  9.2) whilst colonic disease 
carried the greatest relative risk of 5.6 (05% Cl: 2.1 - 12.2). These findings suggest that the 
development of Crohn’s related colon cancer develops in the presence of chronic colonic 
inflammation. Indeed it has been noted that as well as a surprising number of cancers 
arising in fistulae and strictures, the majority of tumours in Crohn’s disease arise in the 
proximal colon unlike sporadic and ulcerative colitis related colon c a n c e r ^ . It is 
possible that Crohn’s disease and ulcerative colitis share the same cancer development 
pathway (colitis-dysplasia-cancer pathway) as both can result in adenocarcinoma from flat, 
dysplastic mucosa rather than polypoid adenomas
Environmental factors in colorectal cancer
Descriptive epidemiological studies have assessed colorectal cancer in 
worldwide populations and not only found that different populations have different 
incidences of colorectal cancer, but that these incidences change. Furthermore, within the 
same population, individuals with different lifestyles have different levels of colorectal 
cancer. Migrants provide further evidence of the environment’s influence as they take on 
the colorectal cancer risk of their adopted country after only one generation of children.
38
The majority of research has been performed on potential dietary influences: animal 
fat and red meat; fruit and vegetables and fibre intake. The World Cancer Research Fund 
(WCRF) in 1997 reviewed the scientific and other expert literature linking foods, nutrition, 
food processing, dietary patterns and related factors with the risk of human cancers 
worldwide^®. They stated that evidence for dietary protection against colorectal cancer was 
strongest for diets high in vegetables. There was not sufficient evidence that fruits 
decreased the risk of colorectal cancer with fibre and starches having only enough evidence 
for WCRF to conclude that a decreased risk may be possible. These findings were 
supported by the World Health Organisation^^. They also set out to estimate the overall 
burden of disease resulting from suboptimal ingestion of fruit and vegetables and found 
that poor diets resulted in 2.635 million deaths a year worldwide. They found that by 
increasing daily intake to 600g/day, the burden of colorectal cancer could be reduced by 
2%.
WCRF also assessed lifestyle influences on colorectal cancer risk^ ®. They 
concluded that regular physical activity (to minimise obesity), avoidance of alcohol and not 
smoking all decreased the risk of developing colorectal cancer, findings that have been 
reported by a number of studies^®’^ "^ . When added to positive dietary influences of a 
vegetable predominant diet that is low in meat, they documented that a potential decrease 
in colorectal cancer incidence of 66-75% could be achieved.
High socioeconomic deprivation has been shown to reduce survival in patients with 
colorectal cancer^^"^ .^ One such study assessed socioeconomic status in 21 905 patients 
with colorectal cancer in England and found significant differences in 5 year survival 
between the most and the least affluent group (40% and 32% respectively)^^. Several 
potential explanations were proposed: delay in patient presentation; more advanced disease
39
at initial presentation or variations in treatment options. However, a study in 2002 
analysed outcomes after pathologically confirmed curative resection in 2269 patients with 
colorectal cancer in varying socioeconomic groups. The authors found poorer overall and 
cancer specific survival rates in the deprived patients^^. Furthermore, there were no 
significant differences between affluent and deprived groups in: mode of presentation; 
extent of disease; proportion of patients undergoing curative resection or postoperative 
mortality. The authors concluded that the tumour-host response, particularly the systemic 
inflammatory response may be involved.
The presence of an elevated systemic inflammatory response has been shown to 
predict reduced disease-free survival and long-term survival in several different types of 
malignant disease^ '^ '^ .^ Colorectal cancer is one of these diseases, with an elevated 
preoperative C-reactive protein predicting reduced time to recurrence, overall survival and 
cancer specific survival in patients undergoing curative resection, independent of cancer 
stage^ '^^  ^ . The exact mechanism behind the increased C-reactive protein is unclear with 
reduced tumour T-lymphocyte infiltration (particularly CD4+ T-lymphocyte infiltration) 
being proposed^^. One study compared socioeconomic deprivation and the systemic 
inflammatory response in 158 patients undergoing curative resection for colorectal 
cancer^^. The authors found that both high deprivation and raised C-reactive protein 
predicted poorer overall survival, independent of tumour stage, after resection. However, 
only elevated C-reactive protein predicted poorer cancer specific survival, leading the 
authors to conclude that the presence of a systemic inflammatory response preoperatively 
has a greater impact on cancer spécifié survival than deprivation.
The influenee of gender on the incidence of colon cancer has been researched with 
analysis of any potential protective effect of hormone replacement therapy. In 2002, the
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Women’s Health Initiative recruited 16 608 postmenopausal women with an intact uterus 
and randomised them to receive hormone replacement therapy (oestrogen and 
progesterone) or placebo'^®. The primary outcomes were the development of coronary heart 
disease and/ or invasive breast cancer, with the development of colorectal cancer, alongside 
other event categories, a secondary aim. After a mean follow up of 5.2years, the estimated 
hazard ratio for colorectal cancer was 0.63 (95% Cl 0.43-0.92) with an absolute risk 
reduction per 10 000 patients of 6. This was the first randomised study and is supported by 
similar findings from two observation studies that have provided enough evidence for 
policy makers including the United States Preventive Service Task Force for chronic 
diseases acknowledging the protective effect of HRT on colorectal cancer development 
A  potential meehanism may be the loss of expression of oestrogen receptor beta. This 
receptor is the predominant oestrogen receptor in colon tissue whose loss correlates with 
increasing Dukes stage and subsequently poorer outcome^^.
1.1.3 Staging and Prognosis of colorectal cancer
After pathological analysis of a biopsy specimen confirms a colorectal 
adenocarcinoma, each patient undergoes staging. Staging is the process of determining the 
local invasion of the primary tumour and the extent of metastatic disease. For colorectal 
cancer this involves preoperative visualisation of the entire lower gastrointestinal tract via 
colonoscopy and radiological imaging of the chest, abdomen and pelvis. Staging serves 
multiple purposes according to the American Joint Committee on Cancer (AJCC)"^ :^ 
planning of appropriate treatment (including consideration of surgical resection); 
indication of prognosis (by staging classifications) and evaluation of the results of 
treatment (i.e. neoadjuvant chemo/radiotherapy).
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Cuthbert Dukes introduced his staging classification in 1932'^ .^ His simple, 
reproducible and clinically relevant classification, initially intended for the staging of rectal 
cancer, is still in widespread use for colorectal cancer today. Dukes divided his 
classification into 3 stages according to the extent of direct and lymphatic tumour spread: 
Dukes A (tumour confined to bowel wall), Dukes B (tumour extends beyond rectal wall, 
but no lymphatic involvement) and Dukes C (tumour has metastasised to regional lymph 
nodes). Dukes classification has undergone modification since 1932 with stages B and C 
subdivided into 1 and 2 and the introduction of distant métastasés as stage D [Figure
The Dukes classification is simple, but this simplicity is also its disadvantage, with 
no account taken of the depth of penetration of the primary tumour or the number of lymph 
nodes involved. The TNM staging was introduced in the 1950s and provides this missing 
information [Figure 3]^*. Subsequently, TNM has developed a prominent clinical role in 
colorectal cancer as well as other malignancies including: breast; gastroesophageal; 
ovarian; bladder and prostate"^ .^ TNM staging can be translated easily into the equivalent 
Dukes stage shown in Table 1.
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Figure 2: The Modified Dukes Classification of colorectal cancer
Stage Description
A limited to mucosa
B 1 extension into, but not through, the muscularis propria
B2 extension through the muscularis propria, no nodal involvement
C 1 limited to bowel wall, métastasés in the lymph nodes
C2 extension through bowel wall, métastasés in the lymph nodes
D distant métastasés
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Figure 3: International Union against cancer: TNM classification of Colorectal cancer 
Tum our (T):
TX primary tumour cannot be assessed 
TO no evidence of primary tumour 
Tis carcinoma in situ 
T1 tumour invades submucosa 
T2 tumour invades muscularis propria
T3 tumour invades muscularis propria into subserosa, or into non-peritonealised pericolic 
or perirectal tissues
T4 tumour invades other organs or structures and/or perforates visceral peritoneum 
Nodes (N):
NX nodes cannot be assessed 
NO no regional lymph nodes metastasis 
N1 metastasis in 1 to 3 regional lymph nodes 
N2 metastasis in 4 or more regional lymph nodes
Métastasés (M);
MX distant métastasés cannot be assessed 
MO no distant métastasés 
M l distant métastasés
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Table 1: Comparison of grades between Dukes’s classification and TNM staging
Dukes TNM Stage T N M 5-year survival (%)
A I T1 orT2 NO MO 90
B II T3 or T4 NO MO 75
C III Any T N1-N2 MO 35-60
D IV Any T AnyN Ml <10
Table modified from International Union Against Cancer.48
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1.1.4 Treatment of Colorectal cancer
Surgery for colorectal cancer
Curative surgical resection of colorectal cancer is the current optimal treatment with 
recent domestic and international figures documenting declining rates of death"^ '^^ .^ In 
1976, the Scottish Cancer Intelligence Unit documented a death rate of 33.6 per 100 000 of 
population in males and 26 in females. Figures in 2001 show improved rates with 24.4 per 
100 000 in males and 14.8 in females, declines of 21% and 29% respectively. One study 
translated these declines into 5 year survivals of 40.1% (1974-1979) and 60.5% (1991- 
1994) after curative surgical resection^'^.
The Association of Coloproctology of Great Britain and Ireland (ACPGBI) issued 
guidelines for the management of colorectal cancer that were updated in 2001^^.
Colonic surgery should be considered in all patients and performed depending on 
the tumour/s sites: right hemicolectomy (lesions of the caecum, ascending colon and 
hepatic flexure); left hemicolectomy (lesions of the splenic flexure and descending eolon) 
and sigmoid colectomy (sigmoid colon). Curative resection is based upon histological 
confirmation of complete excision of the tumour.
Total mesorectal excision (TME) is recommended for cancer in the lower two thirds 
of the rectum as part of an abdomino-perineal resection or low anterior resection. Local 
excision with curative intent should be restricted to T1 tumours, but it must be accepted 
that a small percentage of these will be found to be more advanced on pathological analysis 
and will require further surgery.
Laparoscopic and laparoscopic-assisted colonic surgery have shown promising 
initial results documenting improved morbidity and mortality when compared to open
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colonie surgery There is limited research on laparoscopic rectal surgery which has 
commented on a potential reduction in local recurrence, but as with colonic surgery, long 
term results are required before any definitive decision can be made. Currently, the 
ACPGBI recommends that laparoscopic surgery be performed only by experienced 
operators as part of one of the national trials^^.
Chemoradiotherapy in colorectal cancer
In patients undergoing planned surgical resection, the surgeon must consider when 
and if chemotherapy and/ or radiotherapy will form part of their patient’s treatment. These 
additional therapies can be given either preoperatively (neoadjuvant) or postoperatively 
(adjuvant).
In 1990, a Consensus Conference of the National Institutes of Health strongly 
recommended adjuvant treatment in patients with stage III colon cancer and stage II and III 
rectal cancer^^. This postoperative chemotherapy is based around 5-fluorouracil (5-FU) 
which has a substantial evidence base with one meta-analysis concluding adjuvant 
chemotherapy may reduce the likelihood of death by 10-15% in patients with colorectal 
cancer
More recent trials have focused on combining 5-FU with other chemotherapy 
agents (5-FU/leucovorin or 5-FU/levamisole) with comparative studies finding improved 
disease free survival and overall survival with the 5-FU/leucovorin combination As a 
result, this combination is used widely in clinical practice for stage III/ Dukes C colorectal 
cancers and more recent research is looking at further combinations including irinotecan 
and oxaliplatin.
47
The benefits of chemotherapy in Dukes C cancers raise the question of treating 
Dukes B colorectal cancers. However, the evidence is conflicting, leading several authors, 
including the ACPGBI, to recommend that clinicians decide on an individual basis, 
carefully balancing the side effects of chemotherapy against subsets of stage II that carry a 
poorer prognosis (serosal involvement, extramural vascular invasion, poorly differentiated 
histology)^^’^ .^
Rectal cancer differs from colonic cancer due to the high risk of local recurrence 
that may prove to be fatal. As a result, researchers have assessed the benefits of 
neoadjuvant radiotherapy to the primary rectal tumour in stage II and stage III cancer and 
found that patients show good tolerance as well as improved local control, disease free 
survival and overall survivaf^'^^. It also appears that the combination of chemotherapy and 
radiotherapy may be better than radiotherapy alone as 5-FU is a radiosensitiser^^’^®.
In the postoperative setting, chemoradiotherapy has also shown to be beneficial 
after resection of a rectal tumour resulting in 10-20% of patients having pathologically 
proven complete remissions^^’®’^ ’^^ .^ However, preoperative chemoradiotherapy remains 
the preferred approach (especially in Europe) due to: greater efficacy of radiation therapy 
on well-oxygenated cells (as opposed to the relative ischaemia of remaining cancer cells in 
the postoperative pelvis); decreased spillage of viable tumour cells at the time of operation; 
down staging of the tumour and avoidance of radiating the anastomosis. One active area of 
research is the determination of the optimal chemotherapy agent for combined 
chemoradiotherapy, with new agents currently being assessed (capecitabine, uracil and 
tegafur)^^. There is no evidence for radiotherapy in the management of colonic cancers.
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Inoperable primary colorectal cancer
For a number of patients with colorectal cancer, surgical resection will not be an 
option. The main reasons for this include: advanced local disease that cannot be resected; 
high patient co-morbidity for a general anaesthetic or a combination of the two. There are 
several treatment options.
If the primary disease is rectal cancer that is locally advanced, the outlook is poor, 
with no evidence that surgical resection improves prognosis^^. If the patient is fit (i.e. 
could undergo a general anaesthetic), then the ACPGBI recommend a course of either 
radiotherapy alone or in combination with chemotherapy to see if the tumour can be down 
staged, making resection a future possibility^^. Chemoradiotherapy can also be 
administered to patients whose rectal cancer is unlikely to become resectable, but where a 
decrease in bulk could improve symptomatic control (pain in particular) leading to 
improved quality of life. A similar approach is proposed by the ACPGBI for the 
management of unresectable colonic cancer where a course of chemotherapy may allow 
down staging of the primary tumour leading to surgical resection.
Palliative options for both rectal and colonic cancers should be considered 
especially if the tumour is causing obstructive symptoms. These include: defunctioning 
colostomy or ileostomy; endorectal metallic stent insertion or transanal tumour ablation 
using laser or electrocoagulation There is some debate as to whether surgery should be 
performed to resect as much of the primary tumour as possible to prevent future 
complications including the aforementioned bowel obstruction and bleeding, however the 
literature consists of non-randomised small trials leaving many to conclude that the 
decision should be made on an individual case basis^ "^ .
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1.2 Natural history of colorectal liver métastasés
1.2.1 Incidence of colorectal liver métastasés
Colorectal cancer has an inherent tendency to spread in progressive stages: 
local, then lymphatic, followed by haematogenous and/or transcoelomic. As a result 
colorectal cancer can spread to many organs including: liver (>50%); lung (5%-50%); 
adrenal gland (14%); ovary (3%-8%); bone (5%); brain (5%) and mesentery (10%)^^. The 
venous drainage of colon cancers is directed to the portal vein making it uncommon to have 
distant métastasés without associated disease in the liver. In contrast, the venous drainage 
from rectal tumours can be directed into both the portal and systemic venous systems 
allowing haematogenously disseminated disease that can bypass the liver.
As a result, almost 50% of patients with colorectal cancer will develop liver 
métastasés: up to 25% will have liver métastasés at time of initial presentation with the 
remaining 25% developing liver métastasés during the course of their disease^^"^ .^ Death 
from hepatic métastasés accounts for a large percentage of colorectal cancer mortalities and 
if left untreated the prognosis is poor with median survival from 5 to 21 months with 
almost zero alive at 5 years^ '^^ "^ .
1.2.1 The metastatic process
The metastatic spread of colorectal cancer is a complex process. Colorectal cancer 
has a clonal (single cellular progenitor) origin, but eventually the primary tumour becomes 
heterogenous with multiple subpopulations of cells with varying metastatic potential that 
then have to undergo a multitude of steps to metastasise: selection for detachment of 
primary tumour cells; invasion through the extracellular matrix; migration through blood
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and/ or lymph channels; reattachment to a distant organ; growth and angiogenesis within 
the distant organ and further spread from distant organ to other distant organs® '^^ .^ Each 
stage involves a different set of proteins including: adhesion molecules; matrix degrading 
proteins; endothelial cell receptors and immunological recognition factors. With so many 
steps involved it is not unexpected that molecular research has not clarified the exact 
mechanisms driving the metastatic process.
Research has investigated why the liver is the first targeted organ for métastasés. 
Two theories exist to explain this targeting: homing theory and cascade theory. The first 
believes that it is a property of the metastasising tumour cell to target the appropriate liver 
receptor. This homing theory proposes a non-random, highly organised multistep process, 
which will require years of research to clarify. However, if clarified may offer highly 
specific therapeutic solutions. In contrast, the cascade theory describes a random process. 
With the liver being the main site for venous drainage of the lower gastrointestinal tract, 
the millions of tumour cells that are released into the bloodstream filter through the liver 
and by a process of volume will eventually become embedded in the liver, leaving fewer 
cells to go elsewhere. If the cascade theory is true, then metastatic hepatic spread could be 
difficult to control therapeutically, with prophylactic liver chemotherapy potentially an 
option. It may well be that as molecular genetics progresses, that features of both theories 
are proved correct.
It is thought that lymphatic spread has a limited role in colorectal liver métastasés 
primarily because there are no direct lymphatic channels connecting the colon or the 
rectum directly to the liver. However, it is possible that lymphatic spread could result from 
the pericolic to the para-aortic lymph nodes or from entering the blood system where the 
lymphatics drain directly into the superior vena cava via the thoracic duct. Therefore, in
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patients with colorectal cancer it is uncommon to find metastatic lymph nodes along the 
hepatic artery (irrespective of liver involvement) without lymph node involvement at the 
primary tumour site.
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1.3 Detection of colorectal liver métastasés
1.3.1 Radiological imaging
Radiological imaging plays a fundamental role in the current management of 
colorectal liver métastasés and has several functions: to make an accurate diagnosis of 
métastasés and to differentiate from benign conditions; to clarify the number, size and 
position of métastasés in assessment for potential hepatic resection and to detect changes in 
clinical state after treatment.
Preoperative radiological imaging — transabdominal ultrasound (US)
Ultrasound has been in medical use since the 1950s. It is based upon the pulse-echo 
principle, where pulses of high frequency sound waves are transmitted into the patient, 
reflected off tissue boundaries and returned to the machine as echoes
Initially the instruments were cumbersome and the images were poor in quality. 
The development of real time imaging (or B-mode) and the linking of US to a computer 
(computed sonography) in the 1970s, dramatically improved these problems and took US 
forward to becoming part of routine assessment in many areas, including colorectal liver 
métastasés.
US has many advantages over other available imaging modalities and can be 
applied directly to the skin or directly on to the organ being visualised allowing it to be 
used trans-abdominally, laparoscopically and intra-operatively. The machines are usually 
mobile, if not hand-held, allowing US to be used anywhere. In addition, US is not 
radioactive, easy to perform, well tolerated by patients and takes only a small amount of 
time to perform a fiill examination.
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However, it is widely accepted that transabdominal ultrasound is less sensitive and 
specific in the visualisation of liver métastasés when compared to other imaging modalities 
with the range of documented sensitivity from as low as 53% to as high as 90% This 
wide range is likely a reflection of varied reference standards used in each study and that 
US is operator dependent. As well as interference from body tissues (subcutaneous fat, 
muscle) reducing the acoustic signal, the detection and specificity of US decline as liver 
métastasés become less than 2cm in size^^. In one study, the sensitivity of ultrasound for 
detecting lesions less than 1cm was less than 20%
Preoperative radiological imaging — computerised tomography (CT)
Along with transabdominal US, CT is considered a primary diagnostic tool for 
staging and has the added advantage over US of determining resectability of colorectal 
liver métastasés, CT technology has advanced greatly and it is now widely accepted that 
all CT scans should be contrast-enhanced for superior sensitivity and specificity. In fact, 
un-enhanced CT is likely to produce a poorer image than un-enhanced ultrasound
Carter and co-workers in 1996 compared unenhanced axial CT to pre-operative 
percutaneous US, intra-operative US and findings at laparotomy in 40 patients with 
resectable colorectal liver métastasés They found that CT had a higher sensitivity (94%) 
than percutaneous US (77%). This finding is supported by other early studies that used 
various CT technologies with the sensitivities ranging fi*om 38% to 88%^^’^ '^^ .^
More recent studies using enhanced CT have provided evidence of a higher 
sensitivity and specificity when compared to percutaneous US However, when all the 
studies comparing US with differing types of CT are combined, it becomes apparent that
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with declining lesion size, the accuracy of CT declines accordingly. Therefore, further 
improvements in CT are still required to detect reliably sub-centimetre liver lesions.
Preoperative radiological imaging —magnetic resonance imaging (MRI)
MRI has undergone several recent technological developments, including the 
introduction of liver-specific contrast agents and breath-hold acquisition imaging.
Superparamagnetic iron oxides (SPIO) such as ferumoxides were initially described 
in 1987. Ferumoxides are dextran compounds that are predominately phagocytosed by 
macrophages in the liver and spleen. Normal liver parenchyma contains Kupffer cells 
which phagocytose ferumoxides, reducing the signal intensity. In contrast, liver métastasés 
which do not contain any Kupffer cells remain unaffected and are displayed as areas of 
high intensity signal on MRI.
As the majority of radiology departments in the U.K. have both CT and MRI 
scanners available, there has been much research comparing CT with MRI. A recent study 
by Reimer et al compared spiral CT (enhanced) with unenhanced MRI and ferumoxide 
enhanced MRI. Superior lesion detection was found with ferumoxide enhanced MRI and a 
combination of ferumoxide enhanced MRI and unenhanced MRI. These results are 
replicated in a similar study by Bluemeke et al with both papers concluding that 
enhanced MRI was superior to enhanced CT in the detection of liver métastasés. 
Furthermore, the combination of unenhanced and enhanced MRI was the superior 
technique in lesion characterisation. Although unenhanced MRI is generally accepted to be 
less sensitive than enhanced, it may have decreased the number of false positives that can 
result with enhanced MRI as there is documented difficulty in distinguishing small lesions 
from peripheral vessels that become more conspicuous after SPIO enhancement
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Another recent study by Ward et al (1999) examined 51 hepatic resection 
candidates. Patients underwent SPIO MRI and dual phase helical CT with the reference 
standard being intraoperative ultrasound, surgical palpation and histopathology. This study 
found statistically higher sensitivity with SPIO MRI when compared to CT (79.8% and 
75.3% respectively) in the detection of all liver lesions.
Kinkel et al performed meta-analysis of various non-invasive imaging modalities 
in the detection of liver métastasés. Although the authors accepted that a limitation of their 
meta-analysis was poor documentation of exact imaging modalities performed in the 
studies reviewed, they found mean weighted sensitivities (specificity higher than 85%) of 
55% for conventional ultrasound, 72% for CT (helical, non-helical, enhanced and 
unenhanced) and 76% for MRI (enhanced and unenhanced). Overall, research documents 
marginally improved detection of hepatic métastasés with MRI, particularly when 
ferumoxide enhanced, when compared to CT
There are disadvantages with MRI. Due to the nature of the scan, it cannot be used 
in patients with internal metal. Ferumoxides are not the only contrast agent available to 
MRI, but are the most expensive when compared to gadolinium. Ferumoxides also have 
some side-effects such as low back pain and a long infusion time.
Preoperative radiological imaging -  positron emission tomography (PET)
Positron emission tomography (PET) is a relatively new imaging technique that 
evaluates cell metabolism using a glucose analogue, [^ ^F] fluoro-2-deoxygenase (^^FDG). 
This is quite different to CT and MRI in that it relies on changes in metabolic or 
physiological functions, rather than morphology, to detect disease. Therefore, it has the 
potential to demonstrate métastasés before structural changes are detected.
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Certain malignant cells including colorectal cancer have increased glucose 
utilisation which can be caused by increased glucose transport proteins and/or increased 
enzyme levels of hexokinase and phosphofructokinase that promote glycolysis Like
glucose, ^®FDG is transported intracellularly then phosphorylated by hexokinase to FDG-6- 
phosphate. Unlike glucose, FDG-6 phosphate becomes trapped intracellularly as it is 
negatively charged with low membrane permeability After intravenous administration, 
^^FDG accumulates in colorectal liver metastasis and performing a PET scan displays these 
tumours as areas of high glycolytic activity.
Currently the role of PET in assessing primary colorectal cancer is undetermined, 
however, the value of PET in the detection of recurrent colorectal cancer is well established 
I03;i07-ii3^  The aforementioned meta-analysis by Kinkel et al compared non-invasive 
radiological imaging methods in the detection of hepatic métastasés from gastrointestinal 
malignancies Their analysis included 111 data sets including approximately 3000 
patients [Table I]. The mean weighted sensitivity was calculated for studies with 
specificity higher than 85%. The mean weighted sensitivity for detection of recurrent 
colorectal cancer with FDG-PET was 90% (MRI 76%, CT 72% and US 55%). 
Statistically, FDG-PET was significantly superior to ultrasound and CT. The authors 
concluded that FDG-PET is the most sensitive non-invasive imaging method for the 
detection of hepatic métastasés for colorectal cancer.
In general, the published literature suggests that PET should be first line in 
recurrent colorectal disease as it would allow optimal preoperative identification and 
characterisation of extrahepatic disease, especially in the presence of an elevated 
carcinoembryonic antigen (CEA) 109,110,114-116^
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The major disadvantage of PET is that it cannot determine the extent or depth of 
tumour involvement. As the clinical decision to operate is determined by the anatomical 
position of the liver métastasés (which is information that PET cannot supply), PET has to 
be used in conjunction with CT or MRI to determine resectability.
There are limitations of the use of FDG since it is not tumour specific and any 
tissue with increased tissue metabolism will accumulate FDG and give a false positive 
result. Therefore, a positive result in patients with inflammatory bowel disease, diabetes or 
lung disease should be viewed with caution and a CT or MRI scan arranged to provide 
fiirther information It is generally accepted that performing PET several months after 
any treatment as part of surveillance will reduce the likelihood of false positive results
106;II8;119
Another limitation is that although the majority of colorectal liver métastasés do 
display increased uptake, there are some that do not, particularly the smaller liver 
métastasés. Therefore, these métastasés would remain occult to a FDG-PET scan
Preoperative imaging modalities -  hepatic perfusion measurement
The liver is unique in that it has a dual blood supply. Normal healthy hepatic 
parenchyma derives its main blood supply from the portal vein, with a smaller contribution 
from the hepatic artery. The presence of hepatic métastasés alters the hepatic blood supply 
causing the hepatic artery to be the predominant supplier. Original evidence for this altered 
blood supply comes from both animal and human angiography studies with one of the 
earliest studies was by Breedis and Young in 1954^^\ From their previous unpublished 
work investigating hepatic circulation in rabbits, they found that although hepatic 
parenchyma stained when India ink was injected in to the portal vein, the hepatic tumours
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did not However, the tumours did stain when the injection was into the hepatic artery, 
suggesting that the tumours were supplied mainly, perhaps even exclusively, by arterial 
blood.
In their following experiments using both animal tumour models and human 
autopsy specimens, they injected colloidal pigments (India ink, carmine, gelatine, Prussian 
blue, vinyl acetate) into the hepatic artery and portal vein then fixed the sample in formalin. 
After fixation the specimens were sliced, stained with haematoxylin to visualise the vessels 
that were then counted. The authors confirmed their hypothesis that liver métastasés were 
predominately supplied by the hepatic artery irrespective of the primary tumour, with the 
hepatic artery contributing between 80% - 100% of the blood supply. Microscopically, the 
decreased portal vein contribution was thought to result from the neoplasm invading and 
subsequently occluding the portal branches.
A series of four papers from Ackerman et al from 1969 to 1974 continued the 
investigation in to the alteration in blood supply in colorectal liver metastases^^^"^^ .^ In 
their first paper the authors used isotope distribution (radioiodinated human serum albumin 
and yttrium-90 microspheres) to assess vascularity in animal models. They found that 
small tumours (less than 30mg) were fed by a combination of the hepatic artery and portal 
vein whilst large tumours (more than 30mg) received their main blood supply from the 
hepatic artery.
Their second paper used perfused silicone rubber to assess the microvasculature in 
Walker-256 carcinosarcoma implanted rats (tumour size 25-75pim). They injected silicone 
into 47 animals in various combinations: artery only; portal vein only or artery and portal 
vein together. After preparation, the sections were examined under the microscope. Of the 
nine animals that were perfused via the hepatic artery, the silicone formed a plexus of
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irregular vessels at the periphery of the tumour that were seen to be adjacent to hepatic 
artery branches. In addition, some vessels of the portal vein were also filled. However, in 
the animals that were perfused by the portal vein (n=8), a typical branching pattern of 
treelike vessels was displayed that stopped short of the of the tumour plexus displaying a 
clear line of demarcation between liver and tumour. This not only confirmed that the 
hepatic artery solely supplied the tumour plexus, but suggested that one way hepatic artery 
to portal vein shunting may be present.
In the combined portal vein-hepatic artery perfusion group (n=14), two different 
colours of perfused silicone were used to determine the origin of the silicone. Again, the 
plexus of vessels at the tumour edge filled from the arterial route, whilst mixing of the 
colours was seen proximally to the tumour.
In the last group (n=16), the hepatic artery was ligated (in some animals the ligation 
was performed at the same time as tumour implantation, whilst in the remainder the artery 
was ligated 4 days after implantation) then the liver perfused via the portal vein followed 
by the aorta. Nine of the animals showed no tumour perfusion, reinforcing that the hepatic 
artery is the main tumour supplier. However, in the remaining 7 animals, the ring of 
tumour vessels was filled by the portal vein perfusion suggesting the portal vein can feed 
tumours after hepatic surgery ligation, a role that Nilsson and Zettergren have also 
documented, but not explained^
Ackerman’s group explored this unexpected finding in their next paper where they 
ligated the hepatic artery or the portal vein in Walker-256 carcinosarcoma implanted rats, 
then injected radioactive tracers into the aorta or portal vein respectively. In conjunction 
with their previous findings, acute ligation of the hepatic artery resulted in a significantly 
decreased tumour/liver radioactivity ratio. This decrease was greater than the decrease
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found with acute portal vein ligation, which is an expected finding due to the portal vein 
making a smaller contribution to the tumour as well as the known existence of 
unidirectional shunts from the arterial tree to the intrahepatic venous system. However, 
venous to arterial shunts have not been shown to exist and the authors proposed an acute 
coping mechanism for hepatic artery ligation as the tumor/liver ratio returned to levels seen 
in unligated animals four days later.
The authors found more complexities in their last paper, where the contribution of 
the hepatic artery and portal vein changed according to the size of the tumour. Using the 
same animal models, the authors classified the tumour into groups of small (l-2mm), 
moderate (3-7mm) and massive (7-33mm). Again, perfused silicone was used to assess 
tumour blood supply. Results found that small tumours had a variable blood supply that 
could be arterial, venous or both in origins. Moderate sized tumours had well developed 
arterial circulations that concur with their previous work in paper 2. Finally, massive 
tumours returned to a varied pattern. This paper reflects the varied results from many 
authors analysing the vascularity of c a n c e r s W i t h  different techniques and patient 
and animal populations, definite conclusions are difficult to draw, particularly as 
vascularity appears continually to change.
Researchers have taken advantage of this alteration in blood supply to clinically 
detect colorectal liver métastasés. In 1983, Leveson and co-workers acknowledged the 
restriction of imaging modalities at that time to detect reliably small liver lesions and 
assessed in a prospective non-randomised trial, dynamic scintigraphy as a method of 
studying hepatic arterial and portal blood fiow^^^. Fifty-nine patients with either colorectal 
or gastric carcinoma underwent dynamic flow scintigraphy and static isotope scans that 
were compared to values obtained from twenty healthy volunteers. To calculate the two
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components of hepatic blood flow, a region of interest was drawn over the right kidney and 
the right lobe of liver from the stored dynamic scintigraphy images. This allowed time- 
activity curves to be generated with the peak of the kidney curve used to determine the 
division between the arterial and portal phases of the liver curve. The gradients of the two 
liver phases were calculated and the hepatic perfusion (HPI; arterial inflow gradient 
divided by total hepatic inflow) calculated for each patient/control. The HPI were then 
compared between controls, primary cancer only patients and patients with metastatic 
cancer with the diagnosis of métastasés taken from laparotomy and static isotope scans.
The authors found that 96% of all patients with metastatic disease at laparotomy 
had abnormal perfusion indices (>0.42). The controls in contrast, all recorded normal HPI 
providing initial evidence that dynamic scintigraphy could provide improved detection of 
liver métastasés. What is particularly interesting about this technique, which differs from 
the historical studies documenting altered blood supply, is that the region of interest was 
always placed over the right lobe of the liver, irrespective of the tumour position. Indeed, 
the HPI was recorded as abnormal in patients whose tumour/s were placed in the left lobe 
suggesting either the region of interest is detecting disseminated micrometastases in the 
right lobe or that the alteration in blood flow appears throughout the liver at the level of the 
microcirculation. The authors concluded that these were initial findings and further 
evidence was necessary to determine the clinical role of dynamic scintigraphy.
This group provided the further evidence in 1985 when 150 patients with 
gastrointestinal cancers underwent preoperative dynamic scintigraphy^^^. Again, regions of 
interest were drawn over the right kidney and right liver lobe. Gradients were calculated 
for arterial and venous inflow allowing the HPI to be generated for each patient. Twenty- 
three healthy volunteers were recruited which defined the upper limit of the normal range
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of HPI to be 0.42. Similar detection rates were found in patients with overt liver 
métastasés at laparotomy, where HPI was elevated in 94% of patients (n=47/50). In the 
remaining group with no apparent hepatic métastasés, 50 had one year follow up. Eighteen 
had developed clinically detectable hepatic métastasés all of which had elevated HPI prior 
to resection of their primary, resulting in a positive predictive value of 72% at one year and 
a negative predictive value of 98%.
As imaging technology progressed (primarily in computed tomography) the 
standard of reference for dynamic scintigraphy elevated. Several authors published trials 
that found HPI able to detect overt hepatic métastasés, but of varying predictive value in 
the detection of occult metastases^^'^’^ ^^ . One of these studies concluded by saying that 
although the HPI is weak at detecting occult liver métastasés, an abnormal HPI is 
associated with poor outcome in patients undergoing potentially curative resection for 
colorectal cancer and could be an indication for adjuvant t h e r a p y W i t h  further 
problems with reproducibility, HPI never became routine clinical practice.
The use of Doppler ultrasound in the measurement of hepatic perfusion to detect 
liver métastasés was introduced in 1991 by Leen et al^^ .^ The authors hypothesised that 
duplex sonography would be a simpler and more reproducible technique as it has the 
capacity to measure hepatic blood flow directly. By measuring the cross sectional area and 
blood flow within the hepatic artery and portal vein, the Doppler Perfusion Index could be 
calculated (DPI = hepatic arterial flow / (hepatic arterial flow + portal venous flow).
The authors recruited 46 patients: 16 healthy controls; 11 patients with colorectal 
cancer but apparently disease free livers and 19 patients with overt colorectal liver 
métastasés. The mean DPI results were: controls 0.13 ± 0.07; overt liver métastasés 0.52 ± 
0.13 and disease free patients 0.39 ± 0.17. With clear separation of the control and overt
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liver métastasés groups, the authors proposed that DPI may have the potential to detect 
métastasés below the limits of conventional imaging techniques. The same group extended 
their recruitment and found similar promising results
Further research followed up 68 patients that had DPI measured prior to undergoing 
potentially curative colorectal resection. 38 of these patients had abnormally elevated DPI 
(upper limit of normal 0.25 established from control group) with 21 developing liver 
métastasés by one year follow up. Of 30 patients that had a normal DPI, all remained 
disease free at 1 year.
These results were extremely promising and to overcome potential criticism on 
operator variability a reproducibility study was performed^ Two independent blinded 
sonologists performed DPI on 20 patients and then a further 20 patients were recruited that 
underwent repeated measurements of DPI to determine intraobserver variability. The 
interobserver and intraobserver coefficient of variations were 20% and 16% respectively 
with agreement on DPI in 90% of cases. Leen et al then followed up patients for 5 years 
after resection and concluded that DPI can be used to identify patients at high risk of 
recurrence and that DPI should be incorporated in to widespread clinical practice.
To date, few investigators from other centres have managed to replicate 
successfully Leen et a fs  r e s u l t s I t  is has been suggested that the technique is too 
operator dependent and may require a period of specialist training. In addition, the 
principle of DPI may be flawed, as it measures directly the macroscopic blood supply 
which has been shown to vary in as many as 30% of normal healthy individuals^"^ .^ 
Roumen et al published their findings on the application of DPI in 133 patients with 
colorectal cancer and followed them up for 4 y e a r s I n  addition to reliable DPI
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measurements not being attainable in 29 patients, DPI using the previous normal range did 
not predict the presence of occult liver métastasés.
Invasive imaging modalities -  intraoperative ultrasound (lOUS)
lOUS was developed to combine the practicality of conventional ultrasound with 
the advantage of directly placing the probe over the liver. It was theorised that this direct 
placement would prevent the image degradation that often occurs as the sound beam 
traverses the layers of fat and muscle that comprise the body wall.
Machi et al. evaluated and compared the accuracy of lOUS to percutaneous 
ultrasound, conventional CT and surgical exploration^Intra-operative ultrasound was 
the most sensitive modality in assessing colorectal liver métastasés diagnosing 93.3% of 
métastasés. Pre-operative ultrasound diagnosed 41.3%, CT 47.1% and surgical exploration 
66.3%. Furthermore, intra-operative ultrasound imaged 22 liver métastasés that none of the 
other modalities did. These 22 métastasés were small in size (4 x 4mm to 15-18mm) 
proving that intra-operative ultrasound can visualise tumours less than 1 cm. One reviewer 
comments that intra-operative ultrasound may detect lesions as small as 2mm if they lie 
close to the liver surface Several studies have reported similar findings with resultant 
significant changes in surgical management. As a result, there is widespread acceptance of 
intra-operative ultrasound as the optimal modality for hepatic métastasés imaging
The main drawback with intra-operative ultrasound is the requirement for a 
laparotomy. The worst case scenario is when lOUS detects further lesions and /or 
unexpected locally advanced disease, leaving no surgical resection options. As a result, the 
patient has undergone an unnecessary laparotomy.
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Invasive imaging modalities — laparoscopic ultrasound (LUS)
Laparoscopic ultrasound uses the improved accuracy of lOUS whilst preventing 
patients from an unnecessary laparotomy. Research has documented improved imaging of 
the liver with LUS compared to conventional US and CT, leading to altered patient 
management Rahusen et al found laparoscopic ultrasound prevented unnecessary
laparotomy in 25% of patients when compared to pre-operative enhanced CT and 
percutaneous US^^ .^ However, in patients that have proceeded to laparotomy, lOUS 
detected a small number of previously missed métastasés and it has been suggested that 
there may be a significant learning curve with laparoscopic ultrasound. Laparoscopic 
ultrasound is not a suitable procedure for all patients, especially the clinically obese, 
previous laparotomies and those patients with chronic pulmonary pathology.
Invasive imaging modalities — computed tomography arterial portography (CTAP)
CT arterial portography (CTAP) is an invasive technique that has a high sensitivity 
of 85-91% in the detection of colorectal liver métastasés However, this technique
has a high rate of false positives due to perfusion defects that may result in inappropriate 
conservative treatment In addition, CTAP has a decline in sensitivity to 61-79% for 
lesions less than 1cm. As a result of these limitations and because as an invasive test it 
could never be used for screening, CTAP has struggled to become part of routine practice
96;1S7-161
Preoperative imaging modalities — recent advances
Contrast-enhanced ultrasound (CE-US) is a technique that dates back to 1968, but 
interest has increased recently due to the development of a new generation of contrast
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agents These contrast agents consist of microbubbles that contain air or
perfluorocarbon gas contained in an outer shell of denatured albumin, lipid or surfactant. 
These microbubbles are capable of modifying the acoustic properties of the liver, 
improving the ultrasound visualisation of colorectal liver métastasés
New imaging modes have been developed to maximise the effects of microbubbles: 
Pulse Inversion Harmonic (PIH) imaging was accepted as the superior technology for 
advanced contrast imaging at a recent meeting by leaders in the CE-US field PIH 
enhances signals from the microbubbles over those from the tissues, decreasing visual 
degradation from patients with poor body habitus and increasing image clarity and spatial 
resolution
CE-US with PIH imaging has improved the detection of liver métastasés when 
compared to percutaneous ultrasound imaging in B-mode This difference is
conclusive with CE-US having a documented sensitivity of around 87% compared to 53- 
77% ^^ 175-177 percutaneous ultrasound. CE-US has the capability of detecting sub­
centimetre lesions that are a known restriction of conventional ultrasound i^ 5;i70;i75;i78^  
Harvey et al. stated that CE-US and PIH were capable of detecting lesions of around 
3.14mm in size.
Del Prate et al. documented a narrowing of the detection gap between 
transabdominal CE-US and ferumoxides-enhanced MRI. Although improved, CE-US still 
only detected 90% of liver métastasés seen on MRI. When compared to contrast-enhanced 
dual phase CT, again although inferior, CE-US had narrowed the difference in sensitivity
I69;179-181
In relation to lesion characterisation, several authors have documented that CE-US 
has improved lesion characterisation when compared to conventional US. Early results
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suggest that again the gap may be narrowed between CE-US and CT and MRI
167;168;172;178;182-184
Image fusion is another recent development that combines PET and CT scanning 
This combines anatomical with frmctional imaging and can be done by using specific 
hardware to generate hybrid images. Image fusion is in the early stages, but one paper 
shows interesting results. Cohade et al analysed 45 patients with colorectal liver 
métastasés. The authors compared detection with FDG-PET to FDG-PET and CT 
combined. They found an improvement in staging from 78% to 89% with image fusion. 
Further research will determine its clinical application.
Preoperative and intraoperative imaging modalities — limitations
There are two main areas of concern when discussing radiological imaging 
modalities. As technology has developed, studies have used varied forms of US, CT and 
MRI. Therefore, the reader must be careful to acknowledge that the terms US, CT and 
MRI can refer to completely different imaging techniques and interpret the results 
accordingly. In addition, discussion of the sensitivity of imaging techniques always 
involves a reference standard for comparison. Caution must be applied as the reference 
standards themselves are subject to limitations with none of them having 100% sensitivity 
and specificity.
It may seem that despite significant radiological advances just as many liver lesions 
are being missed as before. It is important to remember that the aforementioned reference 
standards have all progressed too, setting the standard higher. As the gap between the 
standards and imaging modalities is not diverging, we can assume that we are detecting 
smaller lesions at an earlier stage.
68
In summary, there are many imaging modalities currently available to detect 
colorectal liver métastasés. Non-invasive imaging modalities have overlapping benefits 
with individual limitations. The invasive technique of lOUS is the current gold standard, 
but the challenge o f detecting occult liver métastasés and improving patient outcome 
remains.
1.3.2 Tumour markers
Carcinoembryonic antigen (CEA) is the most frequently used tumour marker in 
colorectal cancer. It was first described in 1965 by Gold and Freedman when they 
identified an antigen that was present in foetal colon and colonic adenocarcinoma, but 
absent in healthy adult colon^® ’^^ ^  ^ As a result of only being present in embryonic and 
cancer tissue, the antigen was named carcinoembryonic antigen or CEA. Further work 
found that CEA was present in some healthy tissues, but that serum concentrations were 
greater in patients with colorectal cancer and that these concentrations increased with 
advancing disease^
An ideal or perfect tumour marker should: be highly specific for one disease 
process; appear early in disease process; change as disease progresses or declines; be cost 
effective and be a simple, non-invasive test to allow repeated testing of patient. In relation 
to the last two requirements, a relatively cheap serum test to measure CEA is available in 
most clinical laboratories, resulting in serial blood tests that most patients find convenient. 
However, CEA can be elevated by several disease processes, including smoking and 
benign diseases where excluding cancer is important, although if CEA is found to be 
markedly elevated then benign disease is unlikely
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This finding restricts the usage of CEA as a sole diagnostic tool and the guidelines 
from the Association of Coloproctology of Great Britain and Ireland do not currently 
include routine measurement of CEA. The role of CEA may lie in the surveillance of 
patients with resected colorectal cancer with evidence in the literature to suggest that raised 
serum levels postoperatively can be a good indicator of recurrent/ progressive disease, even 
in asymptomatic p a t i e n t s ^ F u r t h e r m o r e ,  two prospective studies have concluded that 
elevated CEA was highly sensitive in diagnosing liver métastasés, quoting sensitivities of 
94% and 96%'^^’^ '^^ . This role could be extended by monitoring the response of metastatic 
disease in patients undergoing chemotherapy, but data is lacking in this area^^ .^ Another 
potential role is the application of CEA as a prognostic indicator. The Clinical Risk Score 
has included CEA as one of their five variables to predict outcome after liver resection for 
metastatic colorectal cancer
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1.4 Treatment of colorectal liver métastasés
1.4.1 Surgical resection
Long-term survival
Surgical resection of colorectal hepatic métastasés is the only potentially curative 
option. The five year survival rate varies in the literature from 6% to 58%, however, the 
majority of studies document from 25% upwards. This contrasts sharply with untreated 
patients who have a median survival of 5 to 21 months with few alive at 5 years^ "^®^ ’^ ^^ ‘^ ^\ 
Hepatic surgery has evolved from the time when it was found to carry a high morbidity and 
mortality and it is only since the 1990s that an extensive evidence base has been published 
showing improved long term outcomes.
To document the long-term survival, a literature search of Medline, Embase and 
Pubmed was performed. The search included the keywords: colorectal liver métastasés; 
surgical resection; partial hepatectomy; survival and patient outcomes. Over 400 papers 
were returned and the researcher decided to limit the search to include study populations of 
at least one hundred patients. If an author had published more than one paper on the same 
study population, but had analysed different long-term variables, then both papers were 
included. Otherwise, the paper with the greatest number of recruited patients was included. 
Table 2 displays the twenty-three studies in order of year published.
In one of the largest studies Scheele et al (1990) assessed 1209 patients with 
colorectal liver métastasés over a 30 year period with the primary outcome being long term 
survivaP°°. Patients were divided into three groups. Group 1 (n-921) were unresectable 
due to extensive liver métastasés and/or extrahepatic spread found on imaging or 
laparotomy that resulted in 23 patients undergoing palliative hepatic debulking procedures
71
and 113 receiving hepatic arterial chemotherapy. Group 2 (n=62) patients had unresectable 
disease confined to the liver, but with current guidelines could undergo potentially curative 
hepatic resection. Of this group, only eight were treated with intra-arterial chemotherapy. 
The remaining 226 patients formed group 3 and underwent potentially curative resection, 
including 22 patients that underwent resection for other metastatic disease. Of these 226 
patients, 183 had pathologically clear resection margins.
Group 1 patients had an extremely poor prognosis with only 7% alive at 4 years 
post diagnosis and none surviving 5 years. The median survival time was only 6.9 months. 
Group 2 patients with untreated resectable disease confined to the liver had improved 
median survival time of 14.2 months, but again none survived 5 years post diagnosis. 
These results contrast with group 3 that had an overall survival of 31% at 5 years, including 
those 22 patients with positive resection margins. If these 22 patients are excluded, the 5 
year survival increased to 38% with 7 patients alive at 10 years (27%). The authors then 
looked at time to recurrence and found that disease-fi’ee survival in the curative resection 
group was promising with 29% of the patients disease-fi*ee at 5 years. In the 106 patients 
that had confirmed recurrences, liver recurrence accounted for the majority of cases (n=74), 
followed by lung (n=50) then primary tumour (n-16). The longevity of this study allowed 
the authors to assess changes in prognosis over time and although there was an increase in 
the number of curative resections being performed (2% in 1960s vs 9.5% in 1970s vs 
20.5% in 1980s) there was no accompanying increase in 5 year survival (40% in 1960-1979 
vs 39% in 1980-1987, p>0.05).
The authors concluded that hepatic resection is a safe and effective long term 
treatment for colorectal liver métastasés with patients undergoing pathologically confirmed 
curative resections. If the resection margins are returned as positive the long term outcome
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is shortened, but is still superior to untreated, but potentially resectable liver métastasés.
Since 1990, there have been several large single centre studies confirming Scheele 
et al’s results One such study by Kooby et al (2003) from the Memorial Sloan-
Kettering Cancer Center prospectively assessed blood loss and its relationship to survival 
in 1351 patients undergoing curative hepatic resection for colorectal liver métastasés 
The median survival was 42 months (95% Cl 39-46 months) with one, three and five year 
survival rates of 88% (95% Cl 86-90%), 56% (95% Cl 53-59%) and 36% (95% Cl 33- 
39%) respectively.
The majority of the evidence is provided by single centre studies with few 
multicentre trials in the literature. One large multicentre trial (Nordlinger et al 1996) 
analysed survival in 1568 patients from 85 institutions undergoing potentially curative 
resection for colorectal liver metastases^®" .^ No patient had evidence of extrahepatic disease 
and the median follow up was 19 months. After exclusion of 36 postoperative deaths, the 5 
year overall survival was 28% with 5 year disease free survival at 15%. These results, 
although good, are not as good as figures from high volume specialist centres. It would be 
reasonable to conclude that hepatic resection should only be performed by specialist 
centres and indeed there is evidence to support this view^^ .^ However, many studies, 
including Nordlinger’s multicentre study, have been performed over a long time frame^ ®"^ . 
With improvements in hepatic surgery having only occurred during the last 10-15 years, 
one would expect more recent studies to have improved long term outcomes. Indeed, this 
does seem to be the case as shown by improved 5 year survivals of 42%, 51%, 53% and 
58% in studies where the study period is predominately from 1990 onwards^®^’^ ^^ '^ *^ .^
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Disease-free survival
Despite good long-term survival being achieved with hepatic resection, a large 
proportion of patients will recur. The documented range in the literature is from 15% to 
54% at 5 years after surgical resection^^®’^ "^^ ’^ ^^ '^ ^^ . The majority of recurrences happen 
within the first two years after partial hepatectomy, with approximately 50% occurring in 
the liver.
This early recurrence was assessed by researchers in the late 1980s that performed 
growth rate studies^^'^^\ Finlay et al took 15 patients that were undergoing bowel resection 
for their colorectal cancer. A total of 29 hepatic métastasés were found: 11 at laparotomy 
(overt) and 18 with serial CT scanning in the postoperative period (occult). The estimate of 
mean tumour volume doubling time for the overt métastasés was 155 +/- 34 days (+/- 
s.e.m.) compared with 86 +/- 12 days (p<0.05) for the occult métastasés. In addition, the 
estimate of the mean age of the métastasés at laparotomy was 3.7 +/- 0.9 years for the overt 
métastasés and 2.3 +/- 0.4 years for the occult métastasés. The authors concluded that 
colorectal liver métastasés are slow growing. As a result, the high rate of hepatic 
recurrence in the first two years after surgery is more likely due to the growth of métastasés 
that remained occult at the time of initial staging and surgery, rather than new métastasés.
There is no widely regarded optimal treatment for this group of patients with 
systemic chemotherapy and local ablative therapies commonly selected. The role o f repeat 
partial hepatectomy has received some analysis and appears to provide similar results to 
initial surgery with 5 year survival from 25% to 49% However, more research is
required as these studies have only small patient numbers reflecting the small proportion of 
patients that would be suitable for repeat liver surgery.
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Morbidity and mortality
Morbidity of hepatic resection has improved dramatically through the years with 
current postoperative rates lying between 8.2% and 47%^°^,204,209,214-217  ^ Commonest 
hepatic related complications include: blood loss; hepatic dysfunction/failure; perihepatic 
sepsis; biliary (leaks, fistulae) and subphrenic collections. Cardiorespiratory complications 
account for the majority of non-hepatic complications.
It is acknowledged that mortality from hepatic resection should be low, with a 
mortality rate of less than 5% being acceptable 203,204;209,2i4-2i7^  Reasons for mortality vary, 
with hepatic failure, sepsis and cardiorespiratory complications accounting for the majority 
of cases.
Blood loss
Hepatic resection has been traditionally associated with a substantial risk of 
haemorrhage with some authors documenting losses of up to 10 litres in a single patient^ 
This risk is greater in patients with steatosis or cirrhosis of the liver and also increases 
with the volume of liver resected^^^"^^ .^ Table 3 displays documented blood losses from a 
variety of centres to highlight the varied ranges.
Several papers have documented that haemorrhage and subsequent blood 
transfusion during or after hepatic resection increases patient morbidity and mortality
203;227-229
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Table 3: Documented blood losses after hepatic resection in patients with colorectal liver 
métastasés.
blood loss (uiL)
m ain au tho r study
period
year
published
cirrhosis median mean range transfusion
rate
anaesthetic and surgical 
technique
Tanaka K n/a 2005 n/a 1000-
2000
n/a 70-
4030
480mL per 
patient
lO-Pringle (intermittent)
Otsubo T 1995-
2000
2004 poss.
59/103
n/a 910-
1177
n/a 32-42%
patients
transfused
±00-IV C
Kooby DA 1986-
2001
2003 0/1351 n/a n/a n/a 55%
patients
transfused
not elarifred
Descottes B 1986-
2001
2003 poss
16/87
n/a n/a n/a 1,5U/ patient lO-Pringle, 0 0 -IV C  and OO- 
SVC
Jamagin WR 1991-
2001
2002 poss
84/1803
600 871 n/a 4 U/ patient low CVP, lO-Pringle 
(intermittent) and 0 0 -H V
Torzilli G 1994-
1999
2001 135/329 690 853 61-
4072
3.1%
patients
transfused
lO-Pringle (intermittent) OO- 
HV
Melendez JA 1991-
1997
1998 poss
78/496
645 848 40-
9000
2.6 U/ 
patient
low CVP plus lO-Pringle
Fong Y 1991-
1993
1997 8/133 800 1200 50-
8400
n/a lO-Pringle
Gayowski TJ 1981-
1991
1994 n/a n/a n/a n/a 3.7 U/ 
patient
n/a
Cunningham JD 1991-
1993
1994 poss
17/100
1000 n/a 450-
1500
59% patients 
transfused
low CVP, lO-Pringle 
(intermittent), OO-HV
Hannoun L 1981-
1991
1993 n/a n/a n/a n/a 5.3 U/ 
patient
I0 -P rin g le± 0 0 -H V
Bismuth H 1979-
1988
1989 0/51 n/a n/a n/a 4.5 U/ 
patient
OO-SVC+IVC; lO-Pringle 
(continuous)
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Abbreviations to Table 3: central venous pressure (CVP); outflow occlusion by clamping 
hepatic veins (OO-HV), outflow occlusion by clamping/controlling o f inferior vena cava 
(OO-IVC); outflow occlusion by clamping o f superior vena cava (00-SVC); inflow 
occlusion by clamping portal triad/ Pringle’s manoeuvre (lO-Pringle) and continuous v 
intermittent
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Acutely, haemodynamic instability during the operation can occur. This can result 
in: delay or cessation of the operation; increased anaesthetic time; cardiorespiratory arrest 
or end organ damage due to poor tissue perfusion. Haemorrhage will decrease surgical 
field visibility increasing the technical difficulty of the operation and increasing the risk of 
damage to other structures, particularly the hepatic veins^^°. The administration of blood 
products to compensate for the blood loss carries a long list of potential side effects: 
allergic or anaphylactoid reactions; haemolysis; coagulopathy; increased postoperative 
infection rate; viral and bacterial infection transmission
The main long term complication from haemorrhage is reduced disease free 
survival for several types of malignant disease^ ^^ '^^ '^^^ "^^ '*^  Yamamoto et al assessed 
survival in 250 patients undergoing complete resection of hepatocellular carcinoma^^^. 
Recurrence occurred in 55 out of 74 patients (74.3%) who had received a blood transfusion 
compared to 89 out of 178 patients (50%) that did not (p=0.0001). In addition, 
perioperative blood transfusion was found to be a significant predictor for accelerated 
recurrence on multivariate analysis (p=0.003).
In relation to colorectal liver métastasés, the largest study assessing the influence of 
blood transfusion on long term survival after resection is by Kooby et aP^  ^ who analysed 
more than 1300 patients undergoing hepatic resection. Approximately half of these 
patients received a blood transfusion and it was found that these transfused patients were 
more likely to die in the first 60 days following resection. The authors concluded that the 
major effect of transfusion is on perioperative outcome, as although there was a perceptible 
influence on long term survival, other factors were more dominant in predicting survival 
than transfusion administration.
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Documented hlood losses and techniques developed to minimise loss
Discussion of the blood losses documented with hepatic resection must be 
interpreted in the context of the various surgical and anaesthetic techniques that have 
evolved to minimise haemorrhage (Table 3). There are three main phases when bleeding 
can occur during hepatic resection: dissection; parenchymal transection and
revascularisation. Subsequently, a multitude of anaesthetic and surgical techniques have 
been developed that target these 3 phases.
Anaesthetic technique
After the induction of anaesthesia, it was a traditional approach to administer 
intravenous fluid to expand the intravascular volume in anticipation of significant blood 
loss. This additional volume would increase the central venous pressure (CVP), distending 
the central veins and compounding any bleeding from damaged or undetected vessels. 
Maintenance of a low intraoperative CVP during extrahepatic dissection and parenchymal 
transection was introduced and analysed for any effect it may have on intraoperative blood 
loss^^ .^ Cunningham et al assessed blood loss and transfusion requirements in 100 
consecutive patients undergoing partial hepatectomy with a low CVP. They found blood 
losses ranging from 450mL (segmentectomy) to 1500mL (extended left hepatectomy) with 
59% of patients receiving a blood transfusion. The authors concluded that low 
intraoperative CVP resulted in an acceptable and low blood loss.
The same research group published further findings on outcomes with low CVP in 
1998 where the median blood loss in 496 partial hepatectomies performed under low CVP 
was 645mL and only 33% of patients had a perioperative blood transfiision '^^^. Jones et
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performed a randomised controlled study on one hundred patients undergoing hepatic 
resection; group 1 underwent partial hepatectomy with a CVP greater than or equal to 
ScmHaO whilst group 2 underwent partial hepatectomy with a CVP less than ScmHiO. 
Median intraoperative blood loss was significantly lower in the low CVP group (200mL, 
range 0-1000), compared to the high CVP group (lOOOmL, range 0-8000; p<0.001). 
Transfusion rate was also significantly lower in the low CVP group (5% v 48%, p=0.008). 
After further statistical analysis the authors concluded that these results were not influenced 
by other variables: the presence or absence of portal occlusion; the resection type; the 
length of operation; the number of lesions resected; the method of liver dissection or the 
presence or absence of cirrhosis.
Low CVP can be achieved by several routes with the two most commonly used 
being administration of intravenous nitroglycerins and/or intraoperative intravenous fluid 
restriction. Intraoperative haemodynamic instability has been reported as a consequence of 
maintaining a low CVP and has to be carefully balanced against the risk of haemorrhage. 
Intraoperative hypotension can lead to further complications including renal dysfunction 
and/ or failure but the exact incidence is unknown with estimates around 13%^^°. The 
largest study that has analysed renal dysfunction in low CVP conditions, found only 3% of 
496 patients developed renal dysfunction after partial hepatectomy, suggesting that low 
CVP anaesthesia does not appear to compromise renal function^"^ .^
Surgical techniques
In 1908, J. H. Pringle demonstrated that hepatic inflow vascular occlusion could 
reduce hepatic bleeding '^ '^ .^ In 1952, control of hepatic inflow was combined with hepatic
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outflow occlusion to allow the first major anatomical liver resection to be performed 
Since then, the lower morbidity and mortality associated with reductions in blood loss have 
led many authors to experiment with different vascular occlusion techniques. Currently, 
there are many techniques available for the hepatobiliary surgeon: hepatic inflow; hepatic 
inflow and outflow; total or selective occlusion and intermittent or continuous^"^ .^ Each 
technique varies in level of technical difficulty, prevention of haemorrhage, intraoperative 
patient tolerance and hepatic tolerance, with the risk of hepatic failure being foremost^"* .^ 
Indeed, with the documented incidence of hepatic dysfunction and/ or failure being as high 
as 18%, some surgeons have disregarded hepatic occlusion techniques altogether
To understand vascular occlusion techniques, the anatomy of the liver must be 
described. At the hilum of the liver, the dual blood supply (portal vein and hepatic artery) 
divide into right and left branches that supply the right and left lobes respectively. This is 
the classical description, but there are anatomical variations with aberrant hepatic arteries 
commonly arising from the left gastric (aberrant left) and superior mesenteric arteries 
(aberrant right). Venous drainage is provided by three large hepatic veins (right, middle 
and left) that lie posterior to the liver and open into the inferior vena cava just inferior to 
the diaphragm. Again, in 20% of cases there can be variations in the anatomy with the 
presence of: a significant right inferior hepatic vein; communications between the larger 
veins and/or smaller veins and small veins draining the posterior right lobe directly into the 
inferior vena cava. All of these anatomical variations have a significant impact on the 
effectiveness of the chosen approach to hepatic vascular occlusion.
Hepatic pedicle clamping is commonly referred to as Pringle’s Manoeuvre and 
interrupts the arterial and portal venous inflow to the liver. The occlusion requires minimal
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dissection and the pedicle can be occluded with a vascular clamp or encircled with a tape. 
One of the problems with Pringle’s manoeuvre is that there is no attempt to prevent venous 
bleeding (termed back bleeding). This bleeding can be significant and result in the 
morbidity described previously. Another significant problem is the risk of hepatic failure. 
Although the exact duration of clamping that can be safely tolerated by the liver is 
unknown, sixty minutes is a widely quoted figure^ "^ .^ This led to research assessing the 
value of performing Pringle’s manoeuvre intermittently (e.g. 15 minutes clamping followed 
by 5 minutes undamped, repeat as required). Although there appears to be little difference 
between the two approaches in healthy liver (similar blood losses and hepatic dysfunction), 
intermittent clamping may be beneficial in cirrhotic livers^^°. Perhaps more importantly, 
intermittent clamping has led to hepatic preconditioning. Clavien et al found that the 
protective effects of intermittent clamping appeared to arise from the initial period of 
ischaemia (ten minutes) followed by reperfusion^^\ The authors concluded that this initial 
clamp-unclamp sequence could be manipulated to maximise liver function during the 
remainder of the hepatic occlusion.
Selective arterial occlusion interrupts the arterial and venous inflow to the region of 
liver to be resected, avoiding ischaemia to the liver remnant. This technique can be 
performed at two levels: lobe (right or left hepatic artery, for hemi-hepatectomy) or liver 
segment (segmental artery and vein, for hepatic segmentectomy). The haemodynamic 
trauma to the patient is minimised as well as the risk of hepatic dysfunction, making this 
technique attractive. However, this has to be balanced with the need for significant hilar 
dissection accompanied hy potential bleeding from the raw surface of the non-occluded 
liver remnant.
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Outflow occlusion is normally performed in conjunction with inflow occlusion. 
Again there are several options. The conventional technique for hepatic outflow occlusion 
involves clamping of the infra- and supra-hepatic inferior vena cava. The main advantage 
is the minimising of back bleeding. However, complete mobilisation of the liver is 
required as well as dissection of the inferior vena cava from the retroperitoneum. 
Furthermore, the patient has to be carefully monitored, as they are put under significant 
haemodynamic strain: decreased blood pressure; decreased pulmonary artery pressure; 
tachycardia; increased systemic vascular resistance and decreased cardiac output. These 
potential complications have led to other techniques being preferred leaving inferior vena 
caval clamping to be used when others cannot.
Another type of outflow occlusion is extraparenchymal hepatic vein clamping. This 
approach exposes and controls the three main hepatic veins without significant 
haemodynamic insult due to the preservation of caval flow. This technique can also be 
used selectively, by occluding only the appropriate hepatic vein. However, there are 
disadvantages: significant dissection and mobilisation of the liver is required; collateral 
circulation is not controlled and this approach cannot be used if tumour involves the cavo- 
hepatic junction.
Each of these hepatic occlusion techniques has a role to play depending on the 
patient status, tumour location, associated liver disease and experience of the anaesthetist 
and hepatic surgeon. The hepatic surgeon should understand the benefits and potential 
complications associated with each and apply them on an individual basis.
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Liver dysfunction and failure after partial hepatectomy
Liver dysfunction or failure after partial hepatectomy has been documented to occur 
within the range 3-18% with the cirrhotic liver at greater 247,248,252,253  ^ The main
reasons for liver dysfunction are the use of hepatic vascular occlusion techniques and 
resection of a large tumour volume leaving inadequate liver remnant function.
It has been traditionally thought, although not proven, that up to two thirds of the 
liver can be safely resected, with the risk of hepatic dysfunction or failure being low. 
Schindl et al (2005) addressed this question by performing preoperative estimation of 
residual liver volume by CTAP in 104 patients undergoing hepatic resection (colorectal 
métastasés n=92, cirrhotic patients n“ 12) The authors categorised postoperative 
hepatic dysfunction as mild, moderate or severe with a total of 77 patients developing a 
degree of hepatic impairment: mild in 42 patients (40.4%); moderate in 22 (21.2%) and 
severe in 13 (12.5%). The patients who developed severe hepatic dysfunction had a 
significantly smaller %RLV (residual liver volume) compared to those with mild hepatic 
dysfunction (24.5% vs 42.9%, p=0.005) with further analysis determining a critical 
minimum %RLV of 26.6% must be achieved. If less than this threshold, then serious 
hepatic dysfunction is likely to occur.
These results are supported by two other papers which found a residual liver 
volume of <25% significantly increased the likelihood of postoperative hepatic 
dysfunction^^"^’^ ^^ . These authors concluded that volumetric analysis should become part or 
a patient’s preoperative assessment for hepatic resection.
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The rationale fo r  hepatic surgery
The first recorded right lobectomy was performed in 1911 by Wendel, who based 
his approach on Cantlie’s description as well as using hilar ligation^^^. At that time, the 
concept of hepatic segmental anatomy was not accepted and it took until the 1950s with the 
work of Healey (1953) and then Couinaud (1954, 1957, 1981) to achieve acceptance of 
segmental anatomy^^^'^^\
These anatomists divided the liver into functional lobes and segments according to 
the arterial blood supply, portal venous blood supply, biliary drainage and hepatic venous 
drainage. A plane passing through the bed of the gallbladder and the notch of the inferior 
vena cava divides the liver into right and left lobes and is commonly referred to as 
Cantlie’s line [Figure 4]
One of the most widely accepted definitions of liver segments are those by 
Couinaud^^^. Couinaud based his system on the fissures (or scissurae) of the three hepatic 
veins that divide the liver into four sections. This led to 8 segments being described 
(Figure 5). Most of the other well known definitions are similar to Couinaud’s system, but 
there are some differences with much debate on how to classify which lobe the quadrate 
and caudate functionally belong. The quadrate is regarded as belonging functionally to the 
left lobe. The caudate also belongs to the left lobe and is classified as segment I. Some of 
the other nomenclatures are clinically useful, including Healey and Schroy’s subdivision of 
segment IV: I Va (left superomedial segment) and IVb (left inferomedial segment)^^^. In 
addition, Bismuth (who also based his system on the three fissures) described a transverse 
fissure passing through the right and left portal branches, allowing simple diagrammatic 
explanation of the eight segments, (seen in Figure 5)^ ^^ .
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Figure 4: Division of liver into left and right hepatic lobes by Cantlie’s Line.
Right LoW
Carrttie'â line
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This delineation of the liver into planes forms the basis for anatomical liver 
resection as these planes are relatively devoid of major blood vessels and bile ducts.
Table 4 shows the current definitions of hepatic surgery used by one of the major 
hepatobiliary units^^^. Many definitions of hepatic resection are currently in widespread 
use, all based on Couinaud’s work. As a result, attention should be paid to authors’ 
individual nomenclature in the methodology section of their published work.
At the same time the anatomists were documenting their findings, Jean Louis 
Lortat"Jacob and HG Robert performed an anatomical hepatic resection. The operation 
was performed in Paris in 1952 on a patient that had a solitary liver lesion that turned out to 
be a colorectal liver metastasis. Lortat-Jacob and Robert’s work caught the attention of 
surgeons and became a catalyst for hepatic resection being widely performed^"^^’^ ^^ . The 
majority of these resections were major anatomical resections which were thought to 
ensure a clear resection margin, conferring the best long term outcome for the patient with 
metastatic colorectal disease. More recently, segment-oriented surgery has become 
increasingly popular with various approaches available^^^"^^ .^ The popularity is due to 
maximal preservation of the functional liver parenchyma, reducing the risk of hepatic 
failure which is particularly attractive in patients with cirrhosis. Oncologically, the patient 
appears not to be compromised with several studies documenting similar long term survival 
to patients that have undergone traditional lobectomies^^^’^ ^^ ’^ ^  ^ Subsequently tri-, bi- and 
monosegmentectomies are now accepted approaches for small volume or bilobar disease. 
The picture is not as clear for subsegmentectomies, with some authors documenting 
reduced disease free and overall survivaP^^.
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Figure 5: Couinaud’s anatomical segments of the liver
C antlîe 's  line
I caudate lobe
II left posterolateral segment
III left anterolateral segment
IV left medial segment
V right anteroinferior segment
VI right posteroinferior segment
VII right posterosuperior segment
VIII right anterosuperior segment
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Table 4: Extent of hepatic resection definitions.
Type of resection Couinaud segments
Left lobectomy II, III, IV ± I
Right lobectomy V, VI, VII, VIII ± I
Extended left lobectomy II, III, IV, V, VIII ± I
Extended right lobectomy IV, V, VI, VII, VIII ± I
Trisegmentectomy any three segments (adjacent or non- 
adjacent)
Bisegmentectomy any two segments (adjacent or non-adjacent)
Monosegmentectomy one segment
Wedge resection less than one segment
Adapted from nomenclature in Weber et al (2000) from the Memorial Sloan-Kettering 
Cancer Center, New York,
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Synchronous resections
The 20-30% of patients having liver métastasés at the time of initial presentation 
presents an opportunity to perform combined hepatic and colonic resection. This combined 
or synchronous approach would allow the patient only one hospital stay which as well as 
being beneficial to the patient, would be cost effective.
Earlier studies explored patient outcomes after synchronous resections when 
compared to staged or interval resections and found significantly increased morbidity and 
mortality in patients undergoing synchronous resection^^’^ ^^ '^ ^^ . As a result, these studies 
favoured staged resections due to lower postoperative complications with the additional 
benefit of the interval allowing detection of supposed ‘occult’ liver métastasés.
However, the majority of these studies were non-randomised, limited by small 
patient numbers and in addition, were performed before or partly during the time frame of 
significant improvements in patient outcomes after hepatic resection. Also, comparisons 
are difficult as the definition of synchronous resection has varied. For some authors, this 
means hepatic resection at the time of laparotomy for the colonic primary. For others, 
synchronous refers to resection of the hepatic métastasés up to 3 months after the primary 
bowel surgery.
Two recent studies have been published that overcome some of the limitations of 
the earlier studies^^^’^ ^^ . Chua et al (2004) retrospectively analysed 96 patients that 
presented with colorectal cancer and liver metastases^^^. These patients underwent either 
synchronous (n=64) or staged bowel and hepatic resections (n=32) within the same surgical 
unit. For analysis of outcomes in the staged group, variables from both the primary and 
secondary surgery were added together and compared with the synchronous resections
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group. The results found trends for lower volume liver resections (p=0.09) with an 
increased blood transfusion rate after synchronous resections (mean 326mL vs 185mL, 
p=0.08). Postoperative complication rates were similar between groups (53% synchronous 
vs 41% staged, p=0.25) with no operative mortality. The synchronous group experienced a 
significantly shorter hospital stay (mean 11 vs 22 days; p=0.001). In relation to long term 
outcomes, no significant differences between groups (synchronous vs staged) in disease 
free survival or overall survival were found (median 13 vs 13 months, p=0.53; median 27 
vs 34 months, p=0.52). These authors concluded that synchronous resections are safe, 
effective and should be the procedure of choice for selected patients in experienced centres.
Martin and colleagues from the Memorial Sloan-Kettering Cancer Centre 
performed a similar analysis from a prospective database over a 17 year period One 
hundred and thirty four patients (group I) underwent synchronous resections, whilst 106 
patients underwent staged resections (group II). Again, the extent of hepatic disease was 
less in the synchronous resections group (fewer number of tumours, p=0.001; smaller 
tumours, p=0.009) resulting in significantly smaller hepatic resections being performed 
(major resections 34% group I vs 72% group II, p=O.OOI). In addition, right 
hemicolectomy was performed in 40% of synchronous resections compared to only 14% in 
staged resections. Although the blood loss was greater in group II (median 550mL group 1 
vs llOOmL staged, p<0.001), there was no difference in transfusion rates between groups 
(31% group I vs 38% group II). Regarding postoperative complications, the synchronous 
resections had significantly less (49% vs 67%, p<0.003) than group II, which on further 
analysis appeared to be a direct result of a second laparotomy in the staged group. This 
reduced complication rate also contributed to the significantly shorter hospital stay (median
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10 vs 18 days, p=0.001). Perioperative mortality was exactly the same in both groups 
(n=3). Unfortunately this study did not analyse long term outcomes.
These two studies provide promising evidence that synchronous bowel and hepatic 
resections are safe without compromising long term outcome. With the introduction of 
local ablative therapies treating liver métastasés at the same laparotomy for hepatic 
resection the debate for optimal timing of treatment in patients with synchronous colorectal 
cancer and liver métastasés continues.
Patient selection and prognostic indicators after hepatic resection
With the publication of many centres’ work, hepatic resection has finally become 
the widely regarded optimal treatment for colorectal liver métastasés. Exact guidelines for 
selecting patients for hepatic resection currently do not exist and remain an issue for 
discussion.
Patient selection for hepatic resection has been divided into three groups: medical 
fitness for anaesthesia; the absence of disseminated disease and lastly, tumours that are 
confined to the liver so that adequate liver parenchyma is preserved. Several studies have 
set up uni- and multivariant analyses to determine prognostic factors for patient selection 
(Table 3).
In relation to overall survival, the burden of disease is prognostic. Nodal status of 
primary tumour and number and size of hepatic tumours have been found to be important 
outcome markers in many studies. In addition, the presence of extrahepatic disease has 
been shown to be an independent predictor of survival in three of the largest studies, 
resulting in subsequent studies excluding such patients from analysis^ ®"^ .
93
Bilobar disease has previously been an exclusion criterion for undergoing hepatic 
resection. However, approximately half the studies shown in Table 5 have not found 
métastasés on both lobes to be indicative of patient outcome. This disparity between 
studies can be explained in that some cases bilobar disease reflects a high burden of disease 
(i.e. multiple widespread hepatic métastasés) whilst in others only a small burden of disease 
is present (i.e. two small métastasés, one either lobe). It is a similar picture for extent of 
hepatic resection. Assuming enough healthy parenchyma is left behind, the extent of 
resection does not always reflect the burden of disease. Indeed, the decision for the extent 
of resection can be based on surgeons’ preference rather than disease burden (i.e. 
performing a right hepatectomy rather than a monosegmentectomy for a tumour in segment 
6). As a result, many studies have not found extent of resection to be an independent 
prognostic factor.
Achieving adequate resection of the hepatic tumour is an independent prognostic 
factor. An area of debate is what constitutes an adequate margin. The majority of studies 
state that the best survival outcome occurs when the resection margin is greater than 1 
However, Fong et al divided their patient population into resection margins 
>lcm and those <lcm and found no difference in survival between the two groups^^^. The 
general consensus is that any RO margin is acceptable, but ideally a margin of 1cm should 
be achieved.
CEA may have a role in determining prognosis after hepatic resection, with two 
large studies finding that an elevated CEA was an independent determinant of survival after 
hepatic resection However, other studies have not found as convincing evidence for
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CEA, which may be a reflection of the different thresholds for determining what constitutes 
an elevated CEA.
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Prognostic indicators for disease free survival are similar to overall survival, 
reflecting the importance of burden of disease. There has been much research into the role 
of chemotherapy after hepatic resection and this will be discussed in detail in the next 
section. It should be noted that of the studies discussed here, only one has found 
chemotherapy to be an independent prognostic indicator of survivaP^^.
Several authors have tried to collate the prognostic factors to develop a prognostic 
score, clarifying patient selection for undergoing hepatic resection. In one of these, Fong et 
al retrospectively reviewed 1001 patients that were undergoing hepatic resection for 
metastatic colorectal c a n c e r A c t u a r i a l  survival was 37% at 5 years with positive 
resection margin, extrahepatic disease, >1 tumour, elevated CEA, tumor size greater than 
5cm, node positive primary and disease fi*ee interval <12 months all to be independent 
predictors of survival. The authors then selected five clinical criteria and assigned one 
point to each to produce the Clinical Risk Score (CRS) [Table 6]. Patients with a CRS of 
0, 1, or 2 have a highly favourable outcome with a 5 year survival of 40-60%, whilst 
groups 3-5 have a poorer prognosis with patients scoring 5 having a 5 year survival of only 
14%. The authors concluded that patients with scores 0-2 should be considered for 
aggressive treatment with patients scoring 3-4 having a more guarded prognosis, and 
resection should be planned in the context of adjuvant therapies. Finally patients with a 
score of 5 have very poor outcomes, and resection without additional effective adjuvant 
therapy or outside of adjuvant trials is highly questionable. This clinical risk score has 
recently been validated by another centre and further research will determine its 
widespread applicability^°^.
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Table 6: Clinical Risk Score for Tumour Recurrence.
Survival (%)
CRS 1 year 2 year 3 year 4 year 5 year Median (mnths)
0 93 79 72 60 60 74
1 91 76 66 54 44 51
2 89 73 60 51 40 47
3 86 67 42 25 20 33
4 70 45 38 29 25 20
5 71 45 27 14 14 22
Each risk factor is one point: node positive primary; disease free interval <12 months; >1 
tumour; tumor size >5 cm and CEA >200ng/mL
From Fong et al, Clinical score fo r  predicting recurrence after hepatic resection for
metastatic colorectal cancer 198
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Section 1.4.2 Chemotherapy
The role of chemotherapy in primary colorectal cancer is clearly defined. In 
contrast, the indication for chemotherapy in unresectable and post resected colorectal liver 
métastasés remains unclear. Chemotherapy can be administered systemically or regionally 
with the latter dividing into hepatic arterial infusion (HAI) or isolated hepatic perfusion 
(IHP).
Systemic chemotherapy
5-Fluorouracil (5-FU) was one of the first chemotherapeutic agents and is still the 
backbone of chemotherapy for patients with metastatic colorectal cancer. Used alone, 
researchers have found that 15-20% of patients undergo tumour regression, but with no 
evidence of improved survival^^\ When used in conjunction with other agents 
(biomodulation) prolonged survival has been found when compared to patients receiving 
the best supportive care^^ .^ The most commonly prescribed regime (5-FU with folinic 
acid) has been documented to result in a median overall survival of 14.8 months and the 
introduction of new agents (irinotecan, mitomycin, oxaliplatin, cisplatin, topoisomerase I 
inhibitor) has provided a new area of research with delayed disease progression and 
improved long term survival^^ '^^^  ^287-290^
The clinical role and application of systemic chemotherapy is continually changing 
and large multicentred trials are required to determine the exact combination and optimal 
administration of both old and new agents^^\
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Hepatic artery infusion chemotherapy
Hepatic artery infusion (HAI) chemotherapy is based on two principles: liver 
métastasés deriving the majority of their blood supply from the hepatic artery and certain 
drugs having a high first pass hepatic extraction^^^. These result in high doses of 
chemotherapeutic drugs to the tumour yet sparing the normal hepatic parenchyma and 
reducing systemic toxicity, both of which are major disadvantages to systemic treatment.
Several randomised studies have documented improved response rates (reductions 
in liver tumour size, longer time for tumour progression and patient compatibility/ quality 
of life) but no survival advantage for patients with unresectable disease undergoing HAI 
with 5-fluorodeoxyuridine (FUDR; commonly used because of its solubility properties and 
ability to be concentrated in a small volume) compared to systemic Kerr et al in
2003 performed a multicentred, prospective randomised trial comparing HAI to 
intravenous chemotherapy using fluorouracil and folinic acid^ "^^ . The authors found a 
median overall survival of 14-7 months for the HAI group and 14-8 months for the 
intravenous group (hazard ratio 1-04 [95% Cl 0-80-T33], log-rank test p=0-79) with no 
significant difference in disease progression survival. In addition, there were documented 
problems with catheter insertion (resulting in 37% of the patients allocated to receive HAI 
not undergoing HAI) and catheter failure (29% of patients having failure of the catheter 
during their treatment course).
An area that requires more analysis is the use of HAI in combination with systemic 
chemotherapy in patients that have undergone hepatic resection. The Sloan Kettering 
Group in 1999 found improved long term survival with adjuvant HAI (FUDR) when it was
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combined with systemic chemotherapy (5FU) compared to control group that received only 
systemic chemotherapy^^^.
Isolated hepatic perfusion chemotherapy
Isolated hepatic perfusion (IHP) is able to administer high doses of 
chemotherapeutic agents to the liver by isolating the liver from the systemic circulation^^^. 
Outflow catheters are inserted into the inferior vena cava and portal vein which are 
connected into a bypass circuit that drains into the axillary vein^^^.
Conclusions about the disease-free and long-term survival with IHP in patients with 
colorectal liver métastasés are hard to draw due to few comparative studies with other 
approaches and varying methodology, especially in the type of agent administered. The 
largest series analysed only 51 patients and found increased median survival when IHP was 
combined with HAI compared to IHP alone (27 months versus 16 months respectively)^^^. 
Interestingly, in a smaller study from the same group, partial response was attained in 
patients undergoing IHP that had previously not responded to both systemic chemotherapy 
and HAL an area that needs further evaluation^®®.
Section 1.4.3 Radiotherapy
Traditionally, radiotherapy has had a limited role in the treatment of colorectal liver 
métastasés with a recent multicentre trial supporting this statement^®^ Radiotherapy is 
limited in that it cannot treat extrahepatic disease and any dose greater than 30 Gy will have 
a significant risk of developing radiation hepatitis^® '^^®\
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Selective internal radiation therapy (SIRT) is a new modality for patients with 
unresectable disease that takes advantage of the hepatic tumours being predominately 
supplied by the hepatic artery. Treatment consists of delivery of radioactive microspheres 
(usually 90Yttrium) into the hepatic artery supplying the tumour, allowing selective tumour 
uptake that minimises inadvertent perfusion of other non-diseased organs. Initial results 
show good patient compliance and long term results are awaited, especially when used in 
conjunction with postoperative chemotherapy^ ®"^ "^ ®^ .
Section 1.4.4 Local ablative therapies
There are many local ablative treatments available for the treatment of surgical 
unresectable colorectal liver métastasés. There is limited evidence for inclusion into 
clinical practice for the majority, including: hepatic cryosurgery; percutaneous ethanol 
injection; embolisation; focal hyperthermia and high intensity focused ultrasound. More 
recent evidence has focused on the clinical application of laser photocoagulation, 
microwave coagulation and predominately, radiofrequency ablation^ ®®.
Interstitial laser photocoagulation (ILP)
Lasers produce a coherent, monochromatic and highly collimated beam that results 
in tissue vaporisation, necrosis and coagulation when placed inside a solid tumour^® .^ In an 
early study, Amin et al^ ®^ performed ILP on 26 patients with liver métastasés, of which 21 
were colorectal in origin. Each patient had between 1-8 sessions until follow up CT 
confirmed complete necrosis of the liver tumour. The authors concluded that ILP had a 
good safety profile and potential for improving survival with 2 year survival at 70%. One
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of the largest studies assessed long term outcome in 393 patients with colorectal liver 
métastasés that were not suitable for surgical resection (recurrence after previous surgery; 
bilobar disease; irresectable disease or refused surge ry )^Af t e r  undergoing ILP the mean 
survival was 41.8 months with 5 year survival at 30%. Although this group were highly 
selected, compared to the natural progression of untreated metastatic colorectal disease, 
ILP appears to offer a survival advantage^
Microwave coagulation therapy (MCT)
Microwave coagulation therapy produces electromagnetic radiation that is delivered 
into the tumours by a needle, resulting in rapid agitation of the water molecules. This 
agitation causes frictional heating that can achieve temperatures of 60-100°C^^^. There are 
only a few documented clinical trials assessing MCT. In one of these trials, Beppu et al 
(1998) performed percutaneous MCT in 40 patients with colorectal liver métastasés and 
found recurrence in 14/ 40 with 5 year survival of 33%^ "^^ . These results are promising, but 
require further trials to confirm.
Radiofrequency ablation (RF ablation)
An alternating high frequency current is transmitted from the tip of an electrode in 
to the tissue surrounding the electrode. Ions in the tissue try to follow the current and 
become agitated, producing frictional heating that results in coagulation necrosis. RF 
ablation produces temperatures greater than 100°C destroying tissue microvasculature and 
can be performed percutaneously, laparoscopically or at laparotomy.
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A multicentre study group analysed the complications after performing ultrasound 
guided percutaneous RF ablation in 1,139 patients in 11 institutions. The overall 
complication rate was 2.4% with a mortality rate of 0.09%. This study and others have 
concluded that the morbidity and mortality of RF ablation is acceptable® Although 
the long term survival of patients with colorectal liver métastasés that have undergone RF 
ablation is unknown, results to date compare favourably to surgical resection. In by far the 
largest study to date of RF ablation and colorectal liver métastasés, Solbiati et al®^® found 1, 
2 and 3 year survival rates of 93%, 69% and 46% respectively in 117 patients. As more 
research is published, the need for a randomised trial may become apparent.
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Section 2: Hypotheses and Aims of thesis.
The hypotheses and aims of this thesis are:
1) Contrast enhanced ultrasound has a clinical role in the detection and characterisation of 
colorectal liver métastasés that challenges current available imaging modalities.
This study aimed to determine the clinical role by performing four separate 
prospective trials. The first trial aimed to document the percutaneous detection and 
characterisation of colorectal liver métastasés using a second generation ultrasound contrast 
agent. The second trial aimed to investigate the detection of colorectal liver métastasés 
with the first documented use of intraoperative contrast enhanced ultrasound. The next 
trial aimed to develop an original technique using percutaneous contrast enhanced 
ultrasound to measure altered hepatic perfusion that could reliably detect colorectal liver 
métastasés. The final trial assessed changes in hepatic perfusion using contrast enhanced 
ultrasound in patients undergoing curative partial hepatectomy for colorectal liver 
métastasés.
2) The short and long term outcomes in patients undergoing partial hepatectomy for 
colorectal liver métastasés using a novel triphasic approach is superior to the published 
literature.
One centre’s prospective hepatic database on patients undergoing partial 
hepatectomy for colorectal liver métastasés using a novel triphasic approach is analysed 
with emphasis on the perioperative changes in renal and hepatic function in addition to
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blood loss, tumour recurrence and overall survival. Outcomes in relation to synchronous 
bowel and/or hepatic procedures are investigated and the application of prognostic scores 
in this study’s population determined.
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Section 3 -  Investigative chapters
Chapter 1 : The novel application of a second generation ultrasound contrast agent in the 
percutaneous detection and characterisation of colorectal liver métastasés.
Chapter 2: A prospective trial determining a new clinical application of contrast enhanced 
ultrasound in the intraoperative detection of colorectal liver métastasés.
Chapter 3: The development of a novel technique for the functional imaging of hepatic 
perfusion in colorectal liver métastasés using contrast enhanced ultrasound.
Chapter 4: Perioperative changes in hepatic perfusion in patients undergoing curative 
partial hepatectomy for colorectal liver métastasés using contrast enhanced ultrasound.
Chapter 5: Short and long term outcomes in patients with colorectal liver métastasés 
undergoing partial hepatectomy with a novel triphasic approach.
Chapter 6: Conclusions.
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Section 3
C hapter 1: The novel application of a second generation ultrasound contrast agent in the 
percutaneous detection and characterisation of colorectal liver métastasés.
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3.1.1 Introduction and aims
Contrast enhanced ultrasound (CE-US) is an evolving imaging modality. The 
introduction of a new generation of contrast agents, termed microbubbles, and improved 
imaging technology (pulse inversion harmonic imaging) allows diagnosis of focal liver 
lesions based on lesion vascularity. Three vascular phases can be identified (arterial, portal 
and late/sinusoidal) that allow pattern recognition based on the echogenicity of the lesion 
through the phases. Typically, a colorectal liver metastasis appears as a hypoechoic lesion 
during the arterial phase, accompanied by a halo of contrast defining its outer border. The 
metastasis then remains hypoechoic throughout the portal and late phases of scanning.
Several studies have compared CE-US with unenhanced US and found 
improvements in liver lesion detection and characterisation 4^,i67-i69,i75,iso,i8i,3i9-32i^  This
difference appears to be significant with CE-US having a documented sensitivity of 
approximately 87% compared to 53-77% with percutaneous ultrasound In
addition, CE-US appears to have the capability of detecting sub-centimetre lesions that are 
a known limitation of conventional ultrasound i^ 9,170,175,178,179  ^ Further work is required to 
confirm these promising results and to understand the interaction between ultrasound 
contrast agents, ultrasound beam and hepatic microcirculation.
Definity® (DMP 115; Bristol-Myers Squibb Medical Imaging, Billerica, MA, 
USA) is a second generation ultrasound contrast agent comprising octafluoropropane gas 
encapsulated in an outer perflutren lipid shell (Figure 6). Each mL contains a maximum of 
1.2 X 10 °^ perflutren lipid microspheres with a mean diameter of l . lpm -  3.3pm. 
Definity® is a transpulmonary blood pool agent that has a good safety profile with the only
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contraindications in patients with known hypersensitivity to octafluoropropane or in 
patients with cardiac shunts.
Definity® is licensed for use in cardiac imaging, but not for hepatic imaging. As a 
consequence, there is little published work on the application of Definity® in the detection 
of colorectal liver métastasés. The primary aim of this study was to assess the effect of 
three different intravenous doses of ultrasound contrast agent Definity® on the three phase 
vascular enhancement of colorectal liver métastasés, with particular attention paid to late 
phase enhancement. The secondary aim was to compare the detection rate of Definity® 
enhanced ultrasound to unenhanced ultrasound in the detection of colorectal liver 
métastasés.
I l l
Figure 6a: Structural formula of Octafluoropropane 322
F F
Octafluoropropane is chemically characterised as 1, 1, 1, 2, 2, 3, 3, 3-octafluoropropane 
with a molecular weight of 188, empirical formula of CsFg.
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Figure 6b: The three components of the Perflutren lipid microspheres: DPPA; DPPC and
MPEG5000 DPPE.^^^
DPPA
DPPC
Ô
MPEGsooo DPPE
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3.1.2 Patients and Methods
Contrast uptake by colorectal liver metastasis
Ten consecutive patients (mean age 64.7 years, SD 8.1, range 56-79 years) 
undergoing percutaneous ultrasound as part of their pre-treatment assessment of their 
colorectal liver métastasés were recruited from one centre. Ethical approval was obtained 
from the local research and ethics committee and each patient gave their informed consent.
Unenhanced ultrasound (US) was performed first using a HDÏ 5000 scanner 
(Philips, Bothell, Washington, USA) with a percutaneous C5-2Hz probe to target the 
required image: one liver metastasis surrounded with a region of healthy liver parenchyma. 
The patient was instructed to maintain stationery with regular breathing for the duration of 
each scan to minimise movement of the required image.
The scanner setting was then changed to pulse inversion harmonic imaging (PIH) 
with the ultrasound gain, focal zone and output power (Mechanical Index (MI): 0.04-0.08) 
all standardised. PIH is a sequence of two transmitted ultrasound pulses instead of one. 
The first pulse is an in-phase pulse and the second a mirror image of the first. For any 
linear target, the response to the second pulse is an inverted copy of the response to the first 
pulse. These responses are then summated and all linear echoes cancelled. Microbubbles, 
however, are non-linear and oscillate asymmetrically resulting in different responses to the 
two pulses. As a result the fundamental components of the echo are cancelled (i.e. the 
background noise from liver tissue) whilst the non-linear components (i.e. harmonics) are 
added, giving twice the level of a single pulse.
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A bolus injection of 0.4mL of Definity® was administered via a peripheral venous 
cannula followed by a 3mL saline flush and the required image was maintained throughout 
a four minute scan (Figure 7). After this time period, the remaining contrast (Definity® 
has a half life of > 5  minutes post injection) was burst by a high power ultrasound beam 
(MI; 1.00-1.20) and a five minute interval started before the next contrast injection. 
Following the interval, the patient then underwent the same protocol for two further scans 
performed after injections of 0.6mL and 0.8mL of Definity® respectively.
Data analysis
Each four minute scan was recorded onto a video loop and saved to CD to allow 
data analysis by computer quantification software (Q-Lab®, Quantification software. 
Philips, Bothell, USA). In each patient and for each dose, a region of interest (ROI) was 
drawn over the liver metastasis with another duplicate ROI drawn over liver parenchyma 
allowing signal intensity against time curves to be drawn (Figure 8). The liver parenchyma 
to liver metastasis contrast ratio (parenchymal signal intensity divided by liver metastasis 
signal intensity; PMR) was calculated for each dose at selected time points during the four 
minute scans: Os; 60s; 90s; 120s; 150s; 180s; 210s and 240s.
Statistical analysis was performed to compare any differences between the three 
intravenous doses of Definity® using the Mann Whitney test with significance taken at the 
5% level (SPSS for Windows, SPSS Inc., Chicago, Illinois, USA).
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Detection o f colorectal liver métastasés using percutaneous contrast enhanced ultrasound 
A further twenty three consecutive patients (mean age 67.2 years, SD 8.1, range 53- 
78 years) undergoing percutaneous ultrasound as part of their pre-treatment assessment of 
their colorectal liver métastasés were recruited from the same centre. Ethical approval was 
obtained from the local research and ethics committee and each patient gave their informed 
consent. Each patient underwent CT and/or MRI scanning that was used as the standard of 
reference for comparison. Unenhanced ultrasound (US) was performed using a HDI 5000 
scanner with a percutaneous C5-2Hz probe. The scanner setting was then changed to PIH 
with the ultrasound gain, focal zone and output power (MI: 0.04-0.08) all standardised. A 
bolus injection of l.OmL of Definity was intravenously injected. Both ultrasounds were 
performed systematically in axial, sagittal and oblique sweeps to ensure complete liver 
coverage. For each ultrasound the number of métastasés detected were recorded and 
compared to the standard of reference.
CT and MRI scanning
In all patients, CT and/ or MRI were performed as part of the patient’s routine 
assessment to stage their disease. Two phase CT examination was performed using two 
Multidetector CT scanners (Siemens, Sensation 4 and Sensation 16, Erlangen, Germany) 
with 2-4mm slice thickness/ 16 x 1.5mm collimation and enhanced with 150mL of 
Omniscan 300 (Amersham, UK) injected at 3-5mL/second. Scanning was performed at 25- 
30 seconds for the arterial phases and 55-60 seconds for the portal venous phase following 
the start of the bolus contrast injection in a peripheral vein.
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MRI was performed using two 1.5T MRI scanners (Philips, Gyroscan, Eindoven, 
Netherlands; Siemens Vision, Erlangen, Germany) with body and phase coils. Two 
different liver specific MRI contrast agents, MultiHance (Bracco Spa, Milan, Italy; dose 
ImL/kg body weight) and Resovist (Sobering AG, Berlin, Germany; 8 micromols F e/kg 
body weight) were used. Pre contrast axial T2 and T1 weighted 2D scans with and without 
fat saturation were first performed. MultiHance enhanced axial 3D scans were carried out 
at 17 seconds, 45 seconds, 120 seconds and 60 minutes following a bolus peripheral venous 
injection (at 2mL/second followed by 20mL flush at 2mL/second), whilst Resovist 
enhanced axial T2 weighted scan was performed 10 minutes after a bolus injection.
Data analysis
Statistical analysis was performed using non-parametrlc testing (Mann Whitney and 
Wilcoxon Sign Rank Tests) with significance taken at the 5% level (SPSS for Windows, 
SPSS Inc., Chicago, Illinois, USA). Changes in surgical management following CE-US 
were recorded (e.g. abandoned planned resection; more extensive resection; limited 
resection or combined resection with RF ablation). Sensitivity, accuracy and positive 
predictive value were calculated for unenhanced and enhanced ultrasound.
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Figure 7: Percutaneous contrast enhanced ultrasound (portal phase) showing two 
hypoechoic lesions consistent with colorectal liver métastasés (white arrows).
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Figure 8: Demonstration of placement of Regions of Interest (ROI) over hepatic
parenchyma (yellow) and colorectal liver metastasis (red).
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White arrow displays the halo outlining the outer edge o f the liver metastasis.
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3.1.3 Results
Contrast uptake by colorectal liver metastasis
The uptake of contrast was significantly lower in the colorectal liver metastasis for 
each of the three doses of Definity® ultrasound contrast agent (p<0.05, Mann-Whitney). 
The disparity in contrast uptake began at sixty seconds after the administration of contrast, 
with the liver parenchyma having a significantly greater uptake of contrast that was 
maintained throughout the remainder of the four minute scans. Figures 9-11 graphically 
display the contrast uptake for each dose o f Definity® at each measured time point.
Figure 12 displays the PMR for each doses of Definity® ultrasound contrast agent 
at each time point. There were no differences between the three doses up to 180s. At 210s 
and 240s, the PMR was found to be greater in the 0.4mL dose of contrast although this did 
not achieve statistical significance (p>0.05, Mann Whitney).
Detection o f colorectal liver métastasés using percutaneous contrast enhanced ultrasound 
In the twenty three patients studied, a total of 59 colorectal liver métastasés were 
identified on the standard of reference. The mean size of metastasis was 3.24cm (SD 1.84, 
range 0.5cm to 7cm). The mean number (± standard deviation; SD) of métastasés detected 
per patient for each imaging modality was: CT/MRI 2.57 (± 1.68); US 1.65 (± 1.03) and 
CE-US 2.83 (± 2.10), CEUS detected significantly more métastasés than US (p<0.0001) 
and CT/MRI (p<0.0001).
The sensitivity of US in the detection of colorectal liver métastasés was 64.4% 
achieving an accuracy of 64.4% and a positive predictive value of 100%. The sensitivity of 
CE-US was 100% with an accuracy of 90.8% and a positive predictive value of 90.8%.
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Change in surgical management as a result o f  CEUS
CE-US altered the management in 12 of the 23 patients (52.2%). This was due to: 
detection of extra métastasés in 6 patients and close proximity to major vessels and 
structures in the remaining 6 patients. As a consequence, 10 patients underwent RF 
ablation in addition to their planned resection and/or radiofrequency ablation; 1 patient was 
referred for chemotherapy after undergoing radioffequency ablation and 1 patient 
underwent extended hepatic resection.
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Figure 9: Comparison of ultrasound contrast uptake by liver parenchyma and colorectal
liver metastasis after administration of 0.4mL Definity® ultrasound contrast agent.
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Figure 10: Comparison of ultrasound contrast uptake by liver parenchyma and colorectal
liver metastasis after administration of 0.6mL Definity® ultrasound contrast agent.
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Figure 11: Comparison of ultrasound contrast uptake by liver parenchyma and colorectal
liver metastasis after administration of 0.8mL Defmity® ultrasound contrast agent.
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Figure 12; Comparison of liver parenchyma to liver metastasis contrast uptake ratio
(PMR) with three doses of Defmity® ultrasound contrast agent.
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3.1.4 Discussion
Unenhanced percutaneous ultrasound is accepted to have limitations in the 
detection of colorectal liver métastasés. The introduction of ultrasound intravenous 
contrast agents coupled with pulse inversion harmonic imaging technology has overcome 
some of these limitations, resulting in a growing evidence base for the use of CE-US in 
routine clinical practice. Interest has turned to understanding the complex interaction 
between ultrasound contrast agents, the ultrasound beam and the hepatic parenchyma in 
order to optimise CE-US use in the detection of focal liver lesions.
In this study, all three doses of Definity® contrast agent documented early disparity 
in the uptake of contrast between the colorectal liver metastasis and adjacent parenchyma 
that was maintained in to the later phases. The CE-US detection of malignant liver lesions 
occurs in the arterial phase when the lesion appears hypoechoic. Characterisation of this 
malignant liver lesion as a colorectal liver metastasis relies on the lesion remaining 
hypoechoic into the late phase. If these criteria are applied to the results after 
administration of Definity® ultrasound contrast agent, then it would appear that all three 
doses are appropriate for use in the detection and characterisation of colorectal liver 
métastasés.
To compare the three doses, the parenchyma to metastasis ratio was calculated and 
initially, there were no significant differences in the ratios of the three doses. However, at 
180 seconds after administration of the contrast the two smallest doses recorded greater 
ratios than the highest dose of 0.8mL. 0.4mL then continued to increase recording the 
highest ratios at 210 and 240 seconds. The differences in PMR ratio are likely to be a 
reflection of the microbubbles’ interaction with the liver. Not unexpectedly, the 0.4mL
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dose of contrast recorded lower individual contrast uptakes for both metastasis and 
parenchyma when compared to the other higher doses. However, the uptake declines as 
time progresses, suggesting that the contrast is being washed out of the parenchyma and 
liver metastasis, accounting for the higher PMR in the late phase of CE-US. This 
phenomenon is seen partially with the 0.6mls dose with the metastasis and the parenchyma 
having a slow decline in uptake in the late phase, but is completely absent with the O.Smls 
dose. These two higher doses may have saturated the liver, making a greater amount of 
contrast available to the circulation, indirectly increasing the metastasis contrast uptake and 
decreasing the PMR.
Much of the research on Definity® ultrasound contrast agent has focused on its 
effectiveness in cardiac imaging, a role for which is licensed for in the United States and 
has guidelines for its use in routine clinical practice. This novel study has found that 
Definity® also has a role in the detection of colorectal liver métastasés. In comparison to 
unenhanced ultrasound, CE-US found significantly more métastasés (65 vs 38) as well as 
having a higher sensitivity (100% vs 64.4%) and accuracy (90.8% vs 64.4%). 
Furthermore, the use of CE-US changed the management in 52.2% of patients due to not 
only the finding of additional métastasés, but to improved localisation of the métastasés 
defining their proximity to major vessels and structures.
These findings are consistent with other published studies using other ultrasound 
contrast agents, one of which reported an increased mean weighted sensitivity (using CT 
and MRI as the reference) from 70% to 91% after injection of ultrasound contrast 
I69;i75;i80;i8i;3i9-32i;323^  Thcsc improvements havc resulted in leading researchers in the field
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of CE-US to predicted that CE-US will replace unenhanced ultrasound in routine clinical 
practice, working alongside contrast enhanced CT and MRI in lesion characterisation^^^.
In addition to the other findings in this study, CE-US detected 6 additional 
suspected colorectal liver métastasés than the standard of reference of combined CT/MRI. 
Interpretation of this finding must be tempered as no pathological analysis is currently 
available to determine the exact nature of these 6 lesions. Future studies should overcome 
this limitation by taking biopsies for pathological confirmation.
In conclusion, this novel study found that a low dose of Defmity® ultrasound 
contrast agent enhanced the late phase vascular imaging of colorectal liver métastasés. In 
addition, the administration of Defmity® was found to result in improved detection of 
colorectal liver métastasés when compared to unenhanced ultrasound. These findings 
support the potential clinical role of Definity® enhanced ultrasound in the detection and 
characterisation of colorectal liver métastasés.
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Section 3.
Chapter 2: A prospective trial determining a new clinical application of contrast enhanced 
ultrasound in the intraoperative detection of colorectal liver métastasés.
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3.2.1 Introduction and aims
Partial hepatectomy is the only potentially curative option for patients with 
colorectal liver métastasés. Unfortunately, up to 50% of these patients develop hepatic 
recurrence with the majority occurring within the first two years after surgery^°°’^ °®. 
Estimations of the growth rate of colorectal liver métastasés have found them to be slow 
growing^^'^^\ Therefore, it is likely that these early recurrences are not new, but are 
métastasés that were occult at the time of initial radiological staging and operation.
Current preoperative radiological staging of colorectal liver métastasés consists of 
contrast enhanced computerised tomography (CT), magnetic resonance imaging (MRI) 
and/or intraoperative ultrasound (lOUS), the later being the current optimal standard^
Contrast enhanced ultrasound is an evolving technology that is developing an 
extensive evidence base in the transcutaneous detection of colorectal liver 
metastases^^^’^ ^^ ’^ ®^’^ ^^ . This chapter assessed a novel application of this developing 
technology; contrast enhanced intraoperative ultrasound (CE-IOUS).
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3.2.2 Patients and methods
Sixty consecutive patients (mean age 66.7 years, range 40-82; 31 females and 29 
males) scheduled to undergo partial hepatectomy for colorectal liver métastasés were 
recruited from two centres. All patients had been deemed suitable for hepatic resection 
based upon: curative resection of the colorectal primary (or was achievable in those 
undergoing planned synchronous resections); fitness for anaesthesia; no extra-hepatic 
disease (on imaging of the chest, abdomen and pelvis by CT) and surgically resectable 
colorectal liver métastasés. Ethical approval was achieved fi"om the local research and 
ethics committees and all patients gave their informed consent. Fifty-one patients had 
previous resection of their colonic primary, whilst the remaining nine patients were to 
undergo synchronous colonic and liver resection.
CT and MRI scanning
In all patients, CT and/ or MRI were performed within 6 weeks of the operation 
(mean 3.5 weeks) according to a standardised protocol. Two phase CT examination was 
performed using two Multidetector CT scanners (Siemens, Sensation 4 and Sensation 16, 
Erlangen, Germany) with 2-4mm slice thickness/ 16 x 1.5mm collimation and enhanced 
with 150mL of Omniscan 300 (Amersham, UK) injected at 3-5mL/second. Scanning was 
performed at 25-30 seconds for the arterial phases and 55-60 seconds for the portal venous 
phase following the start of the bolus contrast injection in a peripheral vein.
MRI was performed using two 1.5T MRI scanners (Philips, Gyroscan, Eindoven, 
Netherlands; Siemens Vision, Erlangen, Germany) with body and phase coils. Two 
different liver specific MRI contrast agents, MultiHance (Bracco Spa, Milan, Italy; dose
131
ImL/kg body weight) and Resovist (Schering AG, Berlin, Germany; 8 micromols Fe/kg 
body weight) were used. Pre contrast axial T2 and T1 weighted 2D scans with and without 
fat saturation were first performed. MultiHance enhanced axial 3D scans were carried out 
at 17 seconds, 45 seconds, 120 seconds and 60 minutes following a bolus peripheral venous 
injection (at 2mL/second followed by 20mL flush at 2mL/second), whilst Resovist 
enhanced axial T2 weighted scan was performed 10 minutes after a bolus injection.
Preoperative CT scans alone, combined CT and MRI and MRI scans alone were 
performed in 40, 4 and 16 patients respectively.
Intraoperative Ultrasound and Contrast Enhanced Intraoperative Ultrasound
At laparotomy, all patients underwent thorough abdominal and pelvic exploration 
for extrahepatic disease. The liver was mobilised from the diaphragm and bimanually 
palpated to detect the presence of métastasés. Unenhanced ultrasound (intraoperative 
ultrasound; lOUS) was then performed using a HDI 5000 scanner (Philips, Bothell, 
Washington, USA) with a high frequency finger probe (CT8-4, Figure 12). lOUS was done 
systematically in axial, sagittal and oblique sweeps to ascertain complete liver coverage. 
Variables recorded were: number of new métastasés detected; number of previously 
diagnosed métastasés detected; overall number of métastasés detected and proximity to 
major vascular and biliary structures.
Following the lOUS scan, contrast enhanced intraoperative ultrasound was 
performed (CE-IOUS) using the same scanner and finger probe. After changing the 
scanner setting to pulse inversion harmonic imaging (PÏH), a bolus injection of 2.4mL of 
contrast agent (SonoVue®, Bracco Spa, Milan, Italy) was administered via the central line
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followed by a lOmL saline flush (Figure 13). The ultrasound gain, focal zone and output 
power (Mechanical Index: 0.02-0,04) settings were all standardised during PIH imaging. 
Again, scanning was performed systematically with recording of the same variables as 
lOUS.
The number of métastasés identified on CT and/or MRI, lOUS and CE-IOUS were 
counted and mapped according to Couinaud’s classification Benign hepatic cysts were 
excluded and identified lesions were correlated with the findings from histopathology.
SonoVue® is a second generation microbubble contrast agent containing sulphur- 
hexafluoride gas stabilised by a phospholipid shell (mean size 2.5 micron in diameter; 90% 
measuring less than 8 micron) [Figure 13]. It has been extensively researched in 
transabdominal hepatic imaging and is licensed in the United Kingdom for this 
purpose^ 66;320;323;327-330^  SouoVue® was Selected as the characteristics, the optimal dose for
injection, as well as the optimal pulse inversion harmonics settings for SonoVue® have all 
been previously assessed.
Data analysis
Non-parametric statistical testing was performed (Mann Whitney and Wilcoxon 
Sign Rank Tests) with significance taken at the 5% level (SPSS for Windows, SPSS Inc., 
Chicago, Illinois, USA). Changes in surgical management following lOUS and CE-IOUS 
were compared (for example: abandoned resection; more extensive resection; limited 
resection or combined resection with radiofrequency ablation).
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Figure 13: Schematic representation of SonoVue® microbubbles structure.331
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Figure 14: The CT8-4Hz finger probe for intraoperative contrast enhanced ultrasound.
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Figure 15; Ultrasound contrast agent SonoVue® being reconstituted with saline prior to 
intravenous injection.
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3.3.3 Results
CE-IOUS was not performed in three patients due to more extensive disease being 
diagnosed: one patient was found to have more than 10 liver métastasés in a background of 
extensive fatty liver on lOUS and the remaining two patients had peritoneal métastasés. All 
three were excluded from further analysis
Number o f  métastasés detected
A total of 107 lesions were identified on histopathological assessment of biopsies 
and resected specimens, which was taken as the standard of reference. Of note, biopsies 
were taken prior to performing radiofrequency ablation on imaged métastasés. Of these 
107 lesions, 103 were colorectal liver métastasés and 4 were haemangiomas. The mean 
number (± standard deviation; SD) of correctly identified colorectal liver métastasés per 
patient on combined CT /MRI, lOUS and CE-IOUS was 1.54 (± 1.06), 1.65 (±1.19) and 
1.95 (±1.79) respectively with CE-IOUS detecting significantly more liver métastasés than 
lOUS (p-0.029) and combined CT/MRI (p=0.047). There were no statistical differences 
observed in the number of métastasés detected between: lOUS and combined CT/MRI 
(p-0.53) and CE-IOUS and histopathology findings (p~1.00). For combined CT/MRI, 
lOUS and CE-IOUS: the sensitivity was 76.7%, 81.5% and 96.3%; the accuracy 73.8%, 
78.5% and 96.3% and positive predictive values were 95.2%, 95.5% and 98.0% 
respectively.
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Size o f  lesions
The mean size (± standard deviation; SD) of lesions identified on CT/MRI/IOUS 
combined compared to CE-IOUS was 2.73cm (±1.46) and 1.71cm (±1.57) respectively. 
The mean size of the additional lesions identified on CE-IOUS was 0.84cm (±0.27), with 
the smallest lesion identified being 0.4cm.
Change in surgical management following CE-IOUS
CE-IOUS altered surgical management in 17 of the 57 patients (29.8%). This was 
due to: additional métastasés detected in 11 cases (19.3%); fewer métastasés detected in 2 
patients (3.5%); benign haemangioma diagnosed in 2 patients that were thought to have 
métastasés on CT or MRI or lOUS (3.5%); additional arteriovenous malformation detected 
in 1 patient (1.8%); and tumour margin too close in proximity to inferior vena cava in 1 
patient (1.8%). Figures 16 and 17 display the ultrasound images obtained in one of the 
patients that had an additional lesion found on CE-IOUS.
The finding of 11 additional métastasés with CE-IOUS changed the surgical plan 
to: extension to trisegmentectomy in 3 cases; additional non-segmental wedge resection in 
2 cases and radiofrequency ablation of the additional lesions as an adjunct to partial 
hepatectomy, in 6 patients. In the 2 patients that had fewer lesions detected with CE-IOUS, 
both were scheduled to undergo right hepatectomy. These were changed to 
trisegmentectomy in one patient and bisegmentectomy (VII, VIII) and subsegmentectomy 
in the other. In the 3 patients with benign lesions diagnosed on CE-IOUS, all had their 
planned resections cancelled. The remaining patient with the unresectable metastasis due 
to vessel proximity underwent RF ablation instead.
138
Forty of the 57 patients had no alteration in their planned surgical management 
after CE-IOUS was performed. Within this group, CE-IOUS did not detect any additional 
lesions in 37 patients. However, in the remaining 3 cases there were changes in staging 
that did not result in a change in management: 2 patients had additional lesions detected, 
but they did not entail any extended resection or adjunctive surgical procedures and in 1 
patient a lesion was wrongly diagnosed as metastasis on lOUS and CT, that was accurately 
identified on CE-IOUS as a benign haemangioma. Overall, CE-IOUS altered 
CT/MRI/IOUS hepatic staging in 20 out of 57 patients (35.1%).
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Figure 16: Unenhanced intraoperative ultrasound demonstrating no evidence of colorectal
liver métastasés in one patient.
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Figure 17: Contrast enhanced intraoperative ultrasound (CE-IOUS) showing colorectal
liver metastasis in same patient as figure 16.
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3.2.4 Discussion
This paper documents the first description of the use of contrast enhanced 
intraoperative ultrasound (CE-IOUS) with significant improvements described in the 
detection of colorectal liver métastasés. The addition of contrast agents improves every 
imaging modality and the value of contrast agents in CT and MRI in the detection of 
colorectal liver métastasés is established in current clinical practice. The application of 
contrast agents to ultrasound is relatively new, but is gaining increasing support in clinical 
practice. Therefore, the extension of contrast enhanced ultrasound to the intraoperative 
setting is a natural progression.
This trial found CE-IOUS changed the staging in 35.1% of patients when compared 
to preoperative imaging (CT/MRI) and intraoperative imaging (lOUS) combined. The 
detection of additional lesions, fewer lesions and benign lesions in addition to improved 
lesion characterisation, altered surgical management in 29.8% of patients. With a positive 
predictive value of 98%, CE-IOUS is promising and appears capable of detecting 
métastasés that were previously considered occult. This is supported by the smaller size of 
metastasis that CE-IOUS detected in comparison to other imaging modalities.
The use of microbubbles has several advantages over other imaging modalities. 
First, it is not radioactive, allowing several doses to be given at one examination if 
required. Second, it has low protein content with a good allergy and anaphylaxis profile 
and can be used in renal failure. Third, it produces real-time imaging allowing improved 
lesion characterisation. As for transabdominal contrast enhanced ultrasound, the typical 
appearance of a metastasis is of a hypoechoic lesion in the arterial phase that remains 
devoid of microbubbles in the portal and late phases.
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There are some limitations in the CE-IOUS technique. PIH is a prerequisite 
requirement and although widely available, it is not yet available for many of the 
intraoperative fmger-probes. The finger probe used in this study is ideally shaped for 
imaging the liver compared to the hand held probes used for percutaneous ultrasound. 
Another consideration is to the level of mechanical index during scanning. 0.02-0.04 is an 
extremely low ultrasound output power that renders the ultrasound screen display dark until 
the arrival of contrast. Although this can be compensated to some extent by increasing the 
ultrasound gain, there is a degree of observer adaptation with a learning curve. Lastly, the 
duration of contrast enhancement is only 2-3 minutes which may be related to the use of a 
high frequency finger probe as well as interaction with general anaesthetics delivered via 
positive pressure ventilation thereby disrupting the microbubbles. Repeat injections of 
SonoVue® are feasible to complete the examination and future software developments may 
be targeted at improving sensitivity to ultrasound contrast agents optimising the interaction.
In conclusion, these preliminary results suggest that CE-IOUS is superior to other 
imaging modalities in the detection of colorectal liver métastasés. Long term outcome 
studies will determine its true value in clinical practice.
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Section 3
Chapter 3: The development of a novel technique for the functional imaging of hepatic 
perfusion in colorectal liver métastasés using contrast enhanced ultrasound.
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3.3.1 Introduction and aims
Since the 1950s, the development of altered liver perfusion as a result of the 
presence of colorectal liver métastasés has been widely known. The initial works of 
Breedis and Young (1954) followed by Ackermann (1969-1974)^^^’^^  ^found the hepatic 
blood supply changed from the predominant portal vein supply seen in healthy liver 
parenchyma to hepatic arterial supply in the presence of colorectal liver métastasés. 
Although the exact mechanism driving angiogenesis is unknown, the alteration in blood 
supply could provide a means by which occult colorectal liver métastasés could be 
detected.
The measurement of hepatic blood flow is difficult and, despite there being many 
techniques available, there are few that accurately quantify blood flow. Non-invasive 
techniques have the greatest potential to enter routine clinical practice and have provided a 
source of research interest. Leveson and co-workers developed the Hepatic Perfusion 
Index (HPI) in 1983 using dynamic flow scintigraphy and static isotope scans and in 1991, 
Leen et al assessed the use of Doppler ultrasound (DPI) in the measurement of hepatic 
perfusion 3^2; 133, 137- 139  ^ Despite promising results, both the HPI and the DPI suffered from 
reproducibility problems, with other researchers finding poor predictive values in the 
detection of occult métastasés when the two techniques were replicated in different 
centres^ "^^ ’^ ^^ .
Contrast enhanced ultrasound (CE-US) is an evolving non-invasive technology in 
the measurement of cardiac perfusion, combining pulse inversion harmonic imaging with 
ultrasound contrast agents (microbubbles). These gas filled microbubbles are intravascular 
tracers that possess similar rheology to red blood cells. As a result, measurement of the
145
transit of these microbubbles through selected areas of myocardium has been shown to 
allow assessment of regional myocardial perfusion^^^’^ ^^ . With growing evidence in the 
diagnosis of both acute and chronic coronary stenosis, (termed myocardial contrast 
echocardiography, MCE) CE-US is a valuable tool in the assessment of ischaemic heart 
disease that has become incorporated in to routine practice in the United States^ '^^ '^ '^ .^
To date, there has been little work attempting to quantify liver perfusion using 
transabdominal CE-US. The aim of this chapter was to develop a novel and reproducible 
technique using CE-US to measure altered hepatic perfusion in patients with colorectal 
liver métastasés.
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3.4.2 Patients and methods
Fifty two consecutive patients (23 female, 29 male) with pathologically confirmed 
colorectal liver métastasés attending one specialist colorectal centre underwent one 
preoperative percutaneous CE-US. A healthy aged-matched control group (n=26) was 
recruited for comparison who met none of the following exclusion criteria: evidence of a 
systemic inflammatory response (e.g. operation in last 3 months; arthritis; long term anti­
inflammatory medication); parenchymal liver disease (e.g. cirrhosis; hepatitis; alcohol 
excess) or suspected/ confirmed malignancy. Ethical approval was obtained from the local 
research and ethics committee and all subjects gave their written informed consent.
Measurement o f liver perfusion: data acquisition
Each subject was placed supine with right upper quadrant, epigastrium and inferior 
right chest exposed (Figure 18). A cannula with a three way tap was inserted into a 
peripheral vein in the subject’s arm. Fundamental unenhanced ultrasound (US) with a 5- 
2Hz probe on a HDI 5000 scanner (Philips, Bothell, USA) was performed to target a large 
area of hepatic parenchyma. This area excluded the portal vein, hepatic artery or visible 
métastasés. Once the area was targeted, the scanner was switched to pulse inversion 
harmonic imaging (PIH; mechanical index 0.06-0.08) and the subject requested to remain 
still and keep his/her breathing quiet and shallow, allowing the target area to be maintained 
as a static image.
A bolus injection of 2.4mL of contrast (SonoVue®, Bracco Spa, Milan, Italy) 
followed by 2mL bolus saline flush were given and a 45 second video loop was recorded. 
A second scan was performed if the target area was not maintained as a static image due to
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patient movement. The video loop was then saved to CD to allow data analysis.
SonoVue® is a second generation contrast agent consisting of sulphur hexafluoride 
gas (SF6) stabilised by a phospholipid shell '^^^ The mean bubble diameter is 2.5pm and 
the concentration is between 100 and 500 million bubbles per mL. Due to the high 
molecular weight of the SF6 and its low solubility in water, SonoVue has good resistance 
to the pressure changes experienced in the pulmonary and coronary circulations. More 
importantly it has an outstanding safety profile. Following intravenous administration it is 
estimated that the elimination half life is 6 minutes with more than 80% of the gas expired 
via the lungs after 11 minutes.
Measurement o f  liver perfusion: data analysis
Video loops were analysed by computer quantification software (Q-Lab®, 
Quantification software, Philips, Bothell, USA). Each loop was replayed and a region of 
interest (ROI) selected that represented a large area of liver parenchyma (1000-2000mm^) 
[Figure 19]. Q-Lab then analysed the ROI and drew a hepatic perfusion curve (signal 
intensity versus time). The perfusion curve was then cropped to time zero which was 
defined as the first arrival of contrast i.e. all time points after time zero displayed a 
sustained increase in signal intensity that was at least 0.2 dB greater than time zero (Figure 
20). The perfusion curve was exported to Microsoft Excel (Microsoft, Seattle, WA, USA) 
in the form of a series of signal intensity measurements at 0.5 second time intervals. In line 
with previous research, the signal intensity at time zero that corresponded to the 
background signal from the hepatic parenchyma and other tissues, was subtracted from all 
subsequent signal intensities on the perfusion curve (Figures 21 and Each
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perfusion curve was analysed for four parameters: signal intensity at each 0.5s time point; 
areas under the curve; gradients of the curve and hepatic perfusion index.
Areas under the curve were calculated by linear interpolation between data points 
and gradients of the curves were calculated by linear regression analysis. These operations 
were performed over various time intervals as defined in the results section. The Hepatic 
perfusion index (HPI) was calculated: HPI = HI / HI + H2; where HI equals the slope of 
the arterial portion of the time intensity curve and H2 equals the portal venous portion of 
the time intensity curve^ "^ .^ The arterial and portal venous portions of the curve were 
defined according to the individual subject’s perfusion curve as described in the results 
section.
Statistical analysis o f liver perfusion
Signal intensities, peak intensities, areas under the curve, gradients of the curve and 
hepatic perfusion indices were compared between the patients and controls using the 
Mann-Whitney test. A p-value of less than 5% was considered to be significant with SPSS 
used for statistical analysis (SPSS for Windows, SPSS Inc., Chicago, Illinois, USA). To 
display the distribution of data between the two groups, scatter plots were drawn for each 
significant parameter. In addition, Receiver Operator Characteristic (ROC) curves were 
drawn to describe the power of each significant parameter between groups to determine its 
sensitivity and specificity.
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Measurement o f  liver perfusion: development o f CE-US technique
The development of a new technique evolves as each of its components is 
individually assessed, optimised and validated. The following paragraphs explain the 
theory and initial work around the development of liver perfusion measured by CE-US.
The majority of work in myocardial perfusion has focused on administering 
intravenous contrast by continuous infusion^^" .^ The microbubbles are then destroyed by a 
single high power ultrasound pulse that is triggered at a specific time point in the cardiac 
cycle (usually end-systole) with the rate of reappearance of the microbubbles recorded 
(replenishment kinetics) until attainment of a steady state. Using computer quantification 
packages, the reappearance rate was calculated to be equivalent to the mean microbubble 
velocity with the myocardial concentration at steady state indicating microvascular cross 
sectional area^^ .^ Initial work was carried out using animal coronary arteries that were 
incorporated in to a complex tube system that was connected to flow meters, pump infusers 
and pressure monitors. The results from these studies allowed definition and quantification 
of myocardial perfusion that went on to be confirmed with by live miimal and finally, 
human studies^^^’^ ^^ '^ ^^ .
There has also been work done using a bolus administration of contrast. Jayaweera 
et al (1994) used bolus administration of a contrast agent in to the left anterior descending 
coronary artery in eighteen mongrel dogs^^ .^ Using MCE they drew signal intensity versus 
time curves. For comparison, the transit rates of red blood cells labelled with technetium 
99m were recorded. The authors found that the perfusion curves were similar and 
concluded that using a bolus administration of contrast acted as an excellent intravascular 
tracer for measuring myocardial blood flow. Wei et al in 1998 directly compared bolus
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administration to continuous contrast infusion in the measurement of myocardial 
perftision^^\ From this animal study, the authors derived signal intensity versus time 
curves for both types of contrast administration and found that both approaches correlated 
well with the severity of the coronary stenosis. However, the authors concluded by 
favouring continuous contrast infusion as it minimised any influence from contrast 
recirculation, could be customised to the individual and allowed quantification of 
myocardial blood flow without any posterior wall attenuation.
For this chapter, it was hypothesised that if microbubbles have been shown to be 
reliable intravascular tracers, then a bolus administration of the contrast would allow 
quantification of real time functional imaging of liver blood flow (i.e. first pass analysis). 
In addition to the known differences between the cardiac and hepatic circulations (the 
presence of a hepatic artery and portal vein; different autoregulation and the timing of the 
blood supply is not as complex as the cardiac cycle), some contrast agents (including 
SonoVue® used in this study) are pooled in the liver parenchyma during the later phases of 
CE-US which would be likely to bias interpretation of parameters from a steady state. It 
was also thought that bolus administration had practical advantages: infusion machinery is 
not required and most contrast enhanced trained sonographers will already be used to 
administering boluses of contrast for focal liver lesion detection.
To measure the liver blood flow, it was decided to perform CE-US with the static 
image containing the hepatic artery and portal vein, an approach similar to the Doppler 
Perfusion Index. The ROI was then placed over each of these two vessels and the signal 
intensity-time curves drawn. However, after performing this approach in 10 patients, it 
became apparent that maintaining a static image that contained both vessels for 45 seconds
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was significantly affected by respiration. Despite educating the patient to take shallow and 
regular breaths, it was noted that even the smallest movement of a vessel moved it away 
from the ROI. Few patients could hold their breath for the full 45 seconds. Subsequently, 
it was decided to measure the parenchymal micro circulation in an approach similar to 
MCE, by placing a ROI over a large area of hepatic parenchyma that excluded the portal 
vein, the hepatic artery and any visible hypoechoic colorectal liver métastasés. Exclusion 
of visible métastasés meant that if the developed technique was successful, then the same 
area could be targeted in a study designed to detect occult liver métastasés.
Four parameters were selected to quantify hepatic perfusion: signal intensity at each 
0.5s time points (including peak intensity); areas under the curve; gradients of the curve 
and hepatic perfusion index. To date, there are few publications that have tried to define 
and quantify hepatic perfusion using CE-US.
In this chapter, signal intensity was selected as it provided an absolute value of 
contrast uptake at selected time points, including the peak contrast uptake. Peak contrast 
uptake has previously been shown to be significantly higher in patients with cirrhosis when 
compared to healthy controls, using contrast enhanced Doppler^ "^ "^ . The gradients of the 
curves in continuous infusion techniques have been shown to quantify mean microbubble 
velocity in myocardium and it is likely that the gradients from a bolus technique reflect the 
velocity of the microbubbles during the time period analysed^^" .^ Lastly, area under the 
curve could reflect blood volume. However, this, like interpretation of curve gradients, is 
an assumption that would need to be clarified by in-vitro studies using labelled red blood 
cells and flow meters as described previously^^^.
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The Hepatic perfusion index (HPI) is ideally suited to a bolus contrast injection 
technique as it is based on first pass of the contrast agent prior to any influence from 
contrast recirculation^"^^. Hepatic arterial flow is determined by analysis of the integrated 
liver time intensity curve and the integrated left ventricle time intensity curve as described 
by Peters that results in the following: HPI = H 1 / H 1 + H 2 .
Measurement o f  liver perfusion: intra- and interobserver variability
Intra- and interobserver reproducibility studies were performed on data acquisition 
and data interpretation. The first observer (SJ Moug) was aware of the allocation of each 
subject (patient or control) however, the second observer was blinded to each subject’s 
class. Each observer performed and interpreted their CE-US independently of the other.
Interobserver reproducibility of data acquisition was performed using eight subjects 
(n=6 patients, n=2 controls). Each observer administered one bolus of contrast and 
acquired data according to the method described already. On another group of 10 patients, 
the first observer performed two successive CE-US on each patient.
In relation to time zero, an external blinded investigator selected and coded forty- 
four scanning loops. Time zero was then calculated independently on 24 scanning loops 
(n=12 patients, n=12 controls) by the first and second observer. The remaining twenty 
blinded scanning loops (n=I2 patients, n=8 controls) underwent intraobserver 
reproducibility assessment. For each of these twenty loops, the first observer calculated 
time zero. Each scan was then re-coded by the external investigator and the first observer 
repeated the calculation of time zero.
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To determine any potential influence the area of ROI may have on data selection, 
three different regions of interest (ROIs) were drawn on 10 patients: lOOOmm ;^ 1500mm^ 
and 2000mm^. Hepatic perfusion curves were drawn for each ROI with signal intensities at 
each 0,5second time interval compared.
Statistical analysis o f intra- and interobserver variability and ROI comparison
The intraobserver and interobserver bias for data acquisition and interpretation of 
time zero were assessed by using the Student paired t-test. Significance was established at 
a p value less than 5% and SPSS was used for statistical analysis (SPSS for Windows, 
SPSS Inc., Chicago, Illinois, USA).
Intraobserver and interobserver reproducibility were quantified using the intraclass 
correlation coefficient (ICCC). ICCC overcomes a major drawback of the conventional 
Pearson product-moment correlation coefficient which is a measure of linear association 
rather than of agreement. A high product-moment correlation coefficient does not 
necessarily imply close agreement. For example, there may be a consistent additive bias 
between the observers. This contrasts to the ICCC which is a true index of agreement 
between observers’ measurements. The following criteria for agreement were used: poor, 
ICCC less than 0.40; fair, ICCC from 0.40 to 0.59; good, from 0.60 to 0.74; excellent, 
greater than or equal to 0.75. The ICCC is derived from a two-way analysis of variance 
with observers and subjects as factors. The formula used to calculate the ICCC was (MSS 
-  MSB)/ MSS + (k -  1) MSB + k/n (MSO -  MSB) where MSS is the mean squared 
variation between subjects; MSO is the mean squared variation between observers (or
"5
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repeated measurements); MSB, the residual mean squared; k, the number of observations 
and n, the number of subjects.
To quantify the intraobserver and interobserver variability the coefficient of 
variation (CV) was calculated: CV = 100% x standard deviation (SD)/mean.
In relation to the comparison of ROIs, both the ICCC and CV were calculated for 
the following: lOOOmm  ^vs I500mm^; lOOOmm  ^vs 2000mm^ and 1500mm^ vs 2000mm^.
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Figure 18: The positioning of subject, scan probe and ultrasound machine during contrast 
enhanced ultrasound measurement of hepatic perfusion.
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Figure 19: Frame from Q-Lab quantification software showing loop of contrast filled 
hepatic parenchyma with selected region of interest in red.
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Figure 20: Hepatic perfusion (signal intensity-time) curve achieved with CE-US in one 
patient with pathologically confirmed colorectal liver métastasés.
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It can be seen that the echo mean in the first 10 seconds after contrast administration 
fluctuates around 4dB which equates to the signal from background tissues in this patient. 
The grey arrow displays time zero, representing the first arrival of contrast.
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Figure 21: The hepatic perfusion (signal intensity-time) curve seen in Figure 20 with the 
curve now starting at time of contrast arrival (time zero) with the background signal 
subtracted.
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3.4.3 Results
The mean age of the patients with colorectal liver métastasés was 65 years (SD 
11.2, range 22-82 years), which did not differ significantly from the mean age of the 
control group (61 years, SD 7.6, range 50-84 years; Student t-test p>0.05). Percutaneous 
CE-US was completed in all recruited patients and controls successfully with no adverse 
reactions.
Figure 22 displays the median liver perfusion curves for the patient group and 
control group. Patients had a significantly higher signal intensity during the early phase of 
the perfusion curve for each 0.5s time point from 1.0s to 19.5s (p<0.05, Mann-Whitney). 
Table 7 displays the comparison in signal intensities between the groups at each 0.5s time 
point during this time period.
The significant time period was subdivided in to four time intervals according to the 
level of significance of the difference between groups at individual time points, allowing 
areas under the curve to be calculated (Table 8). From 1.0s to 19.5s, area under the curve 
was significantly greater in the patient group (patients median area 179.0 dB.s vs controls 
median area 119.7 dB.s; p=0.001). 4.5s to 8.5s was the time period of greatest disparity 
between the groups (i.e. p <0.001 for each 0.5s time point) and area under the curve during 
this period was also significantly higher in patients with colorectal liver métastasés 
(patients median area 193.1 dB.s vs controls median area 125.8 dB.s; p=0.001).
Visual assessment of the median liver perfusion curves for the patients and controls 
(Figure 22) allowed selection of four time periods where the gradients appeared to differ 
between the two groups: Is to 6s; 4.5s to 8.5s; 4.5s to 11.5s and 20s to 30s. The calculated 
gradients during 4.5s to 8.5s and 4.5s to 11.5s were not significantly different between the
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two groups (p=0.109 and 0.314 respectively). The gradient of the curve from Is to 6 s was 
significantly greater in the patients when compared to the controls: patients median 
gradient was 1.31 dB/s (0.83 -  1.74) versus controls median gradient of 0.74 dB/s (0.43 -  
1.27) [p=0.002]. In addition, the gradient of the curve from 20s to 30s was significantly 
lower in the patient group when compared to the controls: patients median gradient 0.05 
dB/s (-0.02 -  0.125) versus controls median gradient 0.13 dB/s (0.04 -  0.18) [p=0,006].
Two hepatic perfusion indices (HPI 1 and HPI 2) were calculated according to the 
statistically significant curve gradients. For HPI 1, the arterial gradient taken was from 
4.5s to 8.5s and the venous gradient was 20s to 30s. For HPI 2, the same venous gradient 
was used, but the arterial gradient was from Is to 6s. The patient group had significantly 
higher HPIs than the controls for both indices. For HPI 1, the patients’ median HPI was 
0.96 versus the controls’ median HPI of 0.86 (p=0.003). For HPI 2, the patients median 
HPI was 0.97 versus the controls’ median HPI of 0.87 (p=0.001).
Figures 23, 24 (a, b, c, d), 23 (a, b, c) and 25 display the scatter plots for absolute 
signal intensities, areas under the curve, gradients of the curve and HPI. It can be seen that 
there is significant overlap of data between the patients and the controls, especially for 
areas under the curve and gradients of the curve. The absolute signal intensities selected 
(4.5s, 5.0s, 5.5s and 7.5s) occurred within the most significant time period (4.5s to 8.5s) of 
the liver perfusion curve and although there is still significant overlap of data, it can be 
seen that the higher signal intensities occurred in the patient groups, especially at the 4.5s 
and 5s time points.
ROC curves for all four parameters were drawn with results displayed in Table 9. 
To allow comparison between parameters, a cut off point was established. It was thought
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that a moderate specificity with a high sensitivity would be the most clinically relevant 
approach i.e. using 60% specificity would minimise the number of false positives as well as 
reflecting accepted specificities for current imaging modalities like percutaneous 
ultrasound.
The highest areas under the curve and subsequent highest sensitivities (with 
specificity established at 58%) were achieved with the signal intensity parameter: 7.5s had 
an area of 0.77 and sensitivity of 85% and 5.5s had an area of 0.76 with 81% sensitivity. 
The areas under the curve parameter achieved lower areas on ROC curve analysis (range 
0.72 to 0.74) when compared to the signal intensity parameter, with the highest sensitivity 
being 79%. The gradients of the curve had the lowest area results as well as the lowest 
sensitivity at 70% (20s to 30s curve gradient). Figure 25 (a, b, c, d) displays the ROC 
curves for the highest sensitivities from each parameter.
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Figure 22: Comparison of liver perfusion between patients with colorectal liver métastasés
and healthy controls.
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The shaded area displays the region of statistically greater signal intensity (1.0s to 19.5s) in 
the patients with colorectal liver métastasés (p<0.05). Each data point represents the 
median signal intensity at that time point within each group.
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Table 7: Comparison of liver perfusion at individual time points in patients with colorectal
liver métastasés versus healthy controls during contrast enhanced ultrasound.
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signal intensity at time point 
(dB)
time point patients with colorectal liver métastasés controls p value
1.0 0.72 (0.49-0.98) 0.47 (0.14-0.69) 0.018
1.5 1.28 (0.81-2.63) 0.82 (0.42-1.43) 0.009
2.0 2.17(0.98-3.08) 0.92 (0.60-2.02) 0.005
2.5 2 .6 4 (1 .4 9 -4 .7 ) 1 .5 7 (0 .8 6 -2 .4 3 ) 0.002
3.0 3.68 (1 .8 0 -4 .8 9 ) 1.81 (0 .9 1 -3 .1 9 ) 0.003
3.5 4.06 (2 .1 7 -6 .4 6 ) 2.25 (1 .3 0 -3 .8 4 ) 0.01
4.0 5 .15(2 .81-7 .41) 2.29 (1 .4 7 -5 .3 8 ) 0.002
4.5 6.26 (3 .3 8 -8 .2 1 ) 3.25 (2.11 -4.44) 0.000
5.0 6.20 (3 .9 2 -8 .0 3 ) 3.26(1.91 -5 .7 9 ) 0.000
5.5 6.60 (4.84 -  9.54) 4.09 (2.39 -6.07) 0.000
6.0 7.60 (4.83 -1 0 .0 3 ) 4 .84 (2 .1 4 -6 .9 5 ) 0.001
6.5 8.05 (5 .2 6 -  10.61) 5.04 (2.62 -  7.71) 0.001
7.0 8.80 (6 .2 8 -  11.38) 5.07 (3.33 -7 .8 4 ) 0.000
7.5 9.63 (6 .2 6 -1 1 .3 8 ) 5 .3 2 (3 .1 4 -8 .7 6 ) 0.000
8.0 9.83 (6 .7 8 -1 2 .0 1 ) 5.06 (3.76 -  8.76) 0.001
8.5 10.49 (6 .7 6 -  12.24) 5 .3 6 (4 .4 7 -9 .9 5 ) 0.001
9.0 10.70 (7.49 -1 2 .7 2 ) 6.08 (3 .9 6 -1 0 .1 8 ) 0.002
9.5 11.11 (7 .2 7 -  13.05) 6 .4 4 (4 .9 8 -1 0 .1 8 ) 0.001
10.0 1 1 .2 0 (7 .6 6 - 13.65) 6 .7 8 (4 .8 6 -1 0 .0 6 ) 0.000
10.5 1 1 .3 2 (7 .8 0 -  13.74) 7.27 (5 .0 5 -1 0 .4 6 ) 0.001
11.0 11.45 (8 .3 9 -  13.89) 7.87 (5.83 -  11.26) 0.002
signal intensity at time point 
(dB)
time point patients with colorectal liver métastasés controls p value
11.5 11.84 (8 .6 5 -  14.55) 7.68 (5 .4 5 -1 2 .1 0 ) 0.003
12.0 12.71 (8 .7 2 -1 4 .2 0 ) 7.68 (5 .8 9 -1 2 .1 0 ) 0.002
12.5 12.94 (8 .6 3 -  14.95) 8.48 (6 .5 6 -1 2 .0 8 ) 0.003
13.0 13.09 (8 .9 7 -  14.80) 9.14 (6.85 -12.50) 0.004
13.5 12.79 (9 .2 2 -  15.11) 9 .57(6.37- 12.94) 0.001
14.0 12.84 (9 .7 9 -1 5 .2 1 ) 9 .3 7 (6 .9 7 -1 3 .0 7 ) 0.004
14.5 1 3 .1 6 (9 .8 8 -  15.39) 9.51 (7 .0 6 -1 3 .1 0 ) 0.002
15.0 1 3 .6 0 (9 .9 1 -1 5 .4 0 ) 9.93 (7 .5 5 -  13.38) 0.005
15.5 1 3 .7 3 (10 .11 -15 .14 ) 1 0 .1 6 (7 .7 6 -1 4 .0 5 ) 0.005
16.0 13.76 (1 0 .4 6 -  15.53) 10.48 (7 .8 8 -  14.05) 0.010
16.5 1 4 .0 4 (1 0 .6 9 - 15.55) 10.53 (8 .1 7 -1 4 .0 4 ) 0.012
17.0 1 3 .5 9 (10 .85 -15 .71 ) 11.08 (8.46 -14.20) 0.028
17.5 1 3 .86 (1 1 .1 3 -1 5 .7 9 ) 11.60 (8.62-14.40) 0.027
18.0 13.81 (1 1 .4 5 -  15.68) 11.71 (8.69 -14.74) 0.037
18.5 1 4 .1 7 (1 1 .3 4 - 16.20) 11.90 (8.69-14.74) 0.026
19.0 13.95 (1 1 .3 2 -  15.88) 11.84 (8 .9 0 -  15.10 0.043
19.5 14.15(11.58-16.21) 12.25 (8.95-15.13) 0.031
Results expressed in decibels (dB) and shown as median (interquartile range).
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Table 8: Comparison of area under curve for selected time periods in patients with
colorectal liver métastasés versus healthy controls during contrast enhanced ultrasound.
area under curve during time period
time period 
(s)
level o f significance o f each 0.5s 
time point during time period
patients with 
colorectal liver 
métastasés
controls p value
1 to 19.5 p<0.043 179.0
(125 .3 -2 1 5 .0 )
119.7 
(9 1 .4 -  170.9)
0.001
4.0 to 15.5 p<0.005 186.1
(1 3 0 .9 -223 .1 )
121.4 
(93.3 177.7)
0.001
4.0 to 11.5 p<0.002 199.9 
(142.0 -237.4)
130.9 
(90.5 -  192.7)
0.001
4.5 to 8.5 p<0.001 193.1
(1 3 6 .5 -230 .8 )
125.8 
(8 6 .2 -  185.2)
0.001
Results expressed in dB.s and shown as median (interquartile range).
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Figure 23a: Scatter plot displaying distribution of signal intensities at 4.5 seconds after
time zero in patients with colorectal liver métastasés and healthy controls.
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Figure 23b: Scatter plot displaying distribution of signal intensities at 5.0 seconds after
time zero in patients with colorectal liver métastasés and healthy controls.
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Figure 23c: Scatter plot displaying distribution of signal intensities at 5.5 seconds after
time zero in patients with colorectal liver métastasés and healthy controls.
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Figure 23d: Scatter plot displaying distribution of signal intensities at 7.5 seconds after
time zero in patients with colorectal liver métastasés and healthy controls.
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Figure 24a: Scatter plot displaying distribution of area under curve l-19.5s in patients with
colorectal liver métastasés and healthy controls.
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Figure 24b: Scatter plot displaying distribution of area under curve 4-15.5s in patients with
colorectal liver métastasés and healthy controls.
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Figure 24e: Scatter plot displaying distribution of area under curve 4-11.5s in patients with
colorectal liver métastasés and healthy controls.
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Figure 24d: Scatter plot displaying distribution of area under curve 4-8.5s in patients with
colorectal liver métastasés and healthy controls.
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Figure 25a: Scatter plot displaying distribution of gradient of curve from LOs to 6.0s in
patients with colorectal liver métastasés and healthy controls.
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Figure 25b: Scatter plot displaying distribution of gradient of curve from 4.5s to 8.5s in
patients with colorectal liver métastasés and healthy controls.
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Figure 25c: Scatter plot displaying distribution of gradient of curve from 4.5s to 11.5s in
patients with colorectal liver métastasés and healthy controls.
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Figure 25d: Scatter plot displaying distribution of gradient of curve from 20s to 30s in
patients with colorectal liver métastasés and healthy controls.
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Figure 26a: Scatter plot displaying distribution of Hepatic Perfusion Index in patients with
colorectal liver métastasés and healthy controls (arterial: gradient of curve from 1 to 6
seconds; venous: gradient of curve from 20 to 30 seconds).
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Figure 26b: Scatter plot displaying distribution of Hepatic Perfiision Index in patients with
colorectal liver métastasés and healthy controls (arterial: gradient of curve from 4.5 to 8.5s
seconds; venous: gradient of curve from 20 to 30 seconds).
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Controls Patients
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Figure 27a: ROC curve for measurement of liver perfusion (signal intensity at 7.5 seconds)
in patients with colorectal liver métastasés and healthy controls.
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Figure 27b: ROC curve for measurement of liver perfiision (area under curve 4.5 to 8.5
seconds) in patients with colorectal liver métastasés and healthy controls.
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Figure 27c: ROC curve for measurement of liver perfusion (gradient of curve at 20 to 30
seconds) in patients with colorectal liver métastasés and healthy controls.
1.00
.7 5 -
Sensitivity
.5 0 -
.2 5 -
0.00
1.00.25 .50 .750.00
1 - Specificity
183
Figure 28d: ROC curve for measurement of Hepatic Perfusion Index in patients with
colorectal liver métastasés and healthy controls (arterial: gradient of curve from 1 to 6
seconds; venous: gradient of curve from 20 to 30 seconds).
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Table 9: Sensitivity and specificity of four liver perfusion parameters at detecting patients 
with colorectal liver métastasés using ROC curve analysis.
Parameter area under 
ROC curve
95% C l p value sensitivity specificity
signal
intensity 4.5s 0.76 0.65 -0.86 0.000 77% 58%
5.0s 0.74 0.63 -0.86 0.000 71% 58%
5.5s 0.76 0 .6 5 -0 .8 7 0.000 81% 58%
7.5s 0.77 0 .6 7 -0 .8 8 0.000 85% 58%
area under 
the curve 1 to 19.5 0.72 0 .6 1 -0 .8 4 0.001 73% 58%
4 to 15.5 0.73 0 .6 2 -0 .8 5 0.001 79% 58%
4 to 11.5 0.74 0 .6 2 -0 .8 5 0.001 79% 58%
4.5 to 8.5 0.74 0 .6 3 -0 .8 5 0.001 79% 58%
gradient 1.0s to 6.0s 0.72 0 .6 0 -0 .8 4 0.002 75% 58%
4.5s to 8.5s 0.61 0.48 -  0.75 0.109 56% 58%
4.5s to 11.5s 0.57 0.44 -  0.70 0.314 56% 58%
20s to 30s 0.69 0 .5 7 -0 .8 1 0.006 70% 58%
HPI (1) H I/H I +H2 0.71 0.59 - 0.82 0.003 69% 58%
HPI (2) H l/H l + H2 0.73 0.61-0.84) 0.001 77% 58%
The parameters are defined according to absolute time points (signal intensity) or a specific 
time interval (area under the curve, gradient and HPI). Selection of time points for each 
parameter is defined in results section.
185
Reproducibility o f  data acquisition
The interobserver CV was 7.3% with an ICCC of 0.698. There was no evidence of 
bias between observers’ data acquisition (p"0.960). In relation to intraobserver 
reproducibility of data acquisition, the CV was 14.2%, ICCC 0.829 with no significant 
differences between measurements 1 and 2 (p=0.300). Figures 28 and 29 display the 
spread of the data.
Reproducibility o f  data analysis
No significant differences were found in the calculation of time zero between the 
first and second observers (t-test p=0.716) with Figure 30 graphically displaying the 
results. The interobserver CV was 2.5% with an ICCC of 0.992. The intraobserver CV 
was 1.7% with an ICCC of 0.996 with no evidence of bias between first and second 
measurements (p=0.516) [Figure 31].
Influence o f  region o f interest
In the comparison of the three ROIs: lOOOmm  ^against ISOOmm ,^ the mean CV was 
3.2% (range 1.5 -  6.1) with an ICCC of 0.989. Analysis of 1500mm^ versus 2000mm^, the 
mean CV was 2.7% (1.1 -  6.1) and an ICCC of 0.993. The mean CV was 5.2% (1.9 -  
11.8) with an ICCC of 0.971 when ROI lOOOmm  ^was compared to 2000mm^.
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Figure 28: Interobserver variability in data acquisition between the first (1) and second
observer (2).
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Figure 29: Intraobserver variability in calculation of data acquisition with the first
observer.
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Figure 30; Interobserver variability in calculation of time zero between the first (1) and
second observer (2).
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Figure 31: Intraobserver variability in calculation of time zero by the first observer.
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3.4.4 Discussion
Liver blood flow is an important physiological marker of liver function that can 
reflect the liver’s response to injury, regeneration and the presence of malignant 
disease^^^’^ ^^ ’^ "*^. Despite advancing imaging technologies, accurate measurement of liver 
perfusion remains technically difficult due to the dual blood supply and the changing 
contributions of the hepatic artery and the portal vein. The development of a technique that 
can reliably measure liver perfusion could potentially detect early angiogenesis caused by 
colorectal liver métastasés, allowing early diagnosis and initiation of treatment.
This study has developed a novel and reproducible technique for measuring liver 
perfusion that detected altered liver perfusion in patients with colorectal liver métastasés. 
Using a bolus injection of intravenous contrast with low power pulse inversion harmonic 
imaging, the uptake of contrast through the liver allowed signal intensity-time curves to be 
drawn. With previous research documenting that the microbubbles are mimicking red 
blood cell flow, then measurement of the liver’s contrast uptake allows quantification of 
hepatic perfusion. Furthermore, the targeting of a large area of hepatic parenchyma in the 
ROI means that perfusion at the level of the hepatic microcirculation is being measured.
Initial visual comparison of the signal intensity-time curves displayed three 
arbitrary time phases that are likely to reflect the three vascular phases of hepatic imaging 
with contrast enhanced ultrasound: early (arterial); intermediate (portal) and late 
(sinusoidal). The early phase began at the arrival of contrast and involved a steep gradient 
during the first 10 to 15 seconds. The intermediate phase started at approximately 15 
seconds with a flatter slope and continued to approximately 30 seconds before reaching a 
plateau that was maintained through the late phase.
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The majority of differences in hepatic perfusion were found in the early phase with 
the patient group having significantly greater signal intensities, gradients and areas under 
the curve when compared to the control group. The remaining difference was in the 
intermediate phase when the patient group experienced a significantly smaller gradient. 
The differences in the early and intermediate gradients between patients and controls 
resulted in the HPI being significantly elevated in the patient group.
The increased perfusion displayed by the patients during the early phase of the 
perfusion curve is likely to be the result of the predominant hepatic arterial blood supply. 
Since pathologists first documented an altered blood supply in the presence of colorectal 
liver métastasés, many authors using different technologies and approaches have confirmed 
their 5n d i n g s ^ ^ 138;347;34s^  The initial steeper gradient in the patients’ perfusion curve 
reflects the earlier arrival of the microbubbles carried by the dominant hepatic artery, with 
the increased area under the curve suggesting that this increased velocity results in a greater 
blood volume. Later on in the perfusion curve, the portal vein begins to exert its influence. 
A steeper gradient in the controls in the intermediate phase suggests that although the 
patients have an increased arterial supply, they also have a reduction in their portal vein 
contribution. This is a finding that other authors have documented, with some concluding 
that a balance between the two arterial components exists as the overall blood supply (and 
subsequently volume) to the liver does not change. This study would support this theory, 
as it found no significant differences in total area under the curve and in peak intensity, 
suggesting that the overall blood supply and microbubble concentration remains unchanged 
in the presence of colorectal liver métastasés.
192
There were no differences in any of the perfusion parameters between the groups in 
the late phase. It is highly likely that recirculation of the intravenous contrast agent is 
occurring during this time frame, dampening the separation of the arterial and venous 
components. The liver is unusual in that recirculation of a contrast agent occurs through 
two routes: via the splenic circulation and via the splanchnic recirculation. As a result, 
measurement of perfusion parameters in the late stage using a bolus technique may not 
yield any worthwhile information.
Unlike other types of radiological imaging, ultrasound imaging is dependent on the 
experience of the sonographer using it. As a result, the development of any new technique 
using ultrasound needs reproducibility studies to ensure that the technique is transferable 
between sonographers, a limitation that prevented the HPI and DPI from entering routine 
clinical practice. This study performed reproducibility analysis on both acquisition of data 
and interpretation of data and found that contrast enhanced measurement of liver perfusion 
is reproducible.
Data acquisition requires the sonographer to target a large area of liver parenchyma 
that will remain stationery during the 45 seconds of the ultrasound scan. There was a 
learning curve present as the sonographer had to administer the contrast bolus with one 
hand whilst keeping the probe in position with the other. In addition, some subjects have 
difficulty maintaining their breathing shallow and regular during the ultrasound loop. 
However, both these difficulties can be overcome with practice from the sonographer (the 
second observer underwent 20 training scans) and clear directions to the patients.
The arrival of the contrast to the hepatic parenchyma (time zero) was extremely 
important as it determined the start of the liver perfusion curve. If there was found to be
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wide variation in the calculation of time zero, then any statistical interpretation of the 
perfusion curves would be substantially flawed. However, there were no significant 
differences demonstrated by the intraobserver and interobserver reproducibility studies.
The only remaining potential bias was selection of the region of interest. Q-Lab 
allowed any area to be chosen of any shape the observer requested and it was seen that the 
smaller areas (50-100mm^) resulted in substantial variations in data, either due to them 
sitting on a large vessel, or the patient’s respiration moving the region of interest. As a 
result, they were disregarded as they were not reflecting perfusion of the hepatic 
microcirculation. Large areas of hepatic parenchyma (i.e. greater than lOOOmm^) were 
then selected that did not include any tumour, the hepatic artery or the portal vein. 
Reproducibility studies found the three selected areas (1000 mm^, 1500 mm^, 2000 mm^) 
did not significantly affect the acquisition of data and 1000 mm^ was taken as the minimal 
accepted area of the region of interest.
These initial results are promising, making it important to determine the clinical 
applicability of liver perfusion measured by contrast enhanced ultrasound. From the scatter 
plots for each of the four significant parameters (signal intensities; areas under the curves; 
gradients of the curves and hepatic perfusion indices), it can be seen that there is no clear 
separation of data between the two groups. As a result, a cut off point cannot be 
established that confidently differentiates between healthy controls and patients with 
metastatic disease. This is reflected in the range of sensitivities and specificities achieved 
by the four variables. Interestingly, the highest sensitivity of 85% was achieved by signal 
intensity at a single time point (7.5s). Using a single time point to differentiate between 
groups requires the technique to be highly specific, leaving little margin for error and it
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was anticipated that the other three parameters would perform better at differentiating 
between the two groups as they covered a larger data range.
Unfortunately, these results appear to limit the clinical applicability of the contrast 
enhanced ultrasound measurement of liver perfusion. With no parameter capable of 
accurately defining the presence of colorectal liver métastasés in patients with overt 
disease, it is extremely likely that this technique will not be capable of detecting occult 
disease. There are several potential explanations for this. First, targeting and measuring 
the hepatic blood flow at the level of the microcirculation may dampen the individual 
contributions of the hepatic artery and portal vein. As a result, it is possible that the 
significant differences found by measuring perfusion at the level of the microcirculation 
would become magnified if the individual vessel’s components could be measured. This 
study set out to measure the perfusion of the individual vessels, but found that the patients’ 
breathing made this difficult and even impossible in some cases. However, in the future it 
may become possible to track the vessels, minimising the influence of breathing and there 
are early reports of this advanced computer software in the literature^^®.
Another potential factor is the physics of the microbubbles. We know what gas the 
microbubbles contain and how they interact with ultrasound waves as part of pulse 
inversion harmonic imaging. What is uncertain is how the microbubbles interact with the 
hepatic parenchyma on their passage. It has been documented that SonoVue® eventually 
pools in the liver, which suggests that analysis of the arrival of the contrast agent would 
provide the most information, including perhaps the time to arrival. However, the contrast 
agent could be interacting with the hepatic parenchyma upon arrival via the hepatic artery
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and not accurately representing blood flow. In addition, there could be interaction with 
other organs via the portal vein and subsequent recirculation.
Both these limitations could be addressed by starting with laboratory based studies 
where parameters of hepatic blood perfusion are defined. There are obvious differences in 
myocardial and hepatic perfusion and what applies to CE-US in cardiac imaging may not 
be relevant in hepatic imaging. The first step would be a comparison between signal 
intensity versus time curves for CE-US against labelled red blood cells. If good correlation 
was found then this would establish that microbubbles are intravascular tracers for liver 
perfusion. Subsequent experiments would be a combination of animal and human studies 
where the relationship between microbubble transit rates, hepatic blood volume and hepatic 
blood flow would be established, leading to optimal interpretation of signal intensity-time 
perfusion curves. Decisions could then be made as to whether direct measurement of 
hepatic artery and portal vein provides the best data or whether measuring the perfusion of 
the microcirculation is more relevant. In addition, continuous infusion of contrast with 
replenishment kinetics (potentially including a mathematical model) could be analysed.
One final discussion point is the evidence on which this chapter is based on: the 
alteration in hepatic blood supply in the presence of colorectal liver métastasés. The fact 
the hepatic circulation changes is unquestioned. What is less clear is to what extent this 
change occurs, what factors are influencing the change and whether the change is a static 
phenomenon. For example, tumour size appears to be an influencing factor. Ackermann 
found that small tumours (l-2mm) had a variable blood supply that could be arterial, 
venous or both in origins. Moderate sized tumours (3-7mm) had well developed arterial 
circulations whilst massive tumours (7-33mm) returned to a varied pattem^^ '^^^^. It is
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likely that there are other influencing factors (including: age and sex; hepatic pressure, 
portal hypertension, portosystemic shunting; catacholamines, hormones; inflammation,
%cytokines, prostaglandins; growth factors; nitric oxide) and that hepatic vascularity is a 
changing phenomenon.
In conclusion, measurement of altered hepatic perfusion in colorectal liver 
métastasés can be reliably performed by percutaneous contrast enhanced ultrasound.
Further work analysing the individual contributions of the hepatic blood supply alongside 
improved understanding of the physics of the microbubbles in the hepatic circulation may 
develop a clinically applicable technique for the detection of occult colorectal liver 
métastasés.
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Section 3.
Chapter 4: Perioperative changes in hepatic perfiision in patients undergoing curative
partial hepatectomy for colorectal liver métastasés using contrast enhanced ultrasound.
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3.4.1 Introduction and Aims
Previous work has proposed that altered hepatic perfusion present in patients with 
colorectal liver métastasés may have a predictive role in the detection of occult liver 
m é t a s t a s é s Two main approaches have been documented using dynamic 
scintigraphy and Doppler ultrasound, with both groups finding that their individual 
perfusion indices reliably detected the presence of both overt and occult colorectal liver 
métastasés. Leveson et al calculated HPI using dynamic scintigraphy in 50 patients that 
underwent laparotomy for colorectal cancer None of the group had hepatic métastasés 
and were followed up for one year, during which 18 patients developed hepatic métastasés. 
Every one of these 18 patients had an elevated DPI prior to resection of their primary 
leading the authors to conclude that calculation of HPI can detect occult liver métastasés.
Using Doppler ultrasound, Leen et al (1991) also found that altered hepatic 
perfusion in patients undergoing resection for colorectal cancer had the potential to detect 
métastasés below the limits of conventional imaging techniques However, both
approaches suffered from poor reproducibility when other centres attempted to validate 
them^"^\ As a result, neither approach has been accepted into routine medical practice.
We have developed a novel technique using contrast enhanced ultrasound that 
reliably measures hepatic perfusion. Using this technique the principal aim of this chapter 
was to document perioperative hepatic perfiision changes in patients undergoing curative 
partial hepatectomy for colorectal liver métastasés. The secondary aim was to assess any 
relationship between perioperative hepatic perfusion and long-term patient outcomes.
199
3.4.2 Patients and methods
17 consecutive patients (10 female, 7 male) with a mean age 68 years (range 42 -  
82 years, SD 10.1 years) undergoing partial hepatectomy for pathologically confirmed 
colorectal liver métastasés were recruited from one specialist colorectal centre. Ethical 
approval was obtained from the local research and ethics committee and all patients gave 
their written informed consent. Using contrast enhanced ultrasound (CE-US), serial 
measurements of hepatic perfusion were taken: pre-operative; intra-operative; post­
operative days 1, 2 and 3 and at 3 months.
Hepatic perfusion technique consisted of fundamental unenhanced ultrasound (5- 
2Hz probe; HDI 5000 scanner, Philips, Bothell, USA) to target a large area of hepatic 
parenchyma (region of interest 1000mm^-2000mm^). This area excluded the portal vein, 
hepatic artery and visible métastasés and was maintained as a static image throughout a 45 
second loop of CE-US (peripheral bolus injection of 2.4mL SonoVue® with 2mL saline 
flush; pulse inversion harmonic imaging and mechanical index 0.06-0.08). Signal-time 
intensity curves were derived by Q-Lab® (Quantification software, Philips, Bothell, USA). 
Three parameters were selected to allow data interpretation: area under the curve (AUG), 
peak intensity and peak gradient calculated for each curve. The time period for area under 
the curve was from 1.0s to 19.5s, a time period that has been shown to be significant from 
previous analysis (chapter 3). Peak intensity was the highest contrast uptake recorded 
within 20 seconds after contrast administration, a time period found to be significant from 
previous work (chapter 3). It was expressed as a percentage change from baseline [peak 
intensity = (peak intensity/ intensity at time zero) x 100]. Peak gradient was the highest 
gradient calculated during the early phase of the time intensity curve (from Os to 10s).
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Medians (interquartile range) were calculated and Wilcoxon’s signed ranks test performed 
to compare variables on each post-operative day with pre-operative values.
All patients were followed up regularly as part of the routine surveillance 
performed by the specialist centre. CT and/ or MRI scanning was/ were performed at 6 
months then at yearly intervals up to 5 years after their partial hepatectomy. If patients 
became symptomatic, then earlier investigations were instigated. Each patient’s disease 
free survival and overall survival were recorded with comparison made to perioperative 
hepatic perfusion.
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3.4.3 Results
AUC experienced a decrease intra-operatively (242.7dB.s vs 181.5dB.s, p=0.07), 
increased significantly on post-operative day 1 (242.7dB.s vs 262.8dB.s, p=0.025) and 
remained elevated on post-operative days 2 and 3 (242.7dB.s vs 255.4 dB.s, p=0.056 and 
248.6 dB.s, p=0.036 respectively). AUC returned to pre-operative values at 3 months 
(242.7dB.s vs 221.4 dB.s, p>0.05). Figure 32 graphically displays the changes.
Peak intensity experienced a significant decrease intra-operatively (835.0dB vs 
384.4dB, p=0.001), returned to pre-operative values on day 1 and remained unchanged 
throughout the series (Figure 33).
Peak gradient decreased intraoperatively, but not to significance (2.32dB/s vs 
2.15dB/s, p>0.05). It remained unchanged through the remainder of the study time points 
(Figure 34).
The median time of follow up was 16.2 months (range 3.0 -  27.2 months). Six 
patients developed recurrence: liver métastasés in 5 patients and lung métastasés in the 
remaining patient. During follow up, only one patient with confirmed recurrent liver 
métastasés had died due to progression of their disease. Median time to hepatic recurrence 
was 11 months (95% Cl 0.9 -  21.1) with an overall survival at 2 years of 87.5%.
Comparison of hepatic perfusion between patients that had local recurrence (n=5) 
and those that were disease free (n= ll) found no significant differences in AUC and peak 
gradient throughout the perioperative time period. In relation to peak intensity, there were 
no differences between the groups preoperatively and on postoperative days 1 to 3. 
However, at 3 months the recurrence group had a significantly greater peak intensity than 
the patients that had not recurred (1269.9 dB vs 505.7 dB, p~0.003), shown by figure 35.
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Figure 32: Perioperative changes in area under the curve (AUC) in patients undergoing
curative partial hepatectomy for colorectal liver métastasés.
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Figure 33: Perioperative changes in Peak Intensity in patients undergoing curative partial
hepatectomy for colorectal liver métastasés.
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Figure 34: Perioperative changes in Peak Gradient in patients undergoing curative partial
hepatectomy for colorectal liver métastasés.
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Figure 35: Comparison of perioperative changes in peak intensity in patients with and 
without locally recurrent metastatic disease.
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3.4.4 Discussion
This is first study to document perioperative hepatic perfusion in patients
undergoing curative hepatic resection for colorectal liver métastasés using contrast
enhanced ultrasound.
Of the three parameters, AUC experienced the most fluctuation during the time 
period studied. The first change happened intraoperatively and this decrease in AUC was 
accompanied by decreases in both peak intensity (p>0.05) and peak gradient (p<0.05). It is 
likely that these changes are a result of the general anaesthetic. Indeed, all patients had 
anaesthetic agents administered that are known vasodilators, decreasing blood pressure and 
subsequently, hepatic perfusion. Furthermore, all were intubated and were receiving 
positive pressure ventilation that has previously been shown to destruct the 
microbubbles^^\
Whilst the other two parameters returned to normal on postoperative day 1, AUC 
continued to increase up to day 3. This may be a reflection of the acute systemic 
inflammatory response syndrome (SIRS), increasing the blood supply to the liver remnant. 
This response to surgery is physiological, indicating an adequate host response to surgical 
trauma and is well documented in the literature in patients undergoing various types of 
major surgery If the postoperative recovery is uncomplicated, then SIRS declines
over the following weeks. Indeed, AUC had returned to preoperative values by the follow 
up scan performed at three months.
To assess if hepatic perfusion measured by CE-US had the capacity to predict 
occult hepatic métastasés, the three parameters were compared between two groups: 
disease free versus the group that had disease recurrence. AUC and peak gradient were not
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statistically different between the groups at any of the time points. However, peak intensity 
was found to be significantly higher at 3 months after surgery in the patients that had 
recurred than in the disease free group. This allows the tentative suggestion that peak 
intensity may have a potential predictive role although the small patient numbers disallow 
any stronger conclusions.
AUC is easily defined and calculated and may well be the most sensitive parameter 
of quantifying perioperative hepatic perfusion using CE-US. Perioperative changes in 
AUC are likely to reflect the perioperative SIRS, and future work analysing blood markers 
of SIRS (e.g. C-reactive protein and interleukin-6) would provide further information. 
Unfortunately, AUC does not appear to be indicative of occult hepatic disease. This could 
be a reflection of the small study numbers and certainly increased recruitment would allow 
definite conclusions to be drawn. In addition, it is still not understood what aspect of 
hepatic perfusion AUC is representing. It may well be blood volume or capacitance and if 
so, it is not known if this is the best way to interpret hepatic perfusion with CE-US. As 
discussed in the previous chapter, the definition and quantification of hepatic perfusion 
using CE-US needs further research to improve our understanding of the complex 
interactions between the microbubbles, hepatic parenchyma and computer technology.
This study has documented perioperative changes in hepatic perfusion using CE- 
US. Increased numbers with longer follow up are required in addition to improved 
understanding of the interpretation of CE-US to allow definite conclusions to be drawn.
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Section 3.
C hapter 5; Short and long term outcomes in patients with colorectal liver métastasés 
undergoing partial hepatectomy with a novel triphasic approach.
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3.5.1 Introduction and aims
Traditionally, hepatic resection has been associated with a significant risk of 
intraoperative haemorrhage with some authors documenting losses up to 10 litres^^^. 
Improved surgical and anaesthetic techniques have evolved over the last decades, reducing 
the risk of haemorrhage. However, with recent research continuing to document 
intraoperative blood loss and subsequent blood transfusions as major determinants of 
patient morbidity and mortality after hepatic resection, the ideal aim of bloodless hepatic 
resection remains elusive^ ^®’^ ^^ ’^” ’^ ^^ ’^ ^^ .
Since Hogarth Pringle (1908) first demonstrated that hepatic inflow vascular 
occlusion could minimise hepatic bleeding, several vascular occlusion techniques have 
evolved: hepatic inflow with or without outflow occlusion; total or selective and 
intermittent or continuous '^ '^^’^ '^ .^ Each technique varies in level of technical difficulty, 
prevention of haemorrhage, intraoperative patient tolerance and hepatic tolerance, with the 
risk of hepatic failure being foremost^"^ .^ Indeed, with the documented incidence of hepatic 
dysfunction and/ or failure being as high as 18%, some surgeons have disregarded hepatic 
occlusion techniques altogether
Any of the aforementioned surgical techniques can be combined with low central 
venous pressure (CVP) anaesthesia. Maintenance of CVP less than 5cmH20 has been 
shown to minimise back bleeding, intraoperative blood loss and subsequently, blood 
transfusions when compared to higher intraoperative cyp226,242,243^  However, maintenance 
of a low CVP intraoperatively can be problematic, requiring administration of intravenous 
nitroglycerins that could result in haemodynamic instability. Furthermore, prolonged low 
CVP may lead to renal hypoperfusion with subsequent permanent renal compromise.
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As surgical and anaesthetic techniques have evolved and improved patient 
outcomes, the traditional patient selection criteria for partial hepatectomy have extended. 
As a result, there has been interest in developing a prognostic score with the Clinical Risk 
Score having received the most a t t e n t i o n T h e  CRS allocates 1 point for each of the 
following: node positive primary; disease free interval <12 months; >1 tumour; tumor size 
>5cm and CEA >200ng/mL. Patients scoring 0-2 have the best outcomes and should be 
considered for resection. In contrast, patients scoring 4-5 have poorer outcomes and 
surgery should be carefully considered alongside adjuvant therapies. This clinical risk 
score has recently been validated by two other centres and requires further research in 
different populations to determine its widespread applicability^^®’^ ^^ .
The presence of an elevated systemic inflammatory response has been shown to 
predict reduced disease free survival and long term survival in several different types of 
malignant disease, including primary colorectal cancer^^’^ *^^ .^ The exact mechanism behind 
the increased C-reactive protein is unclear, and to date no studies have assessed any 
prognostic value elevated C-reactive protein may have on metastatic colorectal cancer.
The primary aim of this chapter was to evaluate patient outcomes after partial 
hepatectomy for colorectal liver métastasés with a novel triphasic approach: preoperative 
dehydration; intraoperative low CVP anaesthesia and selective continuous vascular 
occlusion. Particular attention was paid to blood loss, hepatic function and renal function. 
The secondary aim was to determine the prognostic value of the clinical risk score in our 
population and to compare it to any prognostic influence C-reactive protein may have.
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3.5.2 Patients and methods
Patients
From 1998 to 2006, 91 consecutive patients were referred to Glasgow Royal 
Infirmary to undergo planned partial hepatectomy for colorectal liver métastasés. Ethical 
approval was obtained from the local research and ethics committee of North Glasgow 
University Hospitals Trust and all subjects gave their written informed consent.
All operations were performed in one surgieal unit by a single consultant surgeon 
and anaesthetist. All patients underwent routine cardiorespiratory assessment to assess 
fitness for general anaesthesia. The only absolute contraindication to surgery was 
extrahepatic disease. Patients being considered for resection underwent radiological 
imaging within 8 weeks of their planned operation: transabdominal ultrasound; contrast 
enhanced computed tomography (of chest, abdomen and pelvis) and/or magnetic resonance 
imaging. Intraoperatively, unenhanced and contrast enhanced ultrasonography were 
routinely performed to confirm preoperative staging and to ensure satisfactory resection 
margins.
Methods
Anaesthetic technique
Preoperatively, patients were given a light meal 12 hours before their operation, and 
then fasted. They received their routine medication, including diuretics, and 3 litres of oral 
bowel preparation (Klean Prep, Norgine Ltd, Harefield, Middlesex, UK). No intravenous
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fluids were administered unless the patient was diabetic in which case they received 
intravenous 5% dextrose at 83mL/hour with insulin administered via a sliding scale.
In the anaesthetic room, intravenous and intra-arterial access was achieved. An 
epidural was inserted at the level of T9/10 and the patient given 12-15 mL of 0.5% 
levobupivacaine. Pre-intubation, patients were pre-oxygenated with 100% oxygen and 
given 150-200pg of fentanyl. Anaesthesia was induced with a propofol infiision at a rate of 
1.5-2.0 pg/mL and increased as required. Once unconscious, 35-50mg of rocuronium was 
administered and the patient was then intubated.
During surgery, general anaesthesia was maintained by propofol infusion with 
boluses of rocuronium or 0.5% levobupivacaine via epidural if required. Patients were 
monitored by: electrocardiogram (ECG); intra-arterial blood pressure; fraction of inspired 
oxygen (FiOi); pulse oximetry (SpOi); CVP; tidal volume; respiratory rate; nasopharyngeal 
temperature and blood loss.
Intraoperative fluid management was divided into two phases: hepatic and 
posthepatic. The hepatic phase began at the induction of anaesthesia and finished when the 
specimen was removed with full haemostasis. During this phase 65mL/hr of Hartmann’s 
solution was administered and urine output was recorded, but did not influence fluid 
management. There was no administration of mannitol or dopamine. Metaraminol (0.5- 
l.Omg) or ephedrine (3-9mg) boluses were given if required for prolonged hypotension 
(systolic blood pressure less than 90mmHg). CVP was maintained less than 5cmH20, 
without administration of intravenous nitroglycerins. After delivery of the specimen, the 
posthepatic phase began with 500-lGQGmL of intravenous crystalloid (Hartmann’s
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solution) administered to increase CVP followed by 500mL of colloid (Gelofiisine) prior to 
the patient leaving theatre.
Postoperatively, the propofol infusion was discontinued when the abdomen was 
closed and the patient was then extubated. The patient spent a short time in recovery where 
the urine output was monitored. Intravenous fluids were administered as alternate 0.9% 
saline and 5% dextrose at a rate of 83-lOOmL/hr and adjusted to maintain urine output 
greater than 30mL/hr. Patients were then transferred to the surgical high dependency unit 
where the epidural infusion was continued for 3 days (0.125% hupivacaine/diamorphine 
50jig/mL, rate of 8-12 mL/hr as required).
Surgical technique
The technique for hepatic resection with vascular inflow occlusion has been 
described previously^^^’^ ^^ . Patients were placed in the 15° head-down tilt position to 
obviate the risk of air embolism. Bilateral subcostal laparotomy with a xiphoid extension 
as appropriate was performed to provide surgical access. The liver was mobilised by 
division of the appropriate triangular ligaments and the vena cava exposed. Selective 
continuous vascular control was achieved without dissection by application of a vascular 
clamp to the appropriate left or right portal structures (Half-Pringle)^^^. This occlusion 
resulted in a visible demarcation line along the proposed line of resection for a 
hemihepatectomy that was marked on the liver surface by diathermy [Figures 36, 37, 38]. 
The appropriate right or left hepatic vein outflow (including the middle vein if back 
bleeding was present after clamping of the left vein) was occluded with a bulldog clamp. 
Parenchymal dissection was performed by an ultrasonic dissector (CUSA, Valley Lab,
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London, UK)^^ .^ Bridging vessels and bile duets vyere repeatedly electrocauterised using 
Ligasure (Autosuture, United States Surgical Corp., Norwalk, CT, USA) and divided with 
scissors. Large vessels were controlled with suture, clip or vascular stapling device. After 
removal of the specimen, the exposed edges were sealed by argon beam coagulation 
(CONMED Corporation, Utica, NY, USA) to achieve haemostasis. Thereafter, inflow and 
outflow occlusion was removed.
Outcome variables and statistical analysis
Patients’ casenotes and the prospective surgical hepatic database were analysed for: 
age, sex and American Society of Anaesthesiologists grading (ASA). The type of hepatic 
resection was classified as: right lobectomy (Couinaud’s segments^^^ V, VI, VII and VIII 
±1); left lobectomy (segments II, III and IV ±1); trisegmentectomy (3 segments); 
bisegmentectomy (2 segments); monosegmentectomy (1 segment) and subsegmentectomy/ 
wedge (<1 segment). For RF ablation, the number of segments ablated and their position 
were recorded.
Thirty day morbidity and mortality were recorded and to standardise reporting a 
published grading system was applied^^^. Grade 0 represents no complications. Grade 1 
complications resolve spontaneously or with minimal intervention i.e. antibiotics, bowel 
rest. Grade 2 requires moderate intervention i.e. intravenous medication, chest drain 
insertion. Grade 3 graded complications require surgical or radiological intervention or 
readmission to hospital. Grade 4 is scored when patients are left with a long standing 
disability, organ resection or enteral division. Grade 5 is death. Overall, minor 
complications are grouped as grades 1 to 2 and major complications 3 to 5.
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Figure 36; Selective placement of a vascular clamp to the portal pedicle allows selective 
control of the hemi-liver for resection with visible demarcation.
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Figure 37: Doppler image illustrating normal flow from both sides o f the liver before
clamp application.
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Figure 38: Doppler image showing no flow from the right liver following clamp
application in same patient as Figure 37.
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Intraoperative blood loss was measured by adding the suction bottle volume to the 
increase in weight of surgical packs/swabs. The indication for intraoperative blood 
transfusion was determined by haemodynamic instability and/or myocardial ischaemia in 
the presence of significant blood loss (>1000mL). Postoperative blood loss was taken as 
the difference between preoperative and postoperative day one haemoglobin. Patients were 
transfused in concordance with post-operative hospital guidelines which are based on SIGN 
guidelines^^^. In those patients undergoing synchronous colonic resection or 
radiofrequency ablation, blood loss included the loss from both these procedures.
To determine perioperative hepatic function after selective continuous vascular 
occlusion, serial measurements of liver function in the last 50 patients with colorectal liver 
métastasés were analysed. Blood samples were taken: preoperative; postoperative days 1 
to 7 and one follow up sample at 4-6 weeks. Samples were analysed for: hepatic 
parenchymal enzymes (aspartate transaminase, AST; alanine transaminase, ALT; alkaline 
phosphatase, Aik Phos; gamma-glutamyltransferase, GGT); hepatic physiological markers 
(bilirubin) and hepatic synthetic markers (prothrombin time, PT; aetivated partial 
thromboplastin time, APTT; thrombin time, TCT; albumin; total protein).
Hepatic function variables on each postoperative day were compared with 
preoperative values using Wilcoxon’s signed rank test. Comparisons between patients 
undergoing major resections (at least 3 lobes resected) and those undergoing minor hepatic 
resections were performed using the Mann-Whitney test. Statistical significance levels are 
reported without adjustment for multiple comparisons to err on the side of over- rather than 
understating changes of possible clinical significance.
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Perioperative renal function was initially assessed retrospectively in 50 consecutive 
patients undergoing partial hepatectomy. Intraoperative urine output was recorded and 
serial blood sampling of serum urea and creatinine taken: 24 hours preoperatively; 
postoperative days 1, 2 and 3. After analysing the data, a prospective controlled trial was 
performed to assess changes in glomerular filtration rate (GFR) in patients undergoing 
partial hepatectomy with perioperative fluid restriction and low intraoperative CVP. 
Twenty nine consecutive patients undergoing hepatic resection for colorectal liver 
métastasés (preoperative bowel preparation with no supplementary intravenous fluids plus 
intraoperative CVP <5cmH20 = fluid restricted group) were compared to thirty controls 
undergoing colonic resection for primary colorectal cancer or diverticular disease 
(preoperative bowel preparation with supplementary intravenous fluids and no fluid 
restriction intraoperatively = not fluid restricted group). Renal function was again 
assessed by serial blood sampling: 24 hours and 1 hour preoperatively; 6 hours 
postoperatively; postoperative days 1 to 5 and at 3 months. Samples were analysed for: 
urea; creatinine; serum osmolality; beta 2 microglobulin and cystatin C.
The most commonly used marker of GFR in clinical practice is plasma (or serum) 
creatinine. Measurement of creatinine is performed routinely by biochemistry laboratories 
and is convenient as well as being low in cost. Unfortunately, plasma creatinine has 
limitations. Not only is there documented variation in measurements on the same sample 
between laboratories, but creatinine levels can vary considerably between individuals with 
levels influenced by gender, age, body composition and dietary factors^^^’^ ^^ . Furthermore, 
when renal function changes rapidly, (e.g. after ischaemic acute renal failure), creatinine
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shows a poor correlation with glomerular filtration rate (GFR) reducing its clinical 
applicability
Beta-2 microglobulin and cystatin C are low molecular weight proteins that do not 
appear to have the same limitations as creatinine in the measurement of GFR. Beta 2 
microglobulin is present on the surface of all nucleated cells and becomes elevated in 
proximal renal tubular injury and according to two recent reports, may be superior to 
creatinine for estimation of g p r 364,365^
Cystatin C is metabolised by the proximal renal tubular epithelial cells and has a 
relatively constant plasma concentration that is independent of gender and age. Again, 
there is evidence that cystatin C is more sensitive in detecting a reduction in GFR than 
creatinine in patients with renal diseases and those that have undergone renal 
transplanation^^ ’^^ ^^ .
Patients were followed up as part of the routine surveillance programme performed 
by the surgical department: clinic appointments at 3 and 6 months postoperative, then 
further clinic appointments with surveillance CT scans at yearly intervals up to 5 years 
after their operation. This follow up allowed time to local recurrence and long term 
survival to be calculated (Kaplan-Meier analysis, SPSS for Windows, SPSS Inc., Chicago, 
Illinois, USA).
All patients had their clinical risk score calculated prior to undergoing partial 
hepatectomy. One point was given for each of the following factors: node positive primary 
tumour; preoperative carcinoembryonic antigen (CEA) >200ng/mL; number of liver 
tumours >1; largest liver tumour >5cm and disease free interval from primary colorectal 
surgery to métastasés <12 months. The primary outcome measure was survival.
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Routine preoperative laboratory measurements of C-reactive protein and albumin 
were recorded in all patients. The limit of detection of the C-reactive protein assay was 
<6mg/l. The coefficient of variation, over the range of measurement, was less than 5% as 
established by routine quality control. The Glasgow Prognostic Score (GPS) was 
calculated as previously described one point for C-reactive protein >10mg/L and one 
point for albumin <35g/L. Patients that had both abnormalities present were allocated a 
score of 2. Patients in whom only one of these biochemical abnormalities was present were 
allocated a score of 1 and a score of 0 was given when both parameters were within normal 
limits. The primary outcome measure was survival.
For both prognostic scores, multivariate survival analysis was performed using a 
stepwise backward procedure to derive a final model of the variables that had a significant 
independent relationship with survival. To remove a variable fi'om the model, the 
corresponding P-value had to be greater than 0.10. Analysis was performed using SPSS 
software.
Synchronous bowel resection and/or hepatic procedures
In patients with synchronous disease, the colon or rectum was resected prior to the 
hepatic resection. In patients with multiple liver métastasés, the hepatic resection was 
performed first, then radio frequency ablation (RF ablation). Each patient that had 
undergone a synchronous procedure was then case matched according to liver procedure 
with a patient who had undergone partial hepatectomy only. Comparison between groups 
was made in relation to: patient demographics; blood loss; morbidity; mortality; hospital 
duration; recurrence and overall survival.
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3.5.3 Results
Patient demographics
51 men and 40 women, mean age 63.8 years (range 22-82), underwent hepatic 
resection in this series. The median ASA grade was 2 (range 1 to 3). Of the 91 patients, 80 
(88%) underwent their planned hepatic procedure with no alteration in management. The 
remaining 11 patients did not undergo hepatic resection due to more advanced disease 
found at laparotomy: 7 patients had their procedure abandoned and 4 underwent open RF 
ablation. These eleven patients were excluded from further analysis.
Type o f hepatic resection performed
The types of hepatic resections performed are displayed in Table 10. It can be seen 
that 51% were major resections with concomitant extra and intrahepatic procedures 
performed in 32 patients. Synchronous bowel resection and/or RF ablation accounted for 
the majority of the synchronous procedures (n=28) with the remaining 4 cases: excision of 
diaphragm; splenectomy; closure of ileostomy and choledochotomy with extraction of 
stones. Cholecystectomies were not included.
Postoperative complications
Table 11 displays the type, number and grade of complications recorded after 80 
partial hepatectomies. Postoperative complications occurred in 19 patients (24%) with no 
mortality recorded. Cardiac complications were the overall commonest complications with 
new onset atrial fibrillation requiring intravenous medication in all cases. In addition, one 
patient developed cardiac failure that required a period of intubation and ventilation in
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intensive care. The most frequent surgery-related complication were bile leaks (n=5) all of 
which were managed conservatively. One patient had transient hepatic dysfunction 
developing jaundice that resolved spontaneously during their hospital admission. Only one 
patient was readmitted to hospital. She presented with severe abdominal pain after an 
uneventful postoperative recovery that was secondary to pneumonia and subsequently 
resolved with appropriate intravenous antibiotics. Overall, the majority of complications 
were classified as minor (n=16; 84%).
Postoperative blood loss and transfusion rate
Median blood loss at surgery was 400mL (range 50 - 3000) with a mean blood loss 
of 535 ± 465mL. Ten patients had a blood loss greater than lOOOmL with only three 
patients losing more than 1500mL. No patient was transfused intraoperatively and no 
patient returned to theatre with postoperative haemorrhage. Major resections experienced a 
significantly greater blood loss than minor resections (500mL v^ ' 400mL; Mann Whitney 
p=0.02). The mean decrease in haemoglobin on postoperative day 1 was 2.0 g/dL (SD 1.2) 
and three patients received units of homologous concentrated red cells (1 , 2  and 4 units 
respectively) after dropping their haemoglobin and developing myocardial ischaemia on 
EC G monitoring.
Perioperative hepatic function
Within the group of 50 patients undergoing resection, no incidence of hepatic 
failure was recorded. Four time points selected to provide an adequate description of 
changes in all hepatic function variables, are shown in Table 12.
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On postoperative day 1, AST and ALT levels rose dramatically, falling rapidly on 
postoperative day 2 and returning to normal clinical levels by day 7 and follow up 
respectively. Aik Phos and GOT had biphasic responses, falling significantly on day 1, 
recovering to cross the baseline on days 3 and 4 then continuing to rise to peak at day 6. 
They started to decline on day 7 and reached normal values at follow up. Bilirubin peaked 
on day 1 then returned to normal range on day 2, remaining within normal limits during the 
remainder of the study. Figure 39 graphically displays the key changes. FT and APTT 
fluctuated during postoperative period, but remained within normal clinical ranges 
throughout. Albumin and total protein fell immediately postoperatively, remaining low for 
next 6 days [Figure 40]. By the end of the first week both had resumed normal levels.
Comparison of hepatic function changes between major and minor resections found 
greater increases in AST and ALT on postoperative days 2 to 7 (p<0.05) after major 
resections. Although there was no difference in alkaline phosphatase between the two 
groups, GGT was significantly higher in the major resection group on day 7 (p=0.016). 
There were no other significant differences between the two groups.
Perioperative renal function
Preoperatively, six of the 50 patients had pre-existing mild renal impairment (urea 
8-12mmol/L, creatinine 130-230mmol/L). During the hepatic phase, the median urine 
output was 28.4 mL/hr (range 13.3 - 40.0) with a median CVP of 4 (range 0 - 11). No 
patient required intravenous vasodilators and metaraminol or ephedrine boluses were 
administered in only 10 patients. The median urine output during the first postoperative 
hour was llOmL (range 30 - 370). Postoperatively the median serum urea and creatinine
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values fluctuated but remained within normal limits. O f the six patients that had mild renal 
impairment preoperatively, five had improved urea and creatinine postoperatively whilst 
the remaining patient returned to preoperative values.
In the prospective trial, the two groups were age matched: fluid restricted patient 
group mean age 61.6 years, S.D. 12.5 and control unrestricted group mean age 62.2 years, 
S.D. 17.4. Preoperatively, 1 patient and 5 controls had mild renal impairment (urea 8- 
12mmol/L, creatinine 130-230mmol/L). Both groups experienced transient fluctuations in 
all parameters when compared to their 24 hour preoperative values with the median value 
at each time point remaining within normal limits for each parameter. Figures 41-44 
graphically display the perioperative changes in urea, creatinine, beta-2 micro globulin and 
cystatin C in both groups. No patient or control developed renal failure and at 5 days 
postoperatively, only 1 patient and 1 control had mild renal impairment.
There were few differences in all parameters between the fluid restricted group and 
the unrestricted group. Beta-2 microglobulin was greater in the control group 24 hours 
preoperatively: median 2.2 (range 1.5-3.5) versus median 2.0 (range 1.3-5.4) [p=0.034]. 
Serum urea at 6 hours postoperatively was significantly higher in the fluid restricted patient 
group: median 5.1 (range 2.2-8.0) versus median 4.2 (range 1.5-10.1) [p=0.019]. At 3 
month follow up, cystatin C was elevated in the control group: median 1.13 (range 0.8-1.6) 
versus median 0.92, (range 0.7-1.9) [p=0.019]. For all three parameters, the medians were 
within normal laboratory limits.
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Disease free and overall survival
Of the 80 patients that underwent partial hepatectomy for colorectal liver 
métastasés, 70 were pathologically confirmed curative procedures. Minimum follow up in 
those patients was 3 months with a median follow up of 44 months. Within this curative 
group, 33 patients (47%) had recurrent disease during follow up with the majority recurring 
in the liver (n=25) in the liver. The Kaplan-Meier estimate of the median time to local 
recurrence was 514 days (17.1 months). Median overall survival was 1307 days (43.6 
months) with 1, 3 and 5 year survivals of 91.7% (95% Cl 84.7-98.7%), 50.4% (95% Cl 
33.8-67.0%) and 25.6% (95% Cl 7.3-43.9%) respectively. Figure 45 displays the survival 
curve.
Clinical Risk Score
Of the 70 patients that had pathologically confirmed curative procedures, 68 had 
their Clinical Risk Score calculated (CRS). The CRS were then divided into 3 prognostic 
groups: good prognosis scores 0-1; intermediate prognosis scores 2-3 and poorer prognosis 
scores 4-5. On univariate analysis, CRS was found to be a significant predictor of survival 
(hazard ratio 2.9, 95% Cl 1.16-7.19%; p-0.026). Figure 46 displays the survival curves for 
the 3 groups. On univariate analysis of the individual components of the CRS, tumour size 
was found to be a significant predictor of survival with preoperative CEA level and disease 
free interval displaying a trend towards significance (Table 13). Node positive primary and 
tumour number were found not to be significant. All 5 variables underwent multivariate 
analysis with tumour size found to be the only significant independent predictor of
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survival. Again, CEA level and disease free interval displayed trends towards significance 
(Tables 14).
Glasgow Prognostic Score
Within the curative hepatic resection group, 56 patients had their Glasgow 
Prognostic Score (GPS) calculated. The majority of patients scored a GPS of 0 (n=34) with 
16 patients scoring 1 and 6 patients scoring 2. In all patients scoring a GPS of 1, an 
elevated C-reactive protein was found. In the 6 patients with hypoalbuminaemia, all had an 
elevated C-reactive protein and subsequently a GPS of 2. On univariate survival analysis, 
GPS was not found to be significant (hazard ratio 0.93, 95% Cl 0.50-1.74%, p=0.817). 
Individually, neither C-reactive protein nor albumin achieved significance (hazard ratio 
0.50, 95% Cl 0.16-1.60, p=0.242 and hazard ratio 2.23, 95% Cl 0.54-9.17, p=0.265 
respectively).
The level of C-reactive protein that indicated an inflammatory response was 
changed to >6mg/L. GPS changed to: 0 in 23 patients; 1 in 27 patients and 2 in 6 patients. 
Neither GPS nor C-reactive protein was found to be significant (p=0.586 and p=0.6 
respectively, log rank test)
Synchronous procedures
Of the twenty eight patients that underwent bowel and/ or RF ablation in addition to 
partial hepatectomy, twenty seven were case matched according to liver procedure with 
twenty seven patients who had undergone partial hepatectomy only. The remaining case
228
was excluded as 3 segments of small bowel had been resected for metastatic peritoneal 
métastasés.
Synchronous procedures performed were: bowel resection and partial hepatectomy 
(n=14); bowel resection, RF ablation and partial hepatectomy (n=8) and RF ablation and 
partial hepatectomy (n=5). Types of bowel resection performed were: anterior resection 
(n=12); sigmoid colectomy (n=4); left hemicolectomy (n=2) and right hemicolectomy 
(n=4). Major hepatic resections accounted for 4 out of the twenty seven cases (13%).
Comparison with the partial hepatectomy only group found both were age matched 
(mean age 64.7 65.6 years; p=0.76) and sex matched (male n=14; female n=13 in each
group). There were no significant differences in ASA grade and number of curative 
operations performed. Mean and median blood losses did not differ significantly between 
the synchronous group and the partial hepatectomy only group: mean 419mL (range 50- 
850mL) vs 514mL (range 50-3000mL), p=0.49 and median 400mL vs 373mL, p=0.60.
The synchronous group experienced higher 30 day morbidity with 9 patients 
developing postoperative complications: atrial fibrillation (n=3); bile leak (n=2); chest 
infection (n=l); wound infection (n=l); urinary tract infection (n=l) and ileus (n=l). The 
partial hepatectomy only group recorded 2 postoperative bile leaks (p=0.03). The majority 
o f complications were grades 1 and 2 (n=10) with the remaining one being grade 3 due to 
hospital readmission for a chest infection in a patient that had undergone synchronous 
resection. All complications were managed either conservatively or with intravenous 
medication. No patient required further laparotomy, re-intubation or a period in intensive 
care. There was no recorded mortality. The synchronous group had longer duration of
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hospital stay than the partial hepatectomy only group (median 11 9 days respectively;
p=0.04).
Liver recurrence occurred in 8 synchronous procedure patients and in 11 partial 
hepatectomy only patients with no significant difference in time to recurrence: synchronous 
group mean 15.1 months (95% Cl 10.8-19.5 months) vs 20.9 months (95% CÏ 15.1-26.7 
months; p=0.83). Only one patient in the partial hepatectomy group developed recurrence 
of the primary colonic tumour. Overall survival for both groups at 3 years was 43% (95% 
Cl 17%-69%) with no significant difference between the synchronous and partial 
hepatectomy only groups: 59% vs 44% respectively, p=0.84 Kaplan-Meier log-rank test).
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Table 11; Postoperative complications after 80 partial hepatectomies for metastatic 
colorectal cancer.
type of complication
Grade of complication 
0 1 2 3 4 5
transient biliary leak 5
arrhythmias/ myocardial infarction 6 1
respiratory infection/ collection 2
urinary retention/ infection 1
transient hepatic dysfunction 1
ileus 1
wound infection 2
Total number of complications 19 (24%)
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Table 12; Changes in hepatic function after partial hepatectomy in 50 patients with
colorectal liver métastasés.
Preop Day I Day 7 Follow up
Bilirubin (fimol/L) 10 (7, 14) 23 (16, 27)*** 14 (9, 19) 12 (8, 16)
AST (U/L) 24 (19, 34) 260 (85, 409)*** 37 (24, 50)*** 27 (21, 40)
ALT (U/L) 21(17 , 28) 277 (95, 459)*** 70 (39, 91)*** 2 4 (1 7 ,3 1 )
Aik Phos (U/L) 228 (174, 285) 175 (130, 224)*** 352 (293, 537)*** 242(195 ,314)
GGT (U/L) 35 (21, 53) 32(21 ,55 )* 135 (77, 192)*** 50 (29, 75)
F T (s) 15 (14, 16) 17(16, 18)*** 16 (14, 17) 15 (14, 16)
APTT (s) 36 (34, 40) 36 (34, 40) 40 (38, 43)* 38 (34, 41)
TCT (s) 10(10, 11) 11 (10, 12)* 11(10, 12) 10(10, 11)
Albumin (g/L) 43 (40, 45) 30 (28, 34)*** 33 (31, 36)*** 41 (37, 44)*
Total Protein (g/L) 72 (68, 75) 54 (48, 56)*** 58 (52, 62)*** 71 (66, 74)
Results shown as median (interquartile range).
*p<0.05, ***p<0.001 relative to preoperative value by Wilcoxon signed rank test.
Hepatic marker normal ranges;-
bilirubin 2-22pmol/L; AST 12-48U/L; ALT 3-55U/L; Alkaline phosphatase 80-280 U/L; 
GGT 5-90U/L; PT 12-16s; APTT 32-44s; TCT 10-13s; albumin 33-55g/L and total protein 
62-82g/L.
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Figure 39: Changes in hepatic function in patients with colorectal liver métastasés after
partial hepatectomy.
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Figure 40: Perioperative changes in remaining hepatic function tests in patients with
colorectal liver métastasés after partial hepatectomy.
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Figure 41: Perioperative changes in serum urea in patients that were fluid restricted
against an unrestricted fluid control group.
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Figure 42; Perioperative changes in serum creatinine in patients that were fluid restricted 
against an unrestricted fluid control group.
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Figure 43: Perioperative changes in beta-2 microglobulin in patients that were fluid
restricted against an unrestricted fluid control group.
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Figure 44: Perioperative changes in cystatin C in patients that were fluid restricted
against an unrestricted fluid control group.
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Figure 45: Survival curve for patients undergoing curative partial hepatectomy for
colorectal liver métastasés.
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Figure 46: Survival after hepatic resection according to Clinical Risk Score.
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Table 13: Univariate predictors of Survival within the Clinical Risk Score.
Hazard ratio 95% Cl P
Liver tumour size >5cm 5.48 1.63-18.46 0.006
Disease free interval <12 months 5.34 0.89-32.11 0.068
CEA >200ng/mL 4.34 0.89-21.08 0.069
Node positive primary 2.15 0.44-10.39 0.342
liver tumour >1 0.58 0.15-2.23 0.431
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Table 14: Multivariate predictors of Survival within the Clinical Risk Score.
Hazard ratio 95% Cl P
Liver tumour size >5 cm 5.26 1.57-17.68 0.007
Disease free interval <12 months 4.32 0.78-23.89 0.093
CEA >200ng/mL 3.91 0.86-17.79 0.078
liver tumour >1 0.58 0.15-2.23 0.431
Node positive primary 1.73 0.38-7.75 0.476
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3.5.4 Discussion
Hepatic vascular occlusion techniques have evolved since the work o f Pringle^ "^ "^ , 
widening both surgical and anaesthetic options for hepatic resection. This study has 
documented patient outcomes after hepatic resection with perioperative fluid restriction 
and the Half-Pringle. This approach consists of three phases: preoperative administration 
of bowel preparation with no supplementary fluids; maintenance of low CVP anaesthesia 
and selective continuous hepatic vascular occlusion.
Triphasic approach
It is this department’s experience that by actively dehydrating the patient 
preoperatively, maintenance of a low intraoperative CVP is easily achieved with no risk 
to the patient’s haemodynamic status. Indeed, no patients required administration of 
intravenous nitroglycerins as some authors have previously r e p o r t e d a n d  only 
occasionally was metaraminol or ephedrine administered to maintain the systolic blood 
pressure with no operation being interrupted for haemodynamic instability. Selective 
continuous hepatic vascular occlusion has the advantage of requiring minimal dissection, 
achieving easy and effective vascular control, which has been confirmed by Doppler 
studies
Blood loss
Of the three components, it is hard to assess which one makes the greatest 
contribution, however, it is clear that this triphasic approach is effective at minimising 
blood loss. With a documented median blood loss of only 400mL, it should be
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highlighted that this result included blood losses from synchronous procedures, 
suggesting that synchronous procedures can be safely performed in conjunction with 
partial hepatectomy. As expected the blood loss was significantly greater with major 
resections compared to minor^^^.
Although direct comparisons with other studies are difficult and must be 
interpreted in the context of the surgical/anaesthetic approach (i.e. major versus minor 
resection, type of surgical occlusion technique used, whether low intraoperative CVP was 
maintained and whether patients with cirrhosis were included in the study’s population), 
the low blood loss and transfusion rate with this triphasic approach remains.
Postoperative morbidity and mortality
Published literature states that a low blood loss results in improved patient 
outcome. For a small volume department this study has reported low incidences of 
morbidity and mortality (24% and zero respectively) with only 3 complications being 
classified as major. These results compare favourably to large hepatobiliary centre 
studies with documented morbidity ranging between 8-46% and mortality up to 5% 
227;228;280;356;370-372^  agreement with large centres, biliary leaks were the commonest 
complication, which all resolved with conservative management during the hospital 
admission.
Perioperative hepatic function
Hepatic failure or severe dysfunction after partial hepatectomy has been 
documented to occur within the range 3-18% with the cirrhotic liver at greater
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No incidence o f hepatic failure was recorded in this study after eighty 
resections providing evidence that the triphasic approach does not compromise the 
residual hepatic remnant. Furthermore, a clear pattern was demonstrated in liver function 
enzymes’ changes during the perioperative period.
The immediate increases in AST and ALT after surgery are likely to reflect the 
degree of hepatic trauma. This phenomenon has been documented in both human and 
animal studies where the rapid increase is followed by an immediate decline that may 
return to normal values or remain mildly elevated for up to two weeks after resection^^^' 
With the major hepatic resections experiencing significantly greater increases in AST 
and ALT than minor resections, it becomes apparent that elevated hepatic enzymes are 
related to increasing tumour mass excised and subsequently, decreasing remnant liver 
volume^ "^ ’^^ ^^ .
Alkaline phosphatase and GGT experienced significant decline one day after 
surgery, but then began to rise steadily, peaking at day 6 postoperative. Limited evidence 
suggests that as alkaline phosphatase and GGT reside in bile canalicular cells the initial 
drop may be due to the excision of these cells^^^’^ ^^ . In contrast, the rise of these markers 
may be an indicator of proliferation of the bile ducts and hepatic regeneration 
starting^"^ ’^^ ^^ ’^ ^^ . Based on this assumption, this study found that regeneration started at 
day four post hepatectomy.
Another potential prognostic indicator is bilirubin^^^’^ ^^ . As demonstrated in this 
study, an initial increase in serum bilirubin is likely as it indicates diminished 
physiological function of the residual hepatic remnant with inability to clear bilirubin.
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Clearly, if this increase persisted over the next few postoperative days, the risk of hepatic 
failure would be high.
Substantial initial decreases in albumin and total protein are expected after partial 
hepatectomy. Furthermore, they can still not have fully recovered by 2-3 months which 
led Aronsen et aP^ ® to suggest that the explanation for these decreases may be 
multifactorial. Fluid retention, haemodilution, intraoperative blood loss, protein leakage, 
impaired protein synthesis and increased amino acid requirement for hepatic regeneration 
have all been suggested and it is beyond the scope of this study to provide any definitive 
explanation.
Taking into account these hepatic function changes, this study proposes serial 
blood samples should be taken after hepatic resection to monitor adequate hepatic 
physiological function and regeneration. The following trends should be expected: rapid, 
transient elevations of AST and ALT accompanied by significant decreases in alkaline 
phosphatase and GGT on postoperative days 1 and 2; mild elevation of bilirubin that 
resolves by day 4 and is accompanied by significant and sustained increases in alkaline 
phosphatase and GGT.
Perioperative renal junction
With patients being actively dehydrated and fluid restricted to minimise blood 
loss, particular attention was paid to analysing perioperative renal function. Initially a 
retrospective study was performed that used everyday laboratory markers to assess renal 
function as well as assessing the perioperative urine output. Despite preoperative 
dehydration and low intraoperative CVP, no patient developed renal impairment
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postoperatively. With intraoperative urine output less than the recommended ImL/kg/hr, 
this study strongly suggested that perioperative fluid restriction does not compromise 
renal function. However, it was thought that caution should be exercised in patients that 
have mild renal impairment preoperatively exemplified by six patients in this study who 
had slightly greater fluctuations in postoperative urea and creatinine that resolved or 
improved by day 3. To build on these findings, a prospective study was performed over a 
3 month period that aimed to directly assess renal function and more specifically, GFR. 
When compared to a non-fluid restricted control group, routine biochemical markers and 
specific GFR serum markers were not significantly different suggesting that the kidneys 
are able to accommodate the transient fluid restriction and then respond as normal when 
fluid is reintroduced. Both these studies confirm that perioperative fluid restriction used 
as part o f the triphasic approach to performing partial hepatectomy did not compromise 
renal function.
Disease fi*ee and overall survival
In relation to long term outcome after partial hepatectomy for colorectal liver 
métastasés, this department has similar figures to large volume specialist centres with 
a median time to local recurrence of approximately 17 months and a 3 year survival of 
50% . This confirms that the combined surgical and anaesthetic approach is not 
oncologically compromising patients with metastatic colorectal disease and longer follow 
up with greater numbers will provide long term evidence.
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Prognostic indicators
As the number of patients being considered for surgical resection increases, it is 
important that prognostic indicators are established to help both the surgeon and the 
multidisciplinary team make the best decision on an individual’s treatment. The Clinical 
Risk Score (CRS) has been developed by one of the world’s largest hepatobiliary units 
performing large numbers of hepatic resection for colorectal liver métastasés. Their point 
scoring system of allocating 1 point for each o f the 5 predetermined variables (through 
univariate and multivariate analysis) creates a final score that is easy to calculate, 
allowing preoperative treatment decisions to be made. Furthermore, unlike other 
proposed scores in the literature, there is growing evidence that the CRS is valid in 
different patient populations^®^’^ ^^ . Indeed, our own study has found the CRS to be 
clinically applicable within a socioeconomically deprived population in the West of 
Scotland. On univariate and multivariate analysis, tumour size greater than 5cm was 
found to be the most significant independent predictor of survival, with an elevated 
preoperative CEA and disease free interval less than 12 months close to significance. 
Node positive primary and tumour number were not significant, but this may be a 
reflection of low patient numbers.
The CRS has its limitations and in the case of synchronous resections, the CRS 
can only be calculated postoperatively, once the nodal status of the primary tumour is 
known. This may not make much of a prognostic difference between scores 0 to 2, but if 
a patient with a score of 3 preoperatively is found to be node positive postoperatively, 
then their 5 year survival has decreased from 40% to 20%. Another limitation is that the 
CRS has no definite exclusion criteria. Certainly the authors’ state that the presence of
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disseminated disease and/or a positive surgical resection margin are absolute 
contraindications to surgical resection, but the CRS itself does not determine whether a 
patient is unresectable. It is possible that some surgeons will consider patients scoring 5 
as unsuitable for resection. There have been advances in chemotherapy since 1999 when 
the paper was published, and chemotherapy may now provide better long term survival 
than the 14% 5 year survival for patients with CRS 5 as stated in Fong’s paper.
There is increasing evidence that the presence of an on-going systemic 
inflammatory response is associated with poor outcome in patients with advanced 
cancers. A number of studies have reported that an elevated C-reactive protein had 
prognostic value independent of clinico-pathological stage in primary operable 
oesophageal colorectal and pancreatic cancer In addition, it has been shown 
that an elevated C-reactive protein and hypoalbuminaemia, may be combined to form the 
Glasgow Prognostic score (GPS), which has prognostic value, independent of stage and 
performance status, in patients with inoperable non-small cell lung cancer Despite 
this, the presence o f a systemic inflammatory response, as evidenced by either C-reactive 
protein or GPS, did not predict cancer specific survival in this study’s group o f patients 
undergoing curative resection for colorectal liver métastasés. The small numbers of 
patients (n=56) in the study is a limiting factor and may go some way to explaining why 
inflammation was not found to be significant. However, it should be highlighted that the 
majority of patients scored 0 (n=34), making it possible that the patient selection process 
for curative hepatic resection is already and unknowingly self-selecting patients with an 
absent inflammatory process. Indeed, only 6 patients within the group scored a GPS o f 2.
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Comparison to a group of patients with unresectable colorectal liver métastasés should
provide more information and is already underway.
Synchronous resections
Colorectal liver métastasés present a unique opportunity to deal simultaneously 
with the primary and secondary disease. A synchronous approach has two potential 
advantages. First, cost effectiveness by reducing anaesthetic and theatre costs in addition 
to ward costs if shorter stays in hospital result. Second, less upset for the patients with 
only one stay in hospital and one recovery period. Despite these advantages, there is 
widespread reluctance to perform synchronous resections due to the suspected greater 
increase in postoperative complications with associated poorer long term outcomes.
It has been the choice of this surgical department to perform combined primary 
and secondary resections, with RF ablation as appropriate. By comparing the 
synchronous procedures to patients undergoing partial hepatectomy alone, we have 
gained insight into patient outcomes. In addition to matching for case performed, both 
groups were matched for age, sex and ASA grade excluding many potentially 
confounding variables.
It had been previously documented that synchronous procedures result in 
significantly greater blood losses^^^. Despite the blood losses of the synchronous 
procedures including the bowel and/ or RF ablation losses, this study found no difference 
between synchronous resections and partial hepatectomy alone groups. As blood losses, 
and subsequent transfusion, have been related to poorer long term survival in colorectal 
liver métastasés this finding suggests that synchronous resections are not compromising
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patients’ long term survival. Indeed, with no significant differences in number of 
recurrences, disease free survival and long term survival between the groups, 
synchronous procedures are performing effective oncological surgery.
The main differences between the two groups were significantly higher 
postoperative complications in the synchronous group (33.3% vs 7.4%, p=0.03), 
associated with a longer hospital stay (median 11 days vs 9 days, p=0.04). These findings 
are consistent with some previous studies, but should be interpreted in the correct context 
to allow full interpretation. First, they are a reflection of a limitation of the study design. 
Complications and hospital stays from the staged groups’ primary colonic resection have 
not been included, mainly because the resections were performed at another hospital with 
the information not being available and/or limited. As a result the complication rate 
would be expected to be higher in synchronous resection than with partial hepatectomy 
alone. In addition, ten of the eleven complications were minor, requiring conservative 
management or intravenous medication. All resolved during the hospital stay and only 
one resulted in readmission to hospital. Furthermore, there were no anastomotic colonic 
leaks. Finally, the incidence of postoperative complications in the synchronous group 
compares favourably to large centre studies with Chua et al documenting 53% 
complication rate for synchronous and 41% for staged resections and Martin et al 49% 
for synchronous and 67% for staged resections^^^’^ ^^.
Some surgeons might consider the department’s approach aggressive. However, 
we feel that the combination o f major colonic resections with synchronous partial 
hepatectomy and /or RF ablation extends the patient population that is being considered 
for surgical intervention. Patients can have their primary and secondary disease dealt
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with at the same operation eliminating the need for two anaesthetics, two laparotomies 
and two recovery periods. Patients with bilobar disease can be considered for resection, 
with either removal of multiple segments (e.g. segment 2, 3 and 7) and/ or the application 
of RF ablation which depending on the needle size used can ablate up to 7cm easily. It is 
hoped that greater patient numbers will build on these initial findings.
Limitations o f  study
This study did not contain large number of patients with cirrhosis, which is a 
reflection of the population who present with colorectal liver métastasés. It is widely 
accepted that patients with underlying liver disease are at greater risk of significant blood 
loss and complications than patients with healthy residual liver parenchyma^^^. Indeed, 
the authors acknowledge that resection of greater numbers of these patients will provide 
further insight into how the combined approach fares with underlying hepatic disease.
Conclusions
With blood loss minimised and outcomes optimised, the indications for hepatic 
resection are widening. This study has shown that resection of colorectal liver métastasés 
using a novel triphasic approach, with each phase being validated, can be safely 
performed with low blood loss, morbidity and mortality as well as improving long term 
survival. In patients that have metastatic colorectal disease at time of diagnosis, 
synchronous resections can be performed safely potentially reducing rehabilitation time 
and hospital costs. In addition, the developing role of RF ablation should be 
acknowledged in that is allows patients with bilobar or multiple métastasés that were
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previously deemed unresectable, to be considered for resection and ablation. Finally, 
prognostic scores, including the clinical risk score, will fulfil an increasingly important 
role in determining the optimal treatment route for patients with colorectal liver 
métastasés.
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Section 3
Chapter 6: Conclusions and future research.
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Conclusions
Radiological imaging plays an essential role in the detection and characterisation 
of colorectal liver métastasés. Accurate staging o f the disease allows patient selection for 
hepatic surgery, which remains the only potentially curative option. Despite recent and 
significant technological advances in radiological imaging, up to 50% of patients that 
have undergone curative partial hepatectomy will develop hepatic recurrence in the first 
two years after surgery. Evidence from growth rate studies has shown that colorectal 
liver métastasés are slow growing and that these recurrences were present at the time of 
initial staging. Therefore, the problem of occult liver métastasés remains.
This thesis has examined the potential clinical role o f contrast enhanced 
ultrasound. The intravenous administration of an ultrasound contrast agent that has been 
used primarily in cardiac imaging was found to enhance late phase vascular imaging in 
percutaneous contrast enhanced ultrasound. The persistence of a hypoechoic liver lesion 
in to the late phase is typical o f a colorectal liver metastasis and an agent that optimises 
the late phase would allow improved characterisation of colorectal liver métastasés. 
Indeed, the administration of Defmity® was found to result in improved sensitivity and 
accuracy in the detection of colorectal liver métastasés when compared to percutaneous 
unenhanced ultrasound (sensitivity 100.8%, accuracy 90.8% versus 64.4% and 64.4% 
respectively). Furthermore, the optimal late phase imaging (quantified by comparing the 
contrast uptake by the hypoechoic metastasis to the hepatic parenchyma) was achieved by 
the lowest dose of agent, 0.4mL that would allow repeated injections before the maximal 
dose was reached.
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These findings support the growing evidence base for CE-US and it is likely that 
in the future, percutaneous unenhanced ultrasound will be replaced by CE-US as first line 
imaging for the staging o f colorectal liver métastasés, working alongside CT, MRI and 
PET.
Unenhanced intraoperative ultrasound (lOUS) is widely regarded as the superior 
imaging modality for colorectal liver métastasés and this thesis has documented the first 
prospective trial using CE-IOUS. The results are promising, with CE-IOUS being 
capable of detecting significantly more lesions than lOUS and preoperative CT/MRI. In 
addition, CE-IOUS detected smaller liver métastasés than the other imaging modalities 
(mean lesion size 1.71cm versus 2.73cm for combined CT/MRI/IOUS), with the smallest 
lesion detected being only 0.4cm in size. With smaller lesions being detected, alterations 
in staging and surgical management would be expected and indeed this occurred in 
35.1% and 29.8% of patients respectively. Inclusion of more patients with long term 
follow up will confirm if CE-IOUS is the superior imaging modality, creating a strong 
case for CE-IOUS to be accepted into widespread clinical practice. There is also the 
potential as CE-US technology advances for CE-IOUS to be performed laparoscopically 
removing the need for a laparotomy.
The presence o f colorectal liver métastasés alters the hepatic blood supply, 
providing an alternative route to the detection o f colorectal liver métastasés. Using CE- 
US, this thesis has developed a novel and reproducible technique to measure hepatic 
perfusion that documented significant differences between healthy controls and patients 
with overt colorectal liver métastasés. Further analysis assessed the ability of this novel 
technique to differentiate accurately between healthy controls and patients with colorectal
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liver métastasés, with a view to determining the role of perfusion in the detection of 
occult liver métastasés. The highest sensitivity and specificity achieved was only 85% 
and 58%, limiting the technique’s clinical applicability as a screening tool for occult 
colorectal liver métastasés.
Hepatic perfusion using CE-US was then used to assess changes in perfusion in 
patients undergoing curative partial hepatectomy with perioperative fluctuations 
occurring that were potentially reflecting the SIRS after surgical trauma. Perioperative 
perfusion changes were analysed for any relationship to hepatic recurrence with one 
parameter significantly higher in the recurrence group 3 months after the operation (peak 
intensity).
These two trials have shown that altered hepatic perftision in colorectal liver 
métastasés can be performed reliably by percutaneous contrast enhanced ultrasound. 
However, measurement of preoperative or postoperative hepatic perfusion does not 
accurately predict the likelihood of hepatic recurrence. Further work analysing the 
relationship between angiogenesis and colorectal liver métastasés, alongside improved 
understanding of the physics of the microbubbles in the hepatic circulation may develop a 
clinically applicable technique for the detection of occult colorectal liver métastasés.
Earlier and increasingly accurate detection of colorectal liver métastasés is likely 
to increase the number of patients being considered for surgical resection. Hepatic 
surgery has evolved greatly during the last two decades, but there is no widely accepted 
optimal approach. This thesis has documented a novel approach to performing partial 
hepatectomy for colorectal liver métastasés. The triphasic approach consists of: 
preoperative dehydration (using bowel preparation with no supplementary fluids);
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intraoperative fluid restriction (to allow CVP <5cmH20) and continuous selective 
vascular occlusion (Half-Pringle). Preoperative dehydration has been shown to be well 
tolerated by patients as well as allowing easy maintenance of a low intraoperative CVP. 
The Half-Pringle renders the hemi liver under resection ischaemic whilst protecting the 
liver remnant. All three components combined to minimise blood loss with a median 
blood loss of 400mL. As a result, postoperative morbidity and mortality were low with 
disease free survival and long term survival comparing favourably to the published 
literature from larger volume centres.
Particular attention was paid to the perioperative changes in renal and hepatic 
function with the triphasic approach. Dysfunction in these organs is likely after 
undergoing partial hepatectomy and very few studies have examined potential changes in 
depth. Using specific markers for GFR, in addition to routine biochemical blood 
markers, it was found that the perioperative dehydration of the triphasic approach did not 
compromise renal function. Hepatic function displayed a distinct pattern in liver function 
tests which can be used as a guide postoperatively.
Colorectal cancer with hepatic métastasés presents a unique opportunity to deal 
with the primary and secondary disease at the same laparotomy, especially as morbidity 
and mortality are declining after hepatic resection. It has been the choice of this surgical 
department to perform combined primary and secondary resections, with RF ablation as 
appropriate. Using a case matched study this thesis has found that patient outcomes 
were similar for staged versus synchronous resections. There were no significant 
differences in: blood loss; number of recurrences; disease free survival and long term 
survival. Increased morbidity and longer hospital stay was found in the synchronous
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group, but both results are likely to be limitations of the study design rather than actual 
differences. The results suggest that the combination of major colonic resections with 
synchronous bowel and /or RF ablation is safe and does not compromise long term 
patient outcomes. It is hoped that greater patient numbers will build on these initial 
findings.
As a result o f improved outcomes after hepatic resection for colorectal liver 
métastasés, interest has increased in the development of prognostic scores to optimise 
patient treatment. This thesis assessed the potential clinical application of preoperative 
C-reactive protein as a predictor of outcome after partial hepatectomy. Although a 
significant predictor in other malignancies, C-reactive protein was not found to be an 
influence in this cohort. Few patients underwent resection with an elevated C-reactive 
protein and the study will be continued to include greater numbers. The clinical risk 
score (CRS) was developed by one o f the largest volume centres for hepatic resections in 
the world. This study found the CRS to be predictive of poor outcome, validating it in 
another population and supporting its use in routine clinical practice.
This thesis has investigated the potential clinical role of contrast enhanced 
ultrasound in the detection of colorectal liver métastasés. Improved percutaneous and 
intraoperative detection of métastasés has led to optimised disease staging with 
significant alterations in surgical management. Partial hepatectomy using the triphasic 
approach has resulted in excellent short and long term patient outcomes and with the 
inclusion of synchronous colonic and hepatic procedures, could extend the number of 
patients considered for surgical resection.
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Future Research
The evidence for the integration o f percutaneous CE-US in the routine detection 
and characterisation of colorectal liver métastasés is growing. The majority of studies are 
based on SonoVue® meaning further work using Defmity® is required to determine its 
application for three phase vascular imaging. This would extend from the work started in 
this thesis ideally taking the form of a prospective multicentred trial with large numbers, 
and using a healthy control group to allow validation of this diagnostic test.
The next progressive step would be a direct comparison between SonoVue® and 
Defmity®. It is likely that the two interact with the hepatic parenchyma and colorectal 
liver métastasés differently allowing their individual advantages to be manipulated to 
improve the role of CE-US. The initial work could be done as a prospective trial using 
blinded sonographers performing CE-US using the two agents, on the same group of 
patients. Determining the exact mechanisms of the contrast-liver interaction would 
require the development of a hepatic perfusion model. This could take the form of a 
laboratory based model with the involvement of physicists and/or mathematicians. 
Indeed, the role of replenishment kinetics in hepatic perfusion measurement could also be 
assessed.
If the contrast-liver interaction becomes better understood, then the microbubbles 
could be used as a carrier shell with the gas inside being replaced. We know that by 
increasing the mechanical index (MI) on the ultrasound machine that we can control the 
bursting of the microbubbles, subsequently releasing the contents inside. The addition of 
chemotherapy agents to inside the shell would allow the sonographer to inject a bolus.
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then burst the bubbles when the contrast appeared in the liver, thus targeting the liver 
(and also the colorectal liver métastasés) specifically.
Chemotherapy agents are not the only possible intra-microbubble additions: 
steroids are a possibility as are antibodies for angiogenesis factors (i.e. vascular 
endothelial growth factor or fibroblast growth factor).
In this thesis, hepatic resection for colorectal liver métastasés using a novel 
approach has been shown to be safe and effective. Attention should now turn to 
improving long term outcomes. One such area is the role of RF ablation. RF ablation is 
currently working alongside resection in our hospital and long term follow up data on RF 
ablation is required as there is little in the literature. Previous authors have been 
confident that it will challenge surgical outcomes, however, there is evidence that a 
higher rate of recurrence might occur with RF ablation. As a result we are currently 
analysing our long term follow up in both our percutaneous RF ablation only group and 
our combined hepatic resection and RF ablation patient group. Another area involved in 
determining long term outcomes is the role of chemotherapy in colorectal liver 
métastasés that are suitable for resection. The results of a multicentred trial are expected 
this year.
This thesis found low morbidity and mortality in patients undergoing 
pathologically confirmed curative hepatic resections for colorectal liver métastasés. 
Despite these, the long term survival was, although reasonable, not markedly different 
from previous studies, suggesting that other influences are at work. One possibility is 
that it is our inability to detect micrometastases preoperatively. If this is the case, then 
we would expect improved disease free and overall survival in the patients that had their
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surgical management altered as part of the CE-IOUS study, something we are currently 
analysing. If this long term follow up data does not show any improvements, then the 
molecular biology and theories o f metastasis need further evaluation to improve our 
understanding and to allow improved treatment of colorectal liver métastasés.
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